simpl
primari
amin
bear
c
h
alkyl
residu
found
display
potent
antiinfluenza
properti
soon
thereaft
antivir
activ
amin
found
rubella
virus
viral
target
soon
follow
antivir
drug
incorpor
adamantan
moieti
quickli
introduc
market
target
pharmaceut
featur
symmetr
bullet
hydrocarbon
success
identifi
word
amantadin
aminoadamantan
antivir
constitut
birth
medicin
chemistri
adamantan
deriv
happen
year
schleyer
semin
synthesi
parent
hydrocarbon
adamantan
tricyclo
decan
lewisacid
induc
rearrang
c
h
precursor
tetrahydrodicyclopentadien
albeit
isol
crude
oil
synthes
chemic
first
time
insecticid
properti
chloroadamantan
report
studi
adamantan
function
limit
adamantan
becam
wide
avail
schleyer
synthesi
synthes
adamantan
deriv
start
fuel
pharmaceut
studi
thereof
continu
date
review
concentr
numer
applic
medicin
chemistri
drug
develop
adamantan
deriv
singular
hydrocarbon
moieti
apart
methyl
group
success
rate
adamantan
improv
provid
pharmacolog
activ
bestsel
pharmaceut
lipophil
bullet
adamantan
often
view
provid
critic
lipophil
readili
avail
addon
known
pharmacophor
use
modif
e
g
hypoglycem
sulfonylurea
anabol
steroid
nucleosid
adamantan
modif
chosen
enhanc
lipophil
stabil
drug
therebi
improv
pharmacokinet
aminoadamantan
like
amantadin
rimantadin
tromantadin
among
first
hit
success
made
pharmaceut
market
still
use
date
remark
bottomofthelin
structur
effici
use
pharmaceut
also
led
improv
understand
molecular
mechan
underli
e
g
replic
influenza
virus
research
area
still
highli
fruit
exemplifi
numer
studi
interact
aminoadamantan
antiinfluenza
agent
target
ion
channel
electrophysiolog
nmr
techniqu
recent
xray
structur
drug
model
target
use
understand
aminoadamantan
mechan
action
molecular
level
also
address
increas
emerg
adamantaneresist
strain
influenza
recent
year
aminoadamantan
synthet
drug
inspir
natur
product
like
numer
drug
howev
also
isol
natur
incorpor
adamantan
motif
like
natur
marvel
tetrodotoxin
like
amantadin
also
block
ion
channel
sodium
channel
potent
pharmaceut
activ
may
least
part
attribut
rigid
dioxaadamantan
core
elabor
develop
pharmaceut
oxaadamantan
azaadamantan
heteroadamantan
could
view
inspir
natur
product
howev
also
natur
product
incorpor
adamantan
skeleton
also
display
interest
biolog
properti
review
focus
medicin
chemistri
parent
hydrocarbon
adamantan
deriv
describ
develop
adamantanebas
chemotherapeut
viral
infect
includ
influenza
herp
simplex
hepat
c
hiv
chapter
four
adamantan
deriv
use
antimalari
also
cover
emerg
adamantan
resist
strain
influenza
may
lead
end
use
aminoadamantan
infect
wherea
util
pronounc
lipophil
properti
adamantan
deriv
pharmaceut
neurolog
disord
still
prosper
focu
field
chapter
five
six
frequent
addit
adamantan
moieti
increas
permeabl
modifi
compound
bloodbrainbarri
therefor
target
cn
today
probabl
promis
academ
commerci
fortuit
find
amantadin
give
symptomat
benefit
parkinson
diseas
approv
memantin
ema
fda
treatment
moder
sever
stage
alzheim
diseas
two
neurodegen
diseas
increas
import
age
societi
address
structur
remark
simpl
adamantan
deriv
memantin
pharmacolog
properti
mechan
action
moder
noncompetit
nmdareceptor
antagonist
studi
extens
target
drug
develop
adamantan
deriv
cn
disord
ampaand
k
atp
channel
gabaerg
system
incorpor
adamantan
moieti
neuropeptid
relat
signal
molecul
frequent
give
increas
select
receptor
subtyp
enhanc
stabil
vivo
may
exemplifi
cck
deriv
equip
adamantan
core
emerg
file
respect
applic
adamantan
deriv
inhibit
enzym
use
adamantan
base
scaffold
cover
field
chapter
seven
import
dppiv
inhibitor
vildagliptin
saxagliptin
current
enter
multibillion
dollar
market
diabet
manag
exampl
enzym
target
adamantanebas
pharmaceut
solubl
epoxid
hydrolas
protein
phosphatas
hydroxysteroid
dehydrogenas
variou
enzym
target
function
adamantanebas
pharmaceut
demonstr
trend
toward
util
adamantan
scaffold
orient
co
pharmacophor
posit
benefici
enhanc
interact
target
activ
site
conclud
chapter
antibiot
natur
product
modifi
adamantan
core
reiter
concept
naturalproduct
inspir
pharmaceut
chapter
eight
add
discuss
three
class
adamantan
deriv
relev
cancer
research
addon
strategi
follow
adamantan
deriv
cisplatin
adaphostin
adamantyl
retinoid
repres
altern
rout
fight
cancer
cell
prolifer
adapalen
antiacn
drug
sold
hydrogel
also
cover
also
retinoid
origin
similar
research
conclud
remark
metabol
adamantan
base
pharmaceut
given
chapter
nine
though
present
review
grown
consider
length
make
still
far
complet
reason
breviti
could
describ
biolog
signal
cascad
life
cycl
virus
parasit
would
certainli
necessari
present
whole
pictur
target
hit
molecul
incorpor
adamantan
reader
refer
review
articl
case
likewis
three
review
smaller
scope
present
one
describ
adamantan
deriv
medicin
chemistri
alreadi
publish
one
revis
present
manuscript
affirm
convict
topic
deserv
present
chemic
review
latest
review
articl
give
clogp
data
adamantyl
deriv
compar
nonadamantyl
analog
clearli
adamantan
present
test
drug
give
molecul
significantli
higher
lipophil
compar
molecul
proton
methyl
group
instead
adamantan
moieti
therefor
chosen
altern
approach
select
case
identifi
lowli
conform
respect
molecul
via
molecular
mechan
mmff
forc
field
conform
search
implement
avogadro
use
alogp
estim
logp
adamantan
deriv
analogu
bulki
lipophil
group
alogp
valu
given
squar
bracket
tabl
scheme
gener
alogp
number
support
convict
case
adamantan
valu
medicin
chemistri
ad
sever
logp
unit
given
pharmaceut
involv
molecular
properti
beyond
lipinski
classic
rule
five
adamantan
magic
bullet
certainli
lipophil
addon
tri
devis
review
natur
oldest
sourc
biolog
activ
substanc
extract
natur
sourc
tradit
fuel
medicin
chemistri
continu
date
one
exampl
natur
product
remark
biolog
activ
potent
toxic
principl
puffer
fish
tora
fugu
tetrodotoxin
scheme
ttx
elabor
chemic
architectur
craft
dens
oxygen
cyclohexan
framework
match
awesom
potenc
select
blocker
voltageg
na
ion
channel
select
potenc
compound
certainli
warrant
sever
factor
one
rigid
central
dioxaadamantan
skeleton
orient
multipl
function
group
fit
tightli
ion
channel
ttx
remain
challeng
synthet
organ
chemist
prototyp
tool
elucid
structur
function
target
ion
channel
muamvatin
first
trioxaadamantan
natur
product
could
extract
limpet
siphonaria
normali
caloundrin
b
siphonaria
zelandica
exampl
natur
product
incorpor
heteroadamantan
skeleton
natur
occur
trioxaadamantan
sed
properti
daigremontianin
extract
plant
orthoacet
structur
motif
reflect
synthet
class
bananin
compound
report
inhibit
replic
sar
corona
viru
heteroadamantan
strikingli
ansabananin
also
incorpor
azaadamantan
moieti
cover
detail
sinc
obvious
chemic
medicin
properti
compound
differ
markedli
adamantan
deriv
howev
also
compound
found
natur
incorpor
adamantan
hydrocarbon
scaffold
scheme
hypericum
sampsonii
guttifera
use
tradit
chines
medicin
centuri
treat
multitud
disord
includ
snakebit
swell
backach
diarrhea
activ
ingredi
yet
identifi
specif
isol
compound
sampsonion
plukenetion
isol
chemic
structur
elucid
investig
constitu
extract
variou
guttifera
identifi
polyprenyl
acylphloroglucinol
sourc
adamantan
deriv
via
secondari
cycliz
substitut
homoadamantan
sampsonion
ah
also
isol
plukenetion
first
isol
clusia
plukenetii
deriv
fruit
clusia
havetiod
var
stenocarpa
compound
ingredi
cuban
propoli
identifi
cytotox
panel
cell
line
differ
cancer
entiti
propoli
antimetastat
mous
model
meanwhil
antiretrovir
activ
report
total
synthesi
natur
product
recent
publish
interest
pharmaceut
activ
fuel
synthet
effort
core
scaffold
sampsonion
well
sampsonion
j
isol
test
cytotox
toward
cell
line
display
cytotox
cell
line
significantli
act
cytotox
likewis
hyperibon
k
isol
uzhbekistan
medicin
plant
hypericum
scrabum
show
moder
cytotox
two
human
cancer
cell
line
author
could
find
antihiv
activ
isol
clusia
obdeltifolia
interestingli
chapada
diamantina
region
brazil
bilog
test
compound
disclos
yet
hetero
adamantan
scaffold
might
play
decis
role
threedimension
adjust
pharmacophor
abovement
natur
product
naturalproduct
inspir
compound
clear
sheer
activ
drug
exert
fit
receptor
bind
pocket
activ
site
essenti
trigger
threedimension
structur
histor
describ
keylock
principl
nowaday
carri
monik
induc
fit
express
dynam
understand
receptorligand
interact
intrigu
relationship
drug
threedimension
structur
adm
characterist
drug
absorpt
e
g
digest
tract
bloodstream
distribut
system
ideal
enrich
target
tissu
depend
amongst
other
e
g
lipophil
structur
prodrug
concept
drug
carrier
design
guid
distribut
drug
frequent
util
metabol
excret
mainli
organicchem
process
drug
action
also
highli
depend
threedimension
structur
natur
design
central
scaffold
e
g
tetrodotoxin
improv
effici
medicin
chemistri
adamantan
deriv
regard
exampl
design
primarili
allsynthet
drug
achiev
ultim
goal
high
potenc
select
natur
product
hitherto
mention
stem
plant
anim
sourc
one
must
forget
adamantan
higher
diamondoid
least
undecamantan
found
trace
amount
raw
petroleum
therefor
natur
product
well
scheme
diamondoid
like
diamantan
triamantan
tetramantan
pentamantan
current
focu
interest
due
readi
access
select
function
yield
build
block
interest
e
g
nanotechnolog
electron
given
recent
reincarn
diamondoid
chemistri
remain
seen
whether
one
hydrocarbon
scaffold
start
career
build
block
medicin
chemistri
fruit
adamantan
fuel
new
widespread
avail
synthet
adamantan
deriv
schleyer
synthesi
parent
hydrocarbon
almost
spheric
lipophil
entiti
use
mainli
addon
known
pharmaceut
replac
lipophil
group
gerzon
et
al
replac
nbutyl
sidechain
popular
sulfonylurea
hypoglycem
drug
sometim
still
prescrib
today
tolbutamid
tabl
variou
hydrophob
residu
includ
sever
adamantan
deriv
compar
rel
potenc
compound
mark
increas
hypoglycem
activ
could
observ
along
longerlast
constant
activ
human
five
time
potent
tolbutamid
weight
basi
mark
decreas
potenc
vari
adamantan
substitu
strike
consid
mechan
action
tolbutamid
sulfonylurea
antidiabet
k
atp
channel
blocker
precis
fit
bind
pocket
sulfonylurea
receptor
sur
subunit
obvious
prerequisit
induct
channel
closur
lead
stimul
insulin
secret
pancreat
see
also
chapter
increas
lipophil
benefici
ovious
size
limit
lipophil
addon
exemplifi
sharp
decreas
potenc
deriv
ad
adamantan
moieti
anabol
steroid
report
group
research
eli
lilli
sinc
alreadi
known
esterif
group
steroid
increas
prolong
anabol
action
palmit
stearic
acid
ester
gave
long
durat
action
reduc
intens
acid
well
methyl
dimethl
deriv
studi
sulfonylurea
potenc
result
drug
strongli
depend
shape
adamantan
moieti
overal
lipophil
markedli
decreas
anabol
potenc
measur
weight
gain
muscl
immatur
male
castrat
rat
scheme
easili
avail
acid
similarli
straightforward
deriv
popular
addon
theraft
exampl
scheme
includ
adamantoyl
nucleosid
deriv
like
whose
increas
lipophil
crucial
medicin
applic
seri
adamantoyl
nucleosid
test
differ
anim
model
numer
disord
e
g
suppress
antibodi
format
antitumor
activ
cytotox
antivir
properti
inhibit
adenosin
deaminas
upon
search
applic
easili
avail
class
compound
crucial
influenc
actual
adamantyl
moieti
use
potenc
test
compound
observ
addit
acid
ester
moieti
gener
improv
compound
distribut
host
enhanc
metabol
stabil
minor
chang
like
addit
substitut
result
markedli
differ
potenc
test
compound
naphthoquinon
wellknown
class
antimalari
encourag
result
use
cyclohexyl
substitut
deriv
substitut
analog
n
prepar
test
plasmodium
berghei
infect
mice
without
success
due
signific
toxic
even
popular
pharmaceut
test
adamantan
addon
build
block
penicillin
give
adamantocilin
dopamin
furnish
dopamintin
recent
exampl
addon
strategi
modif
primari
pharmacophor
adamantan
lipophil
bullet
act
function
subunit
sometim
suitabl
describ
secondari
pharmacophor
includ
glycolipid
amongst
lipophil
residu
ethyl
group
util
modifi
potenc
compound
use
immunolog
adjuv
anoth
exampl
carbohydratederiv
core
structur
modifi
lipophil
bullet
eselectin
antagonist
deriv
tetrasaccharid
epitop
sialyl
lewi
x
scheme
adamantan
moieti
introduc
preorgan
pharmacophor
solut
therebi
lower
entrop
penalti
upon
receptor
bind
treatment
asthma
chronic
obstruct
pulmonari
diseas
antagonist
current
use
clinic
avail
prepar
inhal
twice
daili
consider
interest
improv
pharmacokinet
properti
drug
longer
act
compound
desir
compound
less
like
taken
oral
swallow
inhal
therefor
pharmacokinet
formeterol
deriv
studi
compound
display
excel
select
guinea
pig
tissu
assay
show
prolong
durat
action
vivo
guinea
pig
result
promis
compar
parent
compound
incorpor
adamantan
moieti
author
assign
intrins
poor
cell
permeabl
efflux
via
transport
protein
addit
show
low
microsom
stabil
group
describ
lipophil
tail
recent
util
gener
ligand
peroxisom
proliferatoractiv
receptor
ppar
transcript
factor
activ
fatti
acid
metabolit
ppar
heteodimer
retinoid
x
receptor
upon
ligand
bind
discuss
retinoid
receptor
bind
adamantan
deriv
detail
chapter
eight
heterodim
regul
gene
express
bind
peroxisom
prolifer
respons
element
specif
consensu
dna
sequenc
subtyp
play
pivot
role
lipid
lipoprotein
glucos
homeostasi
simultan
activ
three
subtyp
one
ppar
panagonist
attract
target
treatment
e
g
metabol
syndrom
steric
bulki
distal
benzen
ring
help
achiev
goal
ec
valu
cell
line
transient
transfect
chimer
receptor
nm
respect
gaucher
diseas
herit
lysosom
storag
diseas
caus
defici
lysosom
glucocerebrosidas
consequ
enzym
substrat
glucosylceramid
accumul
ultim
lead
pathogenesi
diseas
hydrophob
adamantyl
deoxynojirimycin
deriv
design
select
potent
inhibitor
nonlysosom
glucosylceramidas
activesitedirect
chemic
chaperon
nnonyldeoxynojirimycin
increas
activ
gaucher
diseas
associ
mutant
glucocerebrosidas
presum
stabil
proteasom
degrad
combin
isofagomin
moieti
activ
site
bind
primari
pharmacophor
hydrophob
alkyl
adamantyl
amid
appropri
linker
gave
small
molecul
scheme
increas
activ
glucocerebrosidas
mutant
patientderiv
fibroblast
use
increas
glucocerebrosidas
activ
observ
repres
highest
drug
potenc
cell
line
report
date
dock
studi
one
adamantan
deriv
also
perform
base
upon
xray
crystal
structur
glucocerebrosidas
nhexano
acid
adamantyl
amid
dnj
model
activ
site
figur
crystal
structur
data
indic
lipophil
cleft
proxim
activ
site
could
fill
adamantylamid
moieti
combin
pharmacophor
facilit
glucocerebrosidas
traffick
increas
activ
patientderiv
cell
line
metabol
glycosphingolipid
associ
atherogenesi
target
glycosphingolipid
metabol
adamantyl
pharmaceut
might
becom
use
also
field
atherosclerosi
underli
caus
death
western
countri
click
chemistri
introduc
triazol
base
linker
variabl
length
deoxynojirimycinand
adamantylcopharmacophor
recent
show
structur
finetun
act
collect
glycosidas
yet
anoth
target
shown
act
corrector
defect
mutant
cystic
fibrosi
transmembran
conduct
regul
cftr
everincreas
need
novel
antibiot
fuel
synthesi
gramicidin
analogu
incorpor
adamantyl
amino
acid
adamantyl
analog
scheme
promis
compound
abil
distinguish
specif
concentr
bacteria
mammalian
cell
sever
drug
drug
candid
discuss
follow
chapter
discov
follow
design
approach
exampl
given
addon
strategi
illustr
nice
import
aspect
adamantan
medicin
chemistri
size
approxim
spheric
shape
obvious
render
interact
favor
mani
lipophil
bind
site
increas
potenc
modifi
drug
druglik
molecul
uniqu
lipophil
well
rel
chemic
stabil
ester
amid
posit
influenc
drug
pharmacokinet
properti
adamantan
easili
function
tertiari
posit
conveni
bromin
use
element
bromin
subsequ
substitut
function
first
strike
applic
simpl
monofunction
adamantan
deriv
medicin
chemistri
origin
clinic
trial
antivir
activ
hydrochlorid
amantadin
scheme
report
shown
previous
ammonium
ion
inhibit
influenza
viru
growth
tissu
cultur
identif
amantadin
antivir
regard
hit
random
screen
subsequ
research
tissu
cultur
chick
embryo
mous
model
confirm
amantadin
strong
activ
sever
strain
influenza
virus
low
toxic
level
ld
mice
mgkg
upon
oral
applic
two
strain
influenza
b
suscept
inhibit
amantadin
find
spark
synthesi
multitud
aminoadamantan
relat
structur
studi
antiinfluenza
agent
well
applic
viral
infecti
diseas
use
model
substrat
studi
mechan
underli
multipl
influenza
virus
target
know
exact
target
found
viru
penetr
host
cell
block
amantadin
caus
viru
remain
suscept
antibodi
inactiv
prolong
period
time
antivir
hit
hand
clinic
trial
numer
structur
variat
alongsid
lipophil
spheric
cage
hydrocarbon
amin
lead
structur
follow
report
display
even
stronger
antiinfluenza
japan
strain
properti
compar
amantadin
primari
calf
kidney
cell
cultur
assay
well
vivo
mice
ferret
guanidin
like
consid
attract
higher
basic
seri
eight
guanidin
prepar
amantadin
via
cyanamid
bear
structur
variat
nalkyat
nonalkyl
parent
structur
r
r
h
significantli
inhibit
influenza
multipl
vitro
vivo
compound
screen
influenza
swine
influenza
japan
strain
chick
embryo
fibroblast
cultur
testb
quantit
comparison
amantadin
show
amin
superior
guanidin
variat
hydrocarbon
moieti
also
perform
bicyclo
octan
amin
like
e
g
bicyclo
case
compar
slightli
higher
antiinfluenza
activ
amantadin
observ
screen
structur
divers
biolog
activ
compound
report
antivir
properti
influenza
influenza
strain
mice
confirm
activ
virus
amantadin
dl
noformicin
alkylamin
materi
lead
structur
compar
cyclooctylamin
amantadin
prove
activ
influenza
loma
strain
lower
concentr
scherm
peteri
prepar
four
n
acetylaminoadamantan
amantadin
via
acetyl
chloroacetylchlorid
subsequ
etherif
aminoethanol
measur
antivir
properti
simpl
plaqu
test
strongli
activ
influenza
virus
also
display
activ
herp
virus
vide
infra
continu
chase
antivir
screen
cage
amin
includ
nand
calkyl
adamantan
amin
methylamin
homoadamantan
amin
consist
structureactivityrelationship
sar
conclud
antivir
dose
avi
quantit
measur
activ
screen
compound
virusinfect
mice
influenza
swine
nsubstitut
compound
screen
none
significantli
higher
potenc
amantadin
increas
size
nsubstitu
activ
diminish
hold
true
function
group
incorpor
nsubstitu
substitut
tertiari
posit
adamantan
nucleu
amantadin
also
found
detriment
compound
antiinfluenza
activ
insert
bridg
one
carbon
amino
group
led
compound
gener
high
antivir
activ
rimantadin
outperform
amantadin
term
activ
alreadi
report
differ
test
setup
rimantadin
incorpor
stereogen
center
carbon
bridg
resolut
enantiom
via
diamid
tartranil
prove
enantiom
rimantadin
essenti
equipot
racem
compound
furthermor
expans
adamantan
skeleton
homoadamantan
provid
enhanc
activ
glycin
display
avi
compar
amantadin
replac
amino
group
amantadin
function
group
like
oh
sh
cn
co
h
cl
br
gave
inact
compound
taken
togeth
earli
find
support
concept
amino
group
act
primari
pharmacophor
assist
prefer
unsubstitut
adamantan
cage
appropri
distanc
act
secondari
pharmacophor
lead
pronounc
antiinfluenza
activ
synergist
manner
parent
compound
amantadin
approv
fda
prevent
treatment
influenza
infect
use
date
howev
see
sold
amantadin
symmetrel
symadin
compound
fdaapprov
market
rimantadin
flumadin
mostli
refer
adamantan
pharmacolog
studi
drug
recent
face
increas
resist
circul
influenza
strain
major
strain
includ
epidem
respond
adamantan
treatment
amantadin
rimantadin
longer
chemotherapi
choic
influenza
epidem
survey
remain
noteworthi
antiinfluenza
adamantan
introduc
success
util
clinic
without
know
target
ever
sinc
day
newli
synthes
amino
adamantan
deriv
test
respect
antivir
activ
adamantanon
readili
avail
larg
scale
antivir
adamantan
scheme
synthes
activ
sever
virus
vitro
plaqu
assay
influenza
japan
mice
studi
compar
amantadin
structur
similar
compound
nmethyl
deriv
three
time
activ
amantadin
vivo
also
show
broader
antivir
spectrum
vitro
test
small
nalkyl
substitu
gener
favor
cage
studi
author
bicyclo
deriv
structur
close
relat
amantadin
turn
activ
amantadin
testb
util
surprisingli
antivir
activ
could
measur
cyclohexan
deriv
alreadi
deduc
alkyl
adamantan
deriv
size
shape
hydrocarbon
copharmacophor
also
matter
spiro
compound
shown
diamantan
incorpor
bornaneor
hydrocarbon
moieti
variat
cage
hydrocarbon
gave
compound
less
activ
amantadin
vivo
sixand
sevenmemb
ring
analogu
spiro
compound
author
face
cytotox
problem
vitro
except
two
piperidin
deriv
antivir
activ
vivo
compar
better
compound
maleat
studi
greater
detail
includ
doubleblind
placebocontrol
clinic
prophylact
trial
human
volunt
regard
effici
amantadin
influenza
hong
kong
studi
potenc
challeng
viru
strain
like
amantadin
quit
ineffect
influenza
b
virus
inhibit
growth
number
influenza
strain
vitro
rhino
virus
albeit
antirhino
viru
activ
could
confirm
man
anoth
doubleblind
placebo
control
trial
volunt
challeng
influenza
examin
suitabl
therapeut
agent
evid
toxic
effect
test
drug
observ
gener
observ
reduct
sever
symptom
signific
new
adamantan
deriv
regard
adamantyl
analog
correspond
drug
eg
halid
alcohol
keton
carboxyl
acid
ester
amid
nitril
etc
subsequ
screen
compar
known
adamantan
deriv
two
vitro
assay
use
newcastl
diseas
viru
novel
compound
reportedli
activ
amantadin
although
particular
function
group
establish
biolog
activ
cytotoxicieti
compound
usual
parallel
antivir
activ
activ
cytotox
appear
similar
concentr
essenti
hold
true
deriv
trimethylenenorbornan
undecan
deriv
use
vitro
testb
number
n
thiourea
eg
also
prepar
screen
influenza
bethesda
mice
significantli
increas
surviv
time
anim
challeng
viru
later
thiourea
also
studi
vitro
test
adamantyl
thiourea
furthermor
show
activ
number
virus
sinc
adamantyl
thiourea
proven
activ
vivo
low
toxic
small
librari
nine
synthes
quantit
antivir
activ
three
mice
challeng
influenza
asian
strain
compound
shown
compar
favor
amantadin
respect
activ
toxic
furthermor
caus
reduc
level
cn
relat
side
effect
produc
mild
tremor
ataxia
anim
high
dose
mg
kg
ip
resembl
result
mention
polycycl
imidazol
like
nmethyl
analog
identifi
activ
influenza
victoria
chick
embryo
vitro
assay
antiinfluenza
activ
even
cage
amin
studi
compar
amantadin
bicyclo
potent
amantadin
trishomocuban
activ
amantadin
low
level
cytotox
detail
review
laboratori
clinic
data
amantadin
antivir
activ
develop
antivir
cage
amin
main
achiv
earli
day
chemotherapi
antiinfluenza
prophylaxi
treatment
correl
known
life
cycl
viru
molecular
level
known
amantadin
analogu
inhibit
earli
step
viru
reproduct
uncoat
step
must
made
clear
precis
point
action
influenza
viru
replic
amantadin
molecular
term
known
detail
earli
stage
influenza
viru
infect
cell
unclear
therefor
point
action
inhibitor
act
amantadin
earli
stage
remain
unestablish
start
mechan
action
aminoadamantan
influenza
elucid
molecular
level
focu
chapter
stress
point
knowledg
drug
target
viru
protein
function
proton
channel
driven
synthesi
screen
drug
candid
small
molecul
could
accomod
target
protein
bind
site
time
aminoadamantan
particular
drug
amantadin
rimantadin
also
highli
use
model
substrat
discoveri
ion
channel
dynam
mechan
proton
conduct
concept
mind
aminoadamantan
motif
refin
focus
conform
propens
drug
candid
use
strong
antiinfluenza
potenc
start
point
vari
distanc
two
pharmacophor
anoth
seri
adamantan
deriv
synthes
start
adamantanon
spiro
scheme
activ
micromolar
concentr
stronger
antivir
assay
use
spiro
activ
mic
lower
concentr
amantadin
even
potent
potent
amantadin
expand
nitrogen
heterocycl
gave
spiro
inhibit
influenza
mic
concentr
time
lower
amantadin
control
experi
use
mdck
cell
line
close
relat
spiro
notabl
less
potent
likewis
conform
somewhat
flexibl
rimantadin
analog
also
activ
rang
mic
like
gold
standard
amantadin
find
much
surpris
consid
close
structur
relationship
molecul
ident
mechan
action
rang
virus
also
studi
compound
display
borderlin
antihiv
activ
see
chapter
take
closer
look
adamantyl
piperidin
author
subsequ
studi
piperidin
like
unsubstitut
parent
compound
r
h
time
activ
influenza
japan
mdckcell
base
assay
mic
cyclo
alkyl
analog
significantli
less
activ
combin
mdand
nmr
studi
author
conclud
probabl
due
chang
conform
piperidin
moieti
upon
nalkyl
pyrrolidin
screen
use
testb
likewis
potent
antiinfluenza
drug
candid
parent
compound
mic
time
activ
amantadin
nalkyl
abat
activ
significantli
howev
introduc
second
amino
function
via
dialkylaminoethyl
substitut
gave
diamin
strong
antiinfluenza
activ
mic
potent
benchmark
antivir
amantadin
rimantadin
one
major
drawback
addit
labori
chemic
synthes
compar
e
g
amantadin
compound
significantli
higher
cytotox
cell
base
assay
well
vivo
issu
address
part
compound
scheme
combin
peptid
fragment
known
immunomodulatori
activ
aminoadamantan
deriv
wellestablish
antiinfluenza
activ
display
compar
potenc
benchmark
amantadin
approxim
fourtim
lower
cytotox
mdck
cell
use
notabl
incorpor
residu
show
mic
influenza
amantadin
mic
incorpor
lgli
residu
display
mic
eight
time
higher
test
drug
candid
subtyp
hand
show
fourtim
activ
modifi
peptid
significantli
less
activ
amantadin
effect
size
nheterocycl
ring
rimantadin
analogu
studi
next
work
begun
pyrrolidin
subsequ
extend
screen
amongst
aminoadamantan
piperidin
azepin
close
rel
potent
amantadin
influenza
japan
homolog
incorpor
sevenmemb
heterocycl
ring
turn
significantli
less
potent
increas
cytotox
reiter
rimantadinederiv
polycycl
author
prepar
pyrrolidin
azetidin
analog
aziridin
deriv
mdck
cell
base
assay
compound
show
reduc
heterocycl
ring
size
fivememb
pyrrolidin
threememb
aziridin
gave
test
drug
decreas
potenc
notic
numer
adamantan
amin
earlier
nmethyl
also
detriment
antiinfluenza
potenc
test
drug
ec
low
micromolar
rang
mean
potent
amantadin
rimantadin
assay
cytotox
also
much
higher
final
minim
cytotox
concentr
ec
reiter
bisamino
adamantan
deriv
studi
librari
substitut
di
amino
deriv
report
piperidin
well
bispiperidin
potent
amantadin
strikingli
morpholin
half
potent
gold
standard
use
benchmark
cellbas
assay
move
heterocycl
nitrogen
atom
one
posit
cf
screen
spiro
along
spiro
resembl
close
observ
made
test
compound
potent
amantadin
rimantadin
albeit
test
slightli
differ
testb
use
influenza
hong
virus
mdck
cell
structur
furthermor
display
good
activ
trypanosoma
brucei
see
chapter
nmethyl
caus
dramat
reduct
compound
antiinfluenza
activ
repres
anoth
recent
studi
class
aminoadamantan
design
screen
antivir
ring
system
also
studi
potenc
along
mark
decreas
activ
nalkyl
compar
amantadin
antiinfluenza
activ
nethyl
deriv
less
potent
amantadin
confirm
sar
previou
public
focus
adamantyl
piperidin
differ
potenc
piperidin
strike
higher
potenc
influenza
hong
rel
amantadin
isom
inact
concentr
rang
studi
probabl
due
conform
ammonium
ion
nhpharmacophor
requir
interact
transmembran
domain
push
equatori
orient
therebi
distort
possibl
interact
favor
via
hydrogen
bond
amino
pharmacophor
howev
import
strong
antiinfluenza
activ
recent
exampl
studi
focus
variat
within
hydrocarbon
copharmacophor
conclud
survey
amino
deriv
noradamantan
one
close
resembl
amantadin
show
antiinfluenza
activ
concentr
rang
like
adamantan
deriv
smaller
bisnoradamantan
less
potent
numer
amino
deriv
adamantan
polycycl
hydrocarbon
cage
relat
shape
size
screen
date
present
herein
summar
four
decad
sar
demonstr
two
copharmacophor
bulki
hydrocarbon
amino
group
optim
gain
best
potenc
time
minor
stereoelectron
conform
chang
strongli
influenc
drug
block
proton
channel
also
demonstr
compar
antivir
potenc
respect
brethren
time
potent
amantadin
time
potent
rimantadin
significantli
less
potent
amantadin
along
increas
occur
resist
current
circul
strain
influenza
includ
avian
flu
well
swine
flu
research
field
also
seem
reach
limit
maximum
potenc
test
compound
date
justifi
introduct
anoth
aminoadamantan
amantadin
rimantadin
also
consid
toxic
data
well
labori
synthesi
structur
somewhat
complex
compound
sar
aminoadamantan
relat
cage
amin
address
resist
howev
still
field
research
activ
pursu
exemplifi
scheme
influenza
strain
resist
adamantan
carri
mutat
transmembran
domain
ringcontract
ringexpand
amantadin
deriv
envisag
valuabl
inde
bisnoradamantan
deriv
could
shown
inhibit
mutant
ion
channel
express
xenopu
oocyt
plaqu
reduct
assay
corrobor
electrophysiolog
measur
face
pauciti
antiinfluenza
drug
target
still
seem
role
classic
adamantan
amantadin
rimantadin
antivir
chemotherapi
influenza
dual
resist
develop
also
neuraminidas
inhibitor
oseltamivir
furthermor
comparison
actual
clinic
efficaci
amantadin
neuraminidas
inhibitor
gave
similar
potenc
two
class
chemotherapeut
least
swine
flu
monitor
genet
sequenc
obvious
fulli
suffic
reflect
sensit
circul
well
pandem
influenza
strain
aminoadamantan
swine
flu
report
resist
amantadin
yet
later
found
sensit
amantadin
mutat
protein
modul
ion
channel
proton
conduct
mildli
togeth
find
tripl
antiinfluenza
chemotherapi
util
ribavirin
neuraminidas
inhibitor
oseltamivir
blocker
amantadin
synergist
superior
vivo
treatment
singl
drug
dual
combin
tripl
combin
significantli
suppress
breakthrough
resist
viru
vitro
still
might
clinic
relev
adamantan
fight
influenza
mechan
action
block
channelin
earli
year
follow
discoveri
amantadin
antiinfluenza
activ
structur
variat
sar
perform
without
even
know
target
drug
known
aminoadamantan
inhibit
viru
replic
earli
step
infect
name
penetr
host
cell
viru
particl
releas
viral
rna
hay
cowork
analyz
suscept
genet
reassort
influenza
obtain
coinfect
amantadineresist
isol
sensit
one
gene
encod
channel
amantadinesensit
parent
strain
requir
sensit
reassort
gene
alon
found
determin
differ
amantadin
sensit
character
drugresist
mutant
determin
natur
locat
amino
acid
substitut
pinpoint
precis
primari
target
drug
action
protein
author
conclud
studi
infrequ
occur
chang
sequenc
influenza
haemagglutinin
ha
amantadineresist
strain
viru
lack
correl
mutat
sequenc
chang
protein
rule
possibl
ha
mutat
would
play
role
determin
adamantan
resist
howev
indirect
effect
protein
mode
oper
ha
matur
function
direct
evid
function
protein
group
attribut
indirect
effect
function
protein
ha
found
capabl
modul
ph
compart
exocyt
pathway
contribut
togeth
protect
integr
acid
sensit
ha
promot
matur
activ
ha
conform
shortli
thereaft
discov
alter
amino
acid
sequenc
transmembran
domain
protein
abrog
antiinfluenza
activ
amantadin
mrna
inject
oocyt
xenopu
laevi
induc
express
amantadinesensit
ion
channel
studi
via
twoelectrod
voltag
clamp
oocyt
express
wildtyp
bath
solut
contain
amantadin
show
ion
channel
activ
wherea
oocyt
express
mrna
amantadineresist
strain
influenza
found
display
ion
channel
activ
littl
influenc
amantadin
bath
solut
furthermor
amplitud
conduct
channel
oocyt
express
wildtyp
protein
could
modul
ph
thu
although
final
proof
channel
activ
requir
purif
reconstitut
protein
artifici
bilay
data
report
taken
togeth
provid
strong
evid
influenza
viru
protein
bona
fide
ion
channel
author
conclud
role
ion
channel
activ
part
replic
cycl
viru
identifi
time
respons
elev
ph
transgolgi
network
viru
infect
cell
elev
lumin
ph
allow
passag
ha
glycoprotein
larg
determin
infect
newli
synthes
viru
particl
without
acid
convers
antivir
drug
amantadin
rimantadin
present
channel
would
abl
perform
function
ha
molecul
would
prematur
undergo
conform
chang
prevent
format
infect
viru
particl
test
hypothesi
proton
channel
transmembran
domain
residu
protein
viral
protein
even
fulllength
function
form
short
residu
synthes
incorpor
voltageclamp
planar
lipid
bilay
amantadin
appli
side
artifici
membran
abl
block
channel
form
transmembran
peptid
tm
within
second
use
oocyt
model
system
channel
found
sensit
amantadineand
rimantadineblock
extent
howev
electrophysiolog
studi
could
rule
adamantylamin
act
alloster
physic
block
pore
form
four
helic
protein
transmembran
domain
instead
act
outsid
fourhelix
bundl
form
function
proton
channel
util
neutron
diffract
deuter
tm
peptid
well
deuter
amantadin
use
studi
locat
interact
two
molecul
dopc
multilay
membran
model
three
differ
tm
peptid
residu
fulllength
studi
amantadin
found
resid
nm
center
model
lipid
bilay
correspond
area
around
residu
consist
concept
steric
blockag
within
ion
channel
interact
found
studi
tm
peptid
correspond
amantadineresist
strain
find
consid
cleancut
evid
mechan
action
aminoadamantan
antivir
howev
tempt
vide
infra
reconstitut
influenza
tmd
lipid
bilay
consid
mileston
studi
protein
signific
pharmacolog
target
achiev
found
previous
amantadin
reduc
rate
fusion
influenza
virion
liposom
viral
strain
sensit
drug
late
effect
vide
infra
amantadin
replic
cycl
prematur
conform
chang
ha
time
transport
transgolgi
network
tgn
lowph
conform
ha
infecti
highph
conform
therefor
ion
channel
within
tgn
act
keep
ph
tgn
lumen
threshold
lowph
conform
chang
reconstitut
protein
planar
bilay
membran
found
regul
ph
channel
open
low
ph
close
high
ph
regul
voltag
block
aminoadamantan
antivir
sourc
strain
amantadin
sensit
display
substanti
ion
select
point
mechan
action
precis
molecular
level
still
date
subject
debat
presum
mechan
amantadin
cork
plug
bottl
precis
enough
explain
find
studi
use
variou
model
experiment
techniqu
demand
precis
model
channel
evid
coexpress
mix
oligom
viru
strain
amantadin
resist
amantadin
sensit
stoichiometri
activ
ion
channel
studi
precis
whole
surfac
current
oocyt
use
measur
electrophysiolog
treatment
amantadin
indic
function
channel
inde
homotetram
normal
replic
cycl
influenza
protein
incorpor
new
virion
correspond
function
ion
channel
model
cy
scan
tm
togeth
electrophysiolog
xenopu
oocyt
shed
light
proton
conduct
need
ph
adjust
function
model
gener
util
techniqu
suggest
fourhelix
bundl
reminisc
fourstrand
coil
coil
central
structur
featur
function
proton
channel
import
phactiv
channel
conduct
nativ
channel
also
stabil
intermolecular
disulfid
bond
phdepend
associ
amantadin
bind
peptid
correspond
transmembran
domain
bind
amantadin
shift
monomertetram
equilibrium
toward
tetramer
speci
studi
dodecylphosphocholin
micel
tetramer
amantadin
bind
favor
higher
ph
pk
associ
side
chain
therefor
author
suggest
drug
compet
proton
bind
residu
via
hydogen
bond
therebi
stabil
tetram
slightli
alter
conform
structur
chang
upon
interact
drug
monitor
amongst
techniqu
studi
ph
depend
trp
fluoresc
drug
present
absent
purifi
fulllength
mutant
synthes
recombinantli
e
coli
use
tetram
phdepend
structur
chang
could
observ
particular
fluoresc
import
part
highli
conserv
hxxxw
motif
protein
shown
quench
ph
quench
could
revers
rimantadin
drug
seem
prevent
proton
phdepend
chang
environ
specif
inhibit
proton
channel
activ
rimantadin
demonstr
earli
sar
call
larg
hydrophob
cage
amin
could
confirm
furthermor
titrat
rimantadin
influenc
fluoresc
amantadinesensit
wildtyp
protein
ph
clearli
show
stoichiometri
drug
function
tetram
reduct
flouresc
ph
could
block
rimantadin
appear
due
quench
fluoresc
busath
cowork
report
singlechannel
proton
current
use
fulllength
protein
reconstitut
planar
lipid
bilay
channel
found
form
highli
select
proton
channel
low
probabl
open
partial
block
amantadin
singlechannel
conduct
found
ps
probabl
channel
open
state
function
ion
channel
review
display
main
featur
confirm
util
aminoadamantan
amantadinesensit
well
amantadineresist
model
system
one
helix
loop
common
influenza
channel
influenza
b
channel
conserv
hxxxw
motif
critic
ion
channel
activ
form
select
filter
wherea
tetrad
form
gate
mechan
channel
inhibit
aminoadamantan
deduc
amantadin
resist
mutant
mutat
lead
drug
resist
presum
introduc
less
lipophil
residu
aqueou
pore
channel
inhibit
channel
occur
readili
elev
ph
aminoadamantan
inhibit
appli
ntermin
ectodomain
furthermor
neutron
diffract
could
shown
amantadin
lie
outer
region
artifici
membran
togeth
ratio
rimantadin
tetram
find
show
aminoadamantan
act
outsid
aqueou
pore
adamantan
copharmacophor
interact
favor
lipophil
residu
line
insid
channel
perhap
ammonium
hydrogen
involv
interact
tetrad
still
probabl
whole
stori
interact
finetun
subtl
conform
chang
upon
drugtarget
interact
mutat
render
drug
resist
also
seem
play
major
role
next
mileston
experiment
detect
highresolut
structur
function
model
proton
channel
came
structur
model
influenza
backbon
structur
block
amantadin
deriv
ssnmr
constraint
data
transmembran
domain
peptid
littl
direct
interact
drug
could
observ
drugresist
mutat
show
signific
chang
backbon
structur
compar
nativ
drugsensit
sequenc
upon
drug
bind
nmr
data
indic
signific
chang
structur
drug
sensit
model
peptid
chang
amantadineresist
tm
peptid
mutant
author
conclud
amantadin
bind
mutant
note
tetramer
channel
structur
model
gener
structur
data
deriv
one
helix
seri
rigidbodi
transform
monom
subunit
group
also
studi
influenc
amantadin
bind
tm
term
chemic
dynam
properti
bind
drug
lower
pk
valu
three
order
magnitud
strongli
interf
channel
main
function
proton
conduct
structur
tm
residu
high
ph
absenc
drug
dynam
structur
heterogen
compar
amantadinebound
structur
furthermor
addit
report
chang
bind
drug
molecul
also
seem
prevent
format
lowbarri
hydrogen
bond
residu
differ
helic
suggest
amantadineblock
base
sole
upon
steric
hindranc
instead
mechan
interfer
hisfacilit
proton
transport
channel
pore
f
nmr
use
resolv
first
time
reson
complex
fluorin
amantadin
scheme
tm
residu
udorn
strain
peptid
complex
studi
dodecylphosphocholin
dpc
micel
earlier
work
lineshap
h
reson
util
found
give
reson
broad
detect
ph
openchannel
bind
amantadin
channel
expect
occur
use
f
nmr
could
circumv
author
found
homotetram
fluorin
tm
model
peptid
appear
ph
unit
ph
threshold
report
use
cd
spectroscopi
experiment
method
conclud
ph
tm
peptid
adopt
neutral
tertramer
form
capabl
bind
drug
high
enough
affin
observ
chang
nmr
spectra
anoth
ssnmr
studi
transmembran
peptid
aim
elucid
atom
resolut
conform
dynam
conduct
dlpc
bilay
without
amantadin
present
focu
lay
conform
chang
within
transmembran
domain
interact
drug
take
place
monitor
use
magic
angl
spin
ma
cand
n
nmr
techniqu
compar
conclus
drawn
amantadin
affect
protein
chang
distribut
exchang
rate
lowenerget
conform
whera
averag
conform
orient
seem
subtli
modifi
signific
structur
perturb
upon
amantadin
bind
could
observ
backbon
well
sidechain
give
strongest
chang
chemic
shift
mutat
residu
known
give
increas
amantadin
resist
apopeptid
backbon
undergo
signific
motion
timescal
bind
amantadin
alter
motion
rate
reduc
conform
distribut
one
decis
featur
tm
structur
model
environ
therefor
appear
presenc
multipl
lowli
conform
modifi
select
via
amantadin
bind
conform
plastic
seem
essenti
proton
conduct
channel
gate
mechan
well
least
part
amantadin
mechan
action
attribut
modifi
select
influenc
conform
distribut
given
abovement
nmr
find
observ
fluoresc
quench
attempt
screen
seri
adamantan
deriv
pure
vitroassay
seri
studi
amongst
number
adamantan
deriv
gave
bind
constant
purifi
fulllength
protein
isol
weybridg
strain
influenza
viru
compar
bind
amantadin
scheme
compound
howev
rel
bind
affin
directli
compar
rel
antivir
potenc
obtain
cell
cultur
author
conclud
observ
rel
potenc
cellbas
assay
due
pure
interact
drug
candid
target
protein
complex
bind
site
also
way
get
mean
membran
diffus
recent
elucid
highresolut
structur
model
system
solut
via
nmr
method
via
xray
crystallographi
without
aminoadamantan
drug
present
fuel
intens
debat
concern
precis
mechan
action
aminoadamantan
howev
seem
settl
today
xray
structur
transmembranespan
region
protein
tetramer
form
report
degrado
cowork
figur
panel
c
obtain
high
resolut
data
seri
peptid
correspond
transmembran
domain
use
model
system
mutant
selenomethionin
instead
could
use
crystal
six
molecul
deterg
form
bilayerlik
environ
cocrystal
amantadin
lower
ph
differ
model
peptid
incorpor
mutat
util
cocryst
drug
amantadin
surround
residu
mutat
clinic
influenza
isol
drug
resist
drugbind
site
within
tetram
tm
peptid
found
nearli
ident
two
structur
without
drug
molecul
residu
howev
includ
residu
respons
phdepend
gate
channel
amantadin
amino
group
orient
toward
directli
touch
via
hbond
imidazolresidu
author
furthermor
model
import
mutat
influenza
respons
widespread
amantadin
resist
model
pore
base
upon
xray
data
asn
residu
amantadineresist
mutant
lead
chang
size
polar
amantadin
bind
site
retard
h
conduct
author
conclud
crystallograph
structur
excel
agreement
wide
bodi
function
spectroscop
data
provid
basi
design
new
inhibitor
target
amantadineresist
mutant
inhibitor
target
caviti
adjac
highli
conserv
residu
might
reclaim
block
class
drug
prophylaxi
treatment
ongo
epidem
outbreak
futur
pandem
deadli
pathogen
backtoback
issu
natur
schnell
chou
report
anoth
highresolut
structur
model
system
model
base
upon
differ
construct
protein
residu
mutat
peptid
incorpor
unstructur
nterminu
transmembranehelix
flexibl
loop
region
ctermin
amphiphat
helix
model
peptid
form
stabl
tetram
dihexanoylphosphatidylcholin
dhpc
deterg
micel
tetram
presenc
without
channelblock
rimantadin
studi
mean
nmr
techniqu
ph
analyz
intermolecular
drug
noe
assign
bind
site
rimantadin
molecul
adjac
helic
cterminu
transmembran
domain
proxim
gate
residu
figur
panel
f
total
four
molecul
rimantadin
bind
four
equival
site
side
helic
face
lipid
layer
therebi
destabil
close
conform
pore
unexpect
find
could
explain
sar
observ
made
mani
year
like
degrado
cowork
schnell
chou
also
discuss
role
amantadineresist
mutant
mutat
assign
helixhelixpack
interfac
wherea
mutat
directli
affect
porelin
sidechain
drugresist
mutat
seem
counter
effect
drug
bind
model
system
either
provid
hydrophil
residu
pore
weaken
pack
four
transmembran
helic
therebi
facilit
channel
open
corkpluggingthebottl
model
suffici
explain
result
conclud
instead
propos
alloster
mechan
action
aminoadamantan
class
drug
drugbind
make
channel
harder
open
ph
chang
mutat
turn
destabil
close
channel
make
easier
open
counter
effect
aminoadamantan
model
could
advantag
drug
design
drug
larger
hydrat
ion
overcom
higher
energet
barrier
find
bind
site
insid
pore
bind
channel
complex
membranefac
outsid
degrado
group
comment
find
state
schnell
chou
model
structur
repres
biolog
relev
close
form
channel
unabl
bind
amantadin
central
caviti
highresolut
structur
howev
model
necessarili
limit
describ
truth
use
fragment
protein
studi
model
bilay
micel
differ
ph
channel
verifi
function
proton
channel
respect
environ
two
group
use
differ
antivir
drug
model
compound
degrado
group
subsequ
studi
electrophysiolog
effect
mutat
lead
drug
resist
ion
channel
activ
studi
sightli
longer
model
peptid
use
residu
addit
put
closer
model
fulllength
structur
function
peptid
also
contain
cy
residu
play
signific
role
form
function
tetramer
channel
via
intermolecular
disulfid
bond
furthermor
function
assay
use
fulllength
mutant
sequenc
variant
shown
thermodynam
stabl
lipid
micel
yet
effect
mutat
stabil
correl
model
environ
mutat
channel
stay
activ
sensit
amantadin
diminish
obviou
contradict
alloster
model
compar
ion
channel
activ
variou
mutant
express
xenopu
laevi
oocyt
specif
proton
channel
activ
mutant
found
time
activ
wildtyp
amantadineresist
channel
addit
two
mutant
resist
amantadin
wildtyp
channel
alloster
model
ask
similar
chang
conduct
characterist
consequ
electrophysiolog
result
agre
better
xray
structurebas
model
amantadin
bind
pore
channel
even
nmrbase
model
schnell
chou
seem
weak
stoichiometri
drug
bind
aminoadamantan
tetram
conclud
experiment
data
locat
mutat
confer
drug
resist
mostli
close
nterminu
transmembran
part
wherea
nmr
model
drug
bind
close
cterminu
transmembran
domain
furthermor
function
studi
degrado
group
mutat
residu
predict
part
alloster
drug
bind
site
interfer
strongli
amantadin
blockag
channel
bind
kinet
slow
also
favor
alloster
inhibit
model
even
nmr
structur
appear
unfil
site
within
channel
could
accomod
amantadin
rimantadin
matter
conclus
author
suggest
alloster
site
nmr
base
structur
model
secondari
site
come
play
certain
condit
like
close
channel
occur
extens
molecular
dynam
perform
transmembran
domain
peptid
without
amantadin
prototyp
activ
drug
shortli
suggest
residu
form
secondari
gate
channel
primari
gate
one
form
sidechain
along
residu
role
hydrophob
sidechain
interrupt
water
wire
insid
channel
upon
amantadin
bind
waterfre
region
expand
therebi
block
proton
conduct
md
simul
confirm
amantadin
bind
site
found
earlier
neutron
diffract
data
form
mainli
residu
amantadin
predict
separ
three
layer
water
proton
relay
primari
proton
gate
hxxxw
recent
studi
via
f
ssnmr
nativ
lipid
environ
aminoadamantan
block
studi
work
studi
transmembran
domain
peptid
lipid
bilay
mean
ssnmr
techniqu
without
amantadin
present
drug
seem
chang
averag
structur
channel
much
spectral
linewidth
narrow
upon
interact
drug
indic
druginduc
chang
protein
dynam
membran
among
residu
show
largest
druginduc
chang
chemic
shift
conform
dynam
conform
disord
residu
therefor
may
amantadin
bind
site
via
hbond
drug
amino
group
md
simul
base
upon
ssnmr
data
transmembran
domain
peptid
popc
bilay
aim
better
understand
amantadin
resist
author
put
focu
bind
site
drug
insid
channel
alloster
model
channel
inhibit
pielak
schnell
chou
focus
alloster
model
particular
bind
site
aminoadamantan
use
nmr
method
mutat
construct
analyz
compar
wildtyp
structur
report
earlier
mutat
littl
effect
pore
structur
hand
mutat
lead
drugresist
circul
virus
led
reduc
bind
observ
via
nmr
model
system
consequ
drugresist
mutant
seem
impair
alloster
drugbind
destabil
helixhelixassembl
directli
interact
rimantadin
degrado
cowork
dicuss
interact
amantadin
function
analysi
liposom
proton
influx
measur
variou
mutant
also
perform
relev
alloster
bind
site
locat
outsid
pore
within
membran
discuss
rimantadin
use
peptid
model
low
phstructur
vide
supra
recent
challeng
find
report
cadi
et
al
use
clabel
peptid
reconstitut
dmpc
vesicl
ssnmr
method
studi
bind
perdeuter
amantadin
high
resolut
differ
drug
peptid
ratio
high
concentr
drug
author
could
detect
bind
aminoadamantan
outsid
channel
highaffin
site
insid
pore
still
occupi
drug
alreadi
amantadin
peptid
ratio
reflect
previous
report
bind
stoichiometri
furthermor
c
h
redor
studi
shed
light
primari
site
within
lumen
indic
amantadin
hydrocarbon
moieti
fit
snugli
ntermin
lumen
amino
group
like
orient
toward
caviti
near
alreadi
postul
earlier
author
howev
found
amantadin
structur
perfectli
optim
channel
pore
thu
suggest
chanc
design
channel
blocker
enhanc
affin
sinc
bind
site
involv
conserv
amino
acid
influenza
novel
drug
lipid
bilay
dodecylphosphocholin
dpc
micel
also
support
insid
bind
mode
amantadin
rimantadin
report
rimantadin
methyl
group
found
proxim
backbon
result
better
spacefil
drug
molecul
consequ
higher
affin
pore
compar
amantadin
compar
amantadin
rimantadin
bind
nmr
studi
suggest
rimantadin
slightli
differ
equilibrium
constant
highaffin
pore
bind
site
alloster
bind
mode
still
design
better
spacefil
inhibitor
could
becom
feasibl
base
upon
data
particular
molecul
better
fill
channel
amantadinesensit
amantadineresist
channel
support
alloster
action
aminoadamantan
outsid
membranefac
bind
tetram
vanish
base
upon
md
simul
use
crystal
structur
data
start
point
studi
proton
state
tetrad
membranebound
transmembran
domain
bound
amantadin
insid
tetramer
bundl
signific
affin
adamantan
extern
bind
site
close
found
extern
bind
report
high
concentr
aminoadamantan
drug
correspond
secondari
bind
pharmacolog
relev
transportertyp
mode
proton
conduct
channel
gate
tetrad
suggest
least
part
explain
two
slightli
differ
bind
mode
insid
channel
plastic
channel
requir
action
proton
pump
highli
depend
drug
bind
also
environ
model
chosen
exemplifi
e
g
membran
thick
likewis
structur
detect
deterg
micel
might
signific
differ
found
lipid
bilay
valid
model
chosen
studi
dynam
pharmacolog
block
therefor
requir
scutini
end
influenza
truncat
model
system
studi
via
ssnmr
techniqu
subsequ
function
reconstitut
lipid
bilay
display
normal
function
term
proton
flux
activ
amantadin
sensit
proton
select
detail
comparison
avail
structur
data
freeenergi
calcul
base
upon
md
simul
indic
porebind
mode
kcalmol
favor
channel
surfacebind
alloster
mode
aminoadamantan
bind
site
pore
aqueou
caviti
adjac
channel
filter
channel
blocker
amantadin
rimantadin
complet
crowd
water
molecul
insid
channel
role
residu
water
molecul
insid
aminoadamantan
complex
studi
base
upon
highresolut
xray
data
water
cluster
insid
channel
also
studi
via
method
show
characterist
proton
transduct
relev
water
flow
channel
open
state
upon
proton
imidazol
new
conform
develop
allow
water
insid
channel
becom
liquid
enabl
diffus
proton
viru
interior
precis
mechan
proton
transport
virion
also
monitor
fluoresc
correl
spectroscopi
one
breath
transporterlik
behavior
channel
take
bound
drug
molecul
occlud
channel
block
breath
solidst
nmr
studi
later
focus
amantadin
block
proton
flux
channel
bind
amantadin
suppress
proton
exchang
water
within
channel
upon
reorient
imidazol
ring
ssnmr
measur
show
pharmacolog
relev
bind
site
aminoadamantan
drug
pore
transmembran
domain
time
use
fulli
function
model
system
dmpc
bilay
drug
bind
fulli
function
channel
model
addit
fragment
model
peptid
constitut
amphipath
cytoplasm
helic
modul
transmembran
domain
abil
bind
channel
inhibitor
aminoadamantan
combin
comput
method
experiment
verif
rational
channel
develop
resist
aminoadamantan
molecular
basi
put
forward
studi
amantadin
fit
snugli
bind
pocket
delimit
wildtyp
channel
drug
posit
charg
amino
group
therebi
abl
block
proton
conduct
electrostat
repuls
drug
resist
channel
either
display
mutat
larger
porelin
sidechain
inhibit
drug
bind
mutat
smaller
sidechain
like
lead
larger
bind
pocket
volum
drug
molecul
bound
inflat
site
remain
mobil
proton
flux
block
suffici
amino
group
perform
largescal
sequenc
analysi
mgene
influenza
viru
isol
oshitani
cowork
conclud
seem
suffici
select
pressur
aminoadamantan
antivir
influenza
gene
fulli
explain
widespread
amantadin
resist
observ
recent
year
strain
mutat
appear
human
popul
earli
decad
discoveri
introduct
amantadin
rimantadin
cluster
gene
mutat
residu
emerg
separ
late
differ
host
viru
subtyp
almost
simultan
could
relat
amantadin
use
gene
mutat
might
increas
genet
drift
instead
recent
isol
show
mutat
back
amantadinesensit
might
give
aminoadamantan
anoth
chanc
futur
conclus
survey
studi
aim
elucid
mechan
action
aminoadamantan
briefli
summar
recent
account
structureact
relationship
novel
compound
mechan
action
aminoadamantan
block
elucid
highresolut
structur
degrado
cowork
util
xray
base
model
inhibit
channel
aminoadamantan
bind
site
insid
pore
tertram
design
inhibitor
amantadineresist
mutant
ion
channel
start
structur
scheme
molecul
known
bind
insid
pore
author
design
test
number
channel
blocker
amantadin
resist
strain
influenza
competit
amantadin
support
bind
mode
aminoadamantan
lie
insid
outer
portion
channel
pore
spiro
undecan
like
found
promis
approach
amantadin
potenc
even
preliminari
screen
small
librari
compound
scheme
reason
seem
possibl
design
antivir
specif
amantadineresist
escap
mutant
influenza
hydrophob
critic
improv
antivir
activ
antiinfluenza
channel
blocker
replac
quaternari
carbon
spiran
amin
inhibitor
silicon
studi
inde
silanamin
steric
demand
found
abl
fill
extra
space
bind
pocket
gener
mutat
render
influenza
amantadin
resist
silaspiran
potent
carbon
analogu
block
wildtyp
potent
target
drug
resist
channel
similar
structureguid
consider
base
upon
md
simul
led
develop
spiranamin
also
target
previous
undrugg
channel
major
mutat
emerg
drug
pressur
longer
extend
drug
compar
amantadin
envis
fill
addit
volum
bind
site
gener
mutat
possibl
reach
closer
water
cluster
associ
respect
molecul
larger
amantadin
requir
still
abl
fit
wildtyp
bind
pocket
first
step
found
inhibit
ic
devoid
block
mutant
homolog
display
even
higher
block
capabl
biscycloheptyl
spiranamin
show
twofold
higher
potenc
amantadin
wildtyp
ic
mutant
diffus
densiti
upper
ring
spiranamin
channel
blocker
led
author
specul
bind
affin
consequ
channel
block
might
enhanc
modul
bulk
ring
end
synthes
spiroadamantan
scheme
inde
adamantan
motif
fill
extra
space
near
ala
amantadineresist
mutant
md
simul
wildtyp
mutant
amino
group
push
closer
tetrad
result
watermedi
hydrogen
bond
amino
group
sidechain
spiroadamantan
show
ic
lower
md
comput
homolog
model
suggest
similar
central
caviti
amantadin
resist
mutant
repect
surpris
also
found
highli
activ
find
corrobor
plaqu
reduct
assay
strikingli
origin
amantadin
resist
structurebas
design
novel
cage
amin
tackl
challeng
first
led
away
adamantan
motif
find
novel
adamantan
deriv
year
later
capabl
inhibit
influenza
replic
least
vitro
assay
conclus
amantadin
deriv
still
signific
impact
elucid
structur
dynam
ion
channel
block
minimalist
ion
channel
two
effect
replic
cyle
influenza
virus
infect
cell
earli
effect
concomit
fusion
endosom
viral
membran
mediat
haemagglutinin
ha
channel
enabl
acidif
viral
interior
insid
endosom
lead
uncoat
releas
ribonucleoprotein
viral
matrix
protein
final
nuclear
infect
late
effect
associ
channel
function
postgolgivesicl
acidif
vesicl
undesir
channel
counter
acidif
block
channel
detriment
viru
replic
replic
cycl
vastli
similar
compar
influenza
influenza
b
viru
moreov
influenza
b
also
encod
protein
featur
ion
channel
activ
bm
channel
influenza
influenza
b
bm
compar
recent
review
articl
base
upon
molecular
structur
dynam
share
decis
hxxxw
helix
loop
align
predict
transmembran
domain
show
bm
share
almost
sequenc
homolog
particular
polar
serin
residu
bm
present
posit
presum
porelin
figur
porelin
hydrophil
residu
would
reduc
affin
pore
bind
lipophil
cage
hydrocarbon
moieti
aminoadamantan
antivir
amantadin
rimantadin
time
enhanc
proton
channel
activ
actual
observ
bm
channel
bm
proton
flux
gradientdriven
channel
breath
mechan
outlin
briefli
probabl
h
transloc
mechan
employ
channel
consequ
chimer
channel
bm
transmembran
domain
likewis
block
aminoadamantan
occlud
channel
pore
approv
amantadin
rimantadin
note
latter
use
eastern
europ
major
achiev
combat
influenza
viru
genet
drift
render
class
drug
essenti
futil
still
play
signific
role
elucid
precis
molecular
mechan
target
ion
channel
compet
model
drug
bind
target
discuss
extens
studi
structur
biolog
led
current
consensu
molecular
mechan
action
aminoadamantan
primarili
channelocclud
process
howev
pictur
much
complex
model
peptid
membran
environ
model
setup
valid
care
howev
structur
mechanist
insight
gain
channel
block
aminoadamantan
shown
offer
opportun
design
new
drug
target
particular
adamantaneresist
strain
oddli
enough
research
againgav
adamantan
deriv
optim
lead
structur
remain
seen
whether
adamantan
deriv
reclaim
pivot
role
field
medicin
chemistri
mani
reason
believ
new
develop
obtain
accur
pictur
drug
inhibit
drug
resist
channel
lead
develop
specif
inhibitor
treat
influenza
infect
synthes
screen
new
aminoadamantan
deriv
antivir
one
earliest
target
virus
combat
chemotherapeut
herp
simplex
viru
hsv
one
strategi
synthes
nucleobas
analogu
introduc
viral
dna
within
dna
replic
dnapolymeras
respect
viru
termin
stop
dna
synthesi
anoth
strategi
inhibit
viral
polymeras
drug
work
former
mechan
aciclovir
zovirax
ganciclovir
scheme
follow
prodrug
approach
earlier
find
adamantanemodifi
nucleobas
deriv
ganciclovir
modifi
topic
applic
esterif
lipophil
carboxyl
acid
prototyp
acid
compar
bispropion
bisadamantanoyl
prodrug
addit
higher
lipophil
see
alogp
data
scheme
also
show
markedli
increas
stabil
acid
condit
facilit
formul
storag
enzymat
saponif
esteras
studi
tissu
homogen
found
rang
two
bisest
ad
benefit
lipophil
bisadamantanoyl
prodrug
consid
project
topic
applic
low
oral
bioavail
probabl
caus
extrem
low
aqueou
solubl
mgml
mgml
gml
anoth
class
compound
proven
effect
herp
simplex
ii
aminoadamantan
result
routin
screen
multitud
deriv
respect
activ
virus
influenza
dialkyl
ester
acid
like
dimethyl
dicarbam
scheme
report
show
degre
protect
herp
simplex
infect
mice
dinpropyl
deriv
howev
inact
scheme
synthes
part
sar
modif
alongsid
antiinfluenza
antivir
lead
structur
identifi
activ
herp
simplex
virus
plaqu
reduct
assay
amantadin
inact
tromantadin
show
disadvantag
pharmacolog
profil
term
acut
chronic
toxic
sensit
skin
irrit
anim
small
librari
compound
includ
synthes
test
establish
initi
sar
close
structureact
relationship
could
found
later
adamantan
carbam
motif
studi
identifi
ethyl
carbam
agent
antivir
activ
border
cytotox
mention
well
chapter
novel
aminoadamantan
frequent
screen
hsv
assay
well
spectacular
insight
mount
evid
tromantadin
sidechain
lipophil
adamantan
moieti
equal
import
antihsv
potenc
report
exot
strategi
combin
antiherpet
activ
calixaren
aminoadamantan
synthesi
antiherpet
activ
n
calix
aren
eg
report
recent
amantadin
identifi
show
symptomat
benefit
doubleblind
placebo
control
clinic
trial
group
patient
infect
herp
zoster
viru
caus
shingl
patient
treat
amantadin
significantli
shorter
durat
pain
mode
action
drug
unknown
herp
zoster
howev
caus
varicella
zoster
viru
albeit
belong
famili
herp
virida
constitut
differ
target
presum
requir
differ
chemotherapeut
howev
round
chapter
mention
studi
tromantadin
hydrochlorid
market
hydrogel
topic
treatment
recurr
infect
herp
simplex
appli
blister
appear
precis
mechan
action
still
unknown
despit
numer
studi
address
compar
clinic
trial
tromantadin
aciclovir
topic
treatment
recurr
herp
orofaciali
show
signific
differ
activ
two
drug
unlik
aciclovir
tromantadin
requir
viral
kinas
becom
activ
tromantadin
particularli
interest
treatment
aciclovirresist
strain
account
hsv
infect
rare
case
contact
dermat
occur
advers
effect
tromantadin
earli
attempt
elucid
tromantadin
moa
examin
time
event
requir
cell
fusion
induc
adamantanon
metabol
inhibitor
block
excess
fusion
infect
hsv
strain
appli
differ
time
point
inocul
two
differ
tissu
cultur
cell
type
ko
strain
viru
tromantadin
activ
well
cytotox
concentr
essenti
function
timepoint
drug
ad
conclus
author
believ
inhibitori
properti
tromantadin
herp
simplex
viru
multipl
show
earli
late
event
viru
reproduct
cycl
tromantadin
side
chain
seem
potenti
effect
studi
metabol
tromantadin
show
drug
elimin
unmodifi
also
see
chapter
confirm
drug
activ
compound
interact
tromantadin
amantadin
model
phospholipid
membran
examin
regard
work
hypothesi
tromantadin
moa
drug
believ
prevent
membran
fusion
hsv
virion
membran
plasma
membran
therefor
balanc
hydrophobichydrophil
group
size
regard
crucial
like
peptidederiv
antivir
cyclosporin
stabil
bilay
phase
biomembran
tromantadin
similar
effect
wherea
amantadin
perturb
model
bilay
next
inhibit
cellcel
fusion
tromantadin
also
inhibit
syncytium
format
seem
affect
synthesi
protein
requir
fusion
summari
tromantadin
antiherpet
adamantan
deriv
appar
least
part
exert
activ
influenc
fusion
assembl
lipid
membran
respect
interest
aspect
respect
moa
tromantadin
report
recent
adamantan
substitut
found
display
antiherpet
activ
also
class
compound
initi
identifi
project
identifi
small
molecul
suppress
excess
ige
respons
allergi
asthma
end
chemic
divers
librari
compound
screen
cell
base
htsassay
hit
like
scheme
subsequ
modifi
identifi
deriv
modifi
aliphat
cycloalkyl
residu
show
increas
block
igerespons
consid
potenc
well
oral
bioavail
author
select
adamantyl
amid
librari
adamantan
deriv
studi
greatli
expand
subsequ
work
also
direct
toward
identifi
mechan
action
compound
similar
potenc
activ
compound
multipl
respons
differ
cell
type
suggest
highli
conserv
target
integr
cell
util
probabl
golgi
endoplasmat
reticulum
activ
structur
strong
prefer
termin
larg
lipophil
group
e
g
adamantan
moieti
target
host
cell
rather
virusencod
protein
offer
significantli
target
molecul
process
howev
cost
higher
potenti
cytotox
moreov
fight
viral
reproduct
level
host
cell
process
pressur
toward
format
resist
mutant
viru
would
lessen
affect
group
protein
within
golgi
organel
appar
left
unperturb
find
suggest
impact
drug
candid
golgi
eukaryot
cell
may
also
affect
propag
number
virus
exploit
golgi
intracellular
matur
mani
virus
appear
reli
golgi
apparatu
instanc
contribut
membran
lipid
envelop
particip
process
critic
viral
protein
end
influenc
golgi
compound
class
nine
virus
eight
famili
studi
virus
includ
report
either
use
membran
golgi
pregolgi
compart
refer
endoplasmat
reticulumgolgi
intermedi
compart
ergic
transgolgi
network
envelop
henc
virus
reli
function
golgi
inde
eg
scheme
analogu
like
shown
inhibitor
propag
cellbas
assay
nanomolar
concentr
topic
model
hsv
infect
guinea
pig
initi
ige
blocker
signific
effect
ointment
complet
suppress
appear
vesicl
dramat
differ
explain
differ
lipid
solubl
would
translat
improv
skin
penetr
addit
potenc
favor
unfortun
tromantadin
includ
studi
result
togeth
suggest
moa
tromantadin
base
upon
earlier
studi
mention
suggest
similar
mode
action
recent
report
novel
antiherpet
adamantan
deriv
might
serv
anoth
exampl
adamantan
modif
enhanc
potenc
pharmacokinet
known
test
drug
monoacyl
deriv
diaminopyridin
render
less
cytotox
maintain
antivir
activ
use
acid
acyl
compon
scheme
among
novel
compound
report
deriv
diaminocyclohexan
e
g
bisurea
compound
inhibit
reproduct
monitor
plaqu
reduct
assay
vero
cell
assay
combin
limit
number
compound
screen
offer
addit
insight
moa
aminoadamantan
herp
simplex
conclus
remark
tromantadin
mark
third
adamantan
specif
aminoadamantan
deriv
sucess
introduc
market
even
though
identif
antiherp
simplex
agent
much
result
research
specif
address
use
rather
find
screen
group
aminoadamantan
respect
rang
potenc
variou
virus
two
antivir
chemotherapeut
incorpor
residu
reach
market
natur
research
intrigu
virucid
effect
combin
mostli
straightforward
chemic
synthes
compound
consequ
adamantan
deriv
consid
screen
chemotherapeut
activ
virus
pose
immin
threat
human
popul
cover
two
hepat
c
hcv
human
immunodefici
viru
hiv
chapter
earliest
report
adamantan
deriv
display
antihepat
properti
date
back
pyridoxan
adamanto
e
g
scheme
propos
agent
suitabl
treatment
viral
hepat
later
oxim
ester
like
report
exhibit
antivir
activ
murin
hepat
viru
subsequ
parallel
part
earli
research
deal
util
lipophil
amin
combat
influenza
ammonium
chlorid
amantadin
methylamin
dansylcadaverin
examin
monkey
cell
line
infect
hepat
lipophil
amin
known
accumul
rais
ph
intracellular
vesicl
therebi
imped
releas
viral
dna
cytoplasma
consequ
lipophil
amin
potent
inhibitor
viral
antigen
synthesi
monitor
immunofluoresc
screen
forti
known
compound
respect
inhibitori
effect
hepat
viru
human
hepatoma
cell
line
gave
four
activ
compound
candid
hepat
chemotherapi
glycyrrhizin
pyrazofurin
ribavirin
cours
amantadin
smith
report
result
clinic
trial
patient
chronic
hepat
c
infect
previous
fail
standard
therapi
time
patient
receiv
amantadin
monotherapi
mg
dose
day
patient
show
mark
improv
serum
level
alanin
aminotransferas
level
hcv
rna
titer
sixmonth
treatment
period
mark
signific
improv
initi
interferon
chemotherapi
hcv
infect
led
sustain
virolog
respons
one
third
patient
initi
report
spark
numer
followup
trial
tri
reproduc
smith
result
compar
amantadin
antihcv
activ
variou
antivir
chemotherapeut
regimen
result
trial
remain
elus
date
sever
biochem
process
util
hcv
replic
cycl
subsequ
studi
regard
possibl
effect
amantadin
author
search
homolog
sequenc
viral
protein
influenza
hcv
signific
sequenc
structur
homolog
particular
influenza
protein
identifi
furthermor
neither
amantadin
rimantadin
display
dosedepend
inhibitori
activ
hcv
enzym
whether
aminoadamantan
suitabl
antihcv
agent
metaphor
speak
whether
amantadin
magic
bullet
yet
anoth
dead
duck
close
call
metaanalys
conduct
summar
differ
aspect
clinic
trial
amantadin
follow
smith
initi
report
one
use
data
total
patient
six
clinic
trial
address
eventu
advantag
interferon
plu
amantadin
versu
interferon
alon
find
absolut
increas
sustain
virolog
respons
ad
amantadin
interferon
around
author
conclud
metaanalysi
proven
benefit
combin
amantadin
interferon
treat
naiv
patient
chronic
hepat
c
howev
anoth
metaanalysi
differ
frame
refer
rais
question
ad
amantadin
antihcv
treatment
use
interferon
alon
show
promis
result
studi
other
confirm
author
report
tripl
therapi
interferon
ribavirin
amantadin
seem
improv
sustain
virolog
respons
overal
subgroup
analysi
nonrespond
previou
chemotherapi
seem
subgroup
patient
show
signific
benefit
use
amantadin
subgroup
hcvinfect
patient
name
drugnaiv
patient
relaps
combin
therapi
amantadin
use
compar
standard
combin
therapi
interferon
ribavirin
recent
clinic
trial
compar
amantadin
combin
pegyl
interferon
ribavirin
tripl
therapi
placebo
ribavirinpegyl
interferon
report
sustain
virolog
respons
patient
infect
difficulttotreat
genotyp
hcv
highest
percentag
sustain
respons
report
amantadin
addit
effect
combin
peginterferon
ribavirin
furthermor
addit
amantadin
regimen
show
initi
addit
effect
aminoadamantan
hcv
dna
level
detect
pcr
week
week
treatment
period
confirm
earlier
report
effect
amantadin
hcv
howev
later
clinic
trial
could
confirm
find
conclud
amantadin
addit
peginterferon
ribavirin
combin
therapi
augment
sustain
virolog
respons
drugnaiv
genotyp
patient
effect
depend
hcv
genotyp
later
trial
interferonna
patient
show
higher
sustain
virolog
respons
rate
tripletherapi
group
peginterferon
ribavirin
amantadin
compar
doubl
therapi
peginterferon
ribavirin
name
genotyp
patient
render
amantadin
benefici
albeit
addit
effect
small
earlyrecogn
difficulttotreat
patient
anoth
recent
clinic
trial
amantadin
hcv
treatment
drugnaiv
patient
howev
addit
mg
day
amantadin
regimen
improv
sustain
virolog
respons
rate
peginterferon
ribavirin
doubl
therapi
trend
benefit
amantadin
reach
statist
signific
studi
retreat
nonrespond
previou
antihcv
chemotherapi
sustain
virolog
respons
observ
retreat
patient
overal
differ
doubl
therapi
peginterferon
ribavirin
tripl
therapi
peginterferon
ribavirin
amantadin
author
conclud
undisput
trend
benefici
effect
amantadin
exist
especi
nonrespond
patient
initi
partial
virolog
respons
use
amantadin
thereaft
probabl
jeopard
emerg
escap
mutant
trend
toward
benefici
effect
amantadin
also
observ
anoth
clinic
trial
nonrespond
conclud
use
tripl
therapi
would
justifi
except
clinic
control
assay
treatment
posttransplant
hcv
patient
amantadin
monotherapi
effect
addit
amantadin
peginterferon
ribavirin
therapi
obvious
reduc
deterior
depress
fatigu
vigor
treatment
one
conclud
numer
trial
probabl
addit
benefit
ad
amantadin
antihcv
chemotherapi
peginterferon
ribavirin
depend
viru
genotyp
subgroup
patient
design
trial
spite
obviou
small
benefici
effect
amantadin
addit
even
current
standard
pegyl
interferon
ribavirin
doubl
therapi
lack
vitro
assay
cellbas
model
hcv
infect
limit
advanc
effici
antihcv
chemotherapi
one
hand
select
group
patient
amantadin
could
effect
aggrav
develop
effici
antihcv
agent
base
upon
aminoadamantan
motif
possibl
goal
drug
develop
would
benefit
identif
target
amantadin
hcv
chemotherapi
best
contradictori
result
amantadinehcv
trial
one
hand
prospect
proteasebas
antivir
therapi
led
piccolo
devis
obituari
lie
amantadin
hydrochlorid
antivir
hcv
mani
year
mani
clinic
trial
gave
us
hope
better
outcom
chronic
hepat
c
unfortun
never
fulfil
evid
remain
contradictori
rest
peac
function
sever
hcv
protein
poorli
understood
inabl
cultur
viru
vitro
retard
drug
discoveri
one
small
protein
encod
hcv
protein
small
lipophil
member
group
viroporin
membraneassoci
mostli
found
within
endoplasm
reticulum
notabl
influenza
protein
belong
class
viral
protein
hcv
protein
predict
display
two
membranespan
helic
link
small
charg
loop
determin
whether
hcv
like
number
viroporin
also
form
oligom
put
ion
channel
structur
protein
express
cell
crosslink
chemic
furthermor
author
also
synthes
recombin
protein
e
coli
fusion
protein
histag
form
ion
channel
insul
artifici
membran
histag
protein
effici
gst
fusion
protein
notabl
context
present
review
find
ion
channel
activ
histag
protein
gst
fusion
protein
could
block
amantadin
demonstr
hcv
form
amantadinesensit
ion
channel
could
explain
amantadin
weak
antihcv
activ
enabl
targetdirect
drug
develop
hcv
chemotheraput
hcv
cultur
system
establish
artifici
black
lipid
membran
bilay
system
reconstitut
chemic
synthes
hcv
protein
ntermin
biotinyl
also
display
ion
channel
activ
could
block
iminosugar
incorpor
longchain
alkyl
sidechain
iminosugar
shorter
sidechain
eg
nbutyl
potent
structur
channel
form
homooligom
hcv
differ
model
system
propos
hexam
deriv
chemic
crosslink
experi
well
transmiss
electron
microscopi
heptam
base
upon
tem
supplement
comput
analys
least
pentam
black
lipid
membran
put
function
aggreg
suggest
two
membranespan
helic
fulllength
protein
one
contribut
inner
side
ion
channel
conserv
basic
loop
connect
helic
import
amantadin
sensit
channel
use
model
system
known
studi
influenza
channel
author
also
abl
demonstr
hcv
ion
channel
activ
live
cell
model
oligomer
hcv
channel
comput
method
gave
first
model
bind
channel
blocker
amantadin
target
channel
approxim
dimens
channel
nm
inner
diamet
nm
outer
diamet
pore
respect
slightli
smaller
result
tem
studi
mention
plausibl
oligom
therefor
hexam
perform
dock
analysi
amantadin
shed
light
bind
mode
adamantylammonium
ion
insid
lumen
model
channel
bind
site
lie
vicin
hydrogen
bond
probabl
model
predict
toward
interior
channel
analog
orient
function
influenza
tetram
suggest
role
hcv
channel
gate
proton
conduct
nmr
studi
recombin
hcv
model
protein
bicel
suggest
bind
amantadin
via
lipophil
cluster
five
transmembran
leu
residu
drawback
howev
amantadin
concentr
clinic
achiev
hcv
proton
channel
block
effici
result
molecular
model
studi
suggest
bind
seven
aminoadamantan
molecul
per
hcv
channel
adamantan
bound
peripher
membraneexpos
site
reminisc
lowaffin
rimantadin
bind
site
membraneexpos
outsid
influenza
channel
discuss
locat
bind
site
corrobor
earlier
nmr
studi
mutat
decreas
calcul
affin
amantadin
observ
genuin
resist
mutat
patient
unrespons
antihcv
tripl
therapi
interferon
ribavirin
amantadin
respons
select
driven
adamantan
low
loss
surviv
fit
singl
mutat
protein
render
drug
sensit
remain
challeng
drug
develop
field
howev
screen
small
librari
aminoadamantan
deriv
dock
score
corrobor
vitro
studi
encourag
drug
develop
target
hcv
viroporin
lack
smallanim
model
hcv
infect
well
practic
highthrouput
assay
screen
hcv
ion
channel
inhibitor
address
current
research
chimer
virus
gener
studi
hcv
channel
genuin
cell
cultur
system
amantadin
reduc
viru
titer
extent
subsequ
differ
group
report
studi
antivir
spectrum
hcv
isol
genotyp
cell
cultur
research
could
find
antihcv
effect
iminosugar
amantadin
found
ineffici
reduc
rna
replic
well
releas
infect
hcv
particl
lack
amantadin
efficaci
even
cytotox
concentr
attribut
differ
protein
use
assay
ionchannel
activ
flaglabel
vitro
system
util
releas
fluoresc
indic
liposom
howev
amantadin
found
activ
albeit
surprisingli
block
carboxyfluorescein
releas
complet
even
addit
assay
rimantadin
hexamethyleneamilorid
scheme
experiment
compound
disclos
report
activ
amantadin
sinc
liposom
permeabl
assay
allow
screen
multipl
hcv
sequenc
variou
genotyp
librari
drug
candid
screen
medium
highthroughput
scale
may
becom
feasibl
nearterm
refin
assay
develop
combin
rapid
throughput
vitro
assay
hcv
infecti
cultur
system
activ
small
molecul
hcv
blocker
assess
channel
activ
well
hcv
assembl
result
indic
genotypedepend
subtypedepend
pattern
sensit
could
impli
hcv
sequenc
determin
whether
influenc
small
molecul
includ
amantadin
rimantadin
hcv
viru
releas
releas
infecti
hcv
cultur
reproduc
block
compound
shown
inhibit
vitro
observ
differenti
sensit
subtyp
parallel
report
clinic
trial
escap
mutant
lastli
lack
small
anim
model
hcv
infect
address
recent
replac
protein
gb
viru
b
hepatotrop
member
flavivirida
famili
close
relat
hcv
amino
acid
ident
hcv
chimer
virus
obtain
infecti
marmoset
amantadin
inhibit
spread
gb
viru
primari
marmoset
hepatocyt
anim
model
urgent
need
hcv
drug
develop
appear
within
reach
apart
hcv
ion
channel
target
obvious
also
hit
lipophil
adamantan
bullet
drug
discoveri
process
seri
complex
identifi
target
interact
membran
protein
signal
antiprolifer
bound
antibodi
glycoprotein
believ
involv
mediat
viral
process
cell
entri
immun
evas
chemic
divers
librari
compound
boraadamantan
eg
scheme
relat
adamantoyl
amid
promis
compound
show
minimum
cytotox
studi
assist
molecular
model
base
upon
xray
structur
data
adamantan
deriv
studi
far
hcv
chemotherapi
compound
obvious
hit
two
target
effici
remain
disput
could
least
serv
start
point
targetdirect
drug
discoveri
imman
problem
establish
suitabl
assay
anim
model
overcom
first
chemotherapeut
viral
infect
amantadin
expect
also
studi
context
human
immunodeficci
viru
hiv
amantadin
first
suggest
potenti
virustat
combat
hiv
first
effect
studi
amantadin
act
weak
base
e
g
amantadin
rais
ph
intracellular
organel
like
endosom
lysosom
entri
follow
bind
host
cell
presum
occur
via
membran
fusion
author
studi
phdepend
entri
show
infect
inhibit
weak
base
like
amantadin
rather
releas
infecti
viru
cell
impair
base
also
find
evid
influenc
base
synthesi
viral
protein
use
differ
testb
cocultur
human
primari
glial
fibrilari
acid
protein
posit
gfap
cell
hivproduc
antihiv
effect
memantin
could
found
effect
least
part
attribut
memantin
known
nmdareceptor
antagon
vide
infra
could
amelior
effect
hiv
coat
protein
increas
calcium
concentr
cultur
author
also
discuss
eventu
particip
neurotox
well
phdepend
uptak
gfap
cell
memantin
mode
action
testb
use
memantin
hivassoci
dementia
propos
neurotox
coat
protein
later
also
confirm
rat
cortic
cell
cultur
memantin
well
altern
nmdareceptor
antagonist
dosedepend
prevent
neurotox
micromolar
concentr
vast
number
aminoadamantan
design
synthes
influenza
channel
blocker
vide
supra
also
screen
respect
possibl
antihiv
effect
compound
inact
borderlin
activ
cell
cultur
could
assign
e
g
compound
scheme
adamantan
deriv
report
group
includ
piperidin
scheme
ec
valu
low
micromolar
rang
significantli
higher
cytotox
concentr
scheme
comparison
known
antihiv
agent
potenc
adamantan
deriv
howev
markedli
lower
alongsid
pharmacophor
known
drug
thalidomid
phenytoin
antiepilept
compound
also
inhibit
bind
hiv
posit
lymphocyt
ameltolid
group
substitut
phtalimid
incorpor
adamantan
moieti
later
synthes
screen
cytopathogen
cem
cell
adamantyl
thalidomid
deriv
display
activ
ec
well
ec
concentr
cytotox
concentr
cc
target
unknown
followup
studi
relat
compound
includ
adamantyl
benzamid
eg
found
analogu
mostli
inact
cytotox
concentr
report
ionchannel
activ
viral
protein
prompt
worker
screen
deriv
known
anticonvuls
hiv
differ
approach
antihiv
compound
incorpor
adamantan
motif
chosen
due
find
leukocyt
dialys
contain
low
molecular
weight
immunoact
fraction
major
compon
peptid
like
htyrglyoh
htyrglyglyoh
resembl
ntermin
fragment
enkephalin
modifi
enkephalin
adamantan
moieti
gave
hydrophob
peptid
like
abl
inhibit
syncytium
format
tlymphocyt
known
tendenc
aminoadamantan
penetr
lipid
bilay
assum
antihiv
activ
possibl
associ
process
surfac
host
cell
e
g
interact
opioid
receptor
polymer
compound
incorpor
aminoadamantan
deriv
link
polyanion
matric
believ
enhanc
membranotrop
activ
polym
also
describ
infect
could
inhibit
sever
cell
line
use
polym
wherea
amantadin
rimantadin
ineffect
control
experi
compound
test
regard
antihiv
activ
hydrazid
like
compound
inhibit
hiv
level
compar
antihiv
drug
retrovir
wherea
ascrib
pharmacophor
alon
analogu
also
show
activ
combin
heterocycl
pharmacophor
lipophil
bullet
adamantan
also
studi
amongst
heterocycl
seri
benzoxazinon
find
show
moder
activ
cell
cultur
micromolar
concentr
final
antihiv
activ
kemantan
low
cytotox
also
report
least
part
attribut
membranotrop
properti
solubl
aqueou
media
anoth
use
adamantan
deriv
patholog
associ
hiv
infect
mention
memantin
uncompetit
faston
fastoff
nmdarecetor
antagonist
see
chapter
success
studi
context
lipton
test
whether
memantin
vitro
setup
amelior
neurotox
exert
hiv
envelop
glycoprotein
togeth
form
oligom
essenti
hostcel
receptor
bind
hi
viru
particl
reduc
certain
neuron
popul
nmdareceptor
mediat
neuron
injuri
may
also
contribut
patholog
summar
associ
cognitivemotor
complex
sever
form
socal
aid
dementia
complex
sever
recombin
nativ
isoform
studi
memantin
dose
low
complet
protect
rat
retin
ganglion
cell
use
neurotox
togeth
gener
effect
viru
growth
neuroprotect
effect
memantin
led
nomin
memantin
treatment
aidsrel
dementia
cerebr
express
fusion
gene
encod
transgen
mous
model
could
demonstr
hiv
glycoprotein
induc
increas
plasma
concentr
corticosteron
result
activ
hypothalamicpituitaryadren
hpa
axi
ca
depend
process
involv
nmda
receptor
stimul
amelior
memantin
chronic
treatment
memantin
initi
earli
antagon
induc
neuron
damag
vivo
transgen
mice
treat
memantin
show
mark
improv
synapt
complex
well
neuron
integr
compar
untreat
litterm
role
neuropathogenesi
infect
elucid
directli
detect
glycoprotein
patient
enceph
author
found
viral
protein
includ
tat
synergist
caus
massiv
derang
neuron
function
particular
calcium
dysregul
neuron
similar
neuroprotect
effect
memantin
discuss
found
mous
model
enceph
memantinetr
mice
display
less
sever
impair
longterm
potenti
memantin
went
clinic
trial
treatment
aid
dementia
first
clinic
trial
memantin
trend
toward
clinic
benefit
could
observ
patient
suffer
hivassoci
distal
sensori
neuropathi
likewis
differ
phase
ii
clinic
trial
memantin
treatment
hivassoci
cognit
impair
confirm
signific
benefit
drug
treat
group
patient
howev
sinc
mr
examin
indic
memantin
may
amelior
neuron
metabol
benefici
effect
drug
might
weak
signific
within
rel
short
week
treatment
drug
trial
overal
posit
result
longterm
studi
week
howev
found
recent
memantin
safe
tolear
least
initi
openlabel
phase
improv
eight
neuropsycholog
test
score
found
addon
approach
attach
adamantan
moieti
known
drug
pharmacophor
also
undertaken
field
hiv
relat
drug
discoveri
azt
azidothymidin
zidovudin
nucleosid
analogu
revers
transcriptas
inhibitor
nrti
first
approv
treatment
hiv
remain
use
clinic
date
particular
combin
therapi
regimen
combivir
trizivir
sinc
azt
abl
cross
bloodbrainbarri
bbb
variou
lipophil
azt
substitut
carboxyl
acid
synthes
studi
vitro
find
higher
resist
plasma
esteras
well
vivo
ester
scheme
could
detect
brain
rat
higher
concentr
azt
combin
antihiv
pharmacophor
phthalimid
vide
supra
adamantan
azt
azt
prodrug
candid
identifi
show
consider
increas
antihiv
potenc
compar
analog
without
adamantan
modif
ec
howev
still
antivir
potenc
lower
azt
said
author
still
propos
compound
evalu
prospect
vivo
pharmacolog
properti
cosalan
deriv
aurintricarboxyl
acid
ata
improv
potenc
act
step
membran
fusion
hi
virion
envelop
host
cell
membran
via
interfer
interact
well
inhibitor
revers
transcriptas
proteas
also
modifi
adamantan
time
steroid
pharmacophor
replac
adamantan
cosalan
sever
deriv
eg
cosalog
also
display
signific
inhibitori
activ
proteas
integras
ic
potent
best
analogu
screen
higher
potenc
cosalan
also
inhibit
proteas
vitro
ic
approxim
four
time
stronger
cosalan
unfortun
howev
cosalan
analogu
potent
inhibitor
cytopath
cosalan
cell
base
assay
time
show
pronounc
cytotox
effect
cemss
cell
use
part
screen
sever
thiourea
deriv
also
adamantan
substitut
thiourea
examin
regard
inhibit
hiv
revers
transcriptas
rt
later
balzarini
et
al
also
screen
dideoxythymidin
deriv
incorpor
adamantan
cage
potenti
inhibitor
recombin
rt
vide
supra
howev
exampl
hit
target
hiv
drug
discoveri
inact
concentr
test
heterocycl
adamantan
deriv
like
adamantyloxadiazolin
thion
scheme
exhibit
borderlin
activ
hiv
cellbas
assay
vari
heterocycl
moieti
structur
close
relat
class
compound
util
mani
field
medicin
chemistri
includ
use
nonnucleosid
hiv
revers
transcriptas
inhibitor
nnrti
result
compound
potenc
cell
cultur
adamantan
substitut
thiazolidinon
display
ec
cem
cell
methyl
substitut
analogu
activ
concentr
high
r
enantiom
two
time
potent
enantiom
antihiv
activ
cell
cultur
reflect
least
part
inhibitori
profil
compound
recombin
hiv
revers
transcriptas
ic
r
ic
word
novel
class
nnrti
obligatorili
requir
adamantan
copharmacophor
activ
followup
studi
includ
larger
librari
test
compound
e
g
pyrimidin
gave
mostli
activ
compound
albeit
inferior
potenc
compar
compar
measur
compound
inhibitori
activ
rt
rt
clearli
show
select
nnrti
rt
potenc
rt
inhibit
parallel
virustat
effect
measur
cem
cell
tabl
hit
hiv
target
straightforwardli
come
reader
mind
consid
previou
chapter
either
via
classic
sar
via
improv
known
pharmaceut
ad
lipophil
bullet
also
appear
obviou
target
biochem
function
har
virus
least
part
elucid
use
pharmaceut
deriv
adamantan
motif
prototyp
function
concept
blockad
pore
ion
channel
form
protein
encod
viru
small
viral
protein
call
viroporin
oligomer
within
membran
give
rise
hydrophil
pore
membran
cell
infect
reprogram
viru
usual
pore
essenti
viral
replic
howev
enhanc
viru
growth
alreadi
discuss
depth
influenza
ion
channel
residu
tetram
present
far
beststudi
viroporin
great
deal
insight
structur
dynam
function
gain
util
blocker
name
aminoadamantan
antivir
influenza
b
channel
residu
tetram
may
present
differ
sequenc
share
structur
motif
well
residu
crucial
function
hxxxw
motif
influenza
channel
likewis
also
learn
hcv
viroporin
residu
presum
heptam
whose
valid
target
chemotherapeut
also
involv
aminoadamantan
encod
type
transmembran
phosphoprotein
vpu
play
role
enhanc
viru
releas
infect
cell
well
degrad
receptor
host
cell
share
characterist
abovement
viroporin
includ
proton
channel
function
earli
molecular
model
studi
suggest
homooligom
vpu
form
weakli
cationselect
ion
channel
sinc
obvious
viroporin
influenza
vpu
protein
share
sever
similar
exchang
vpu
consid
replac
transmembran
domain
vpu
simianhuman
immunodefici
viru
shiv
transmembran
domain
amantadinesensit
gave
chimer
viru
chang
properti
matur
pattern
similar
parent
shiv
remain
infecti
caus
sever
loss
cell
aid
macaqu
indic
modifi
vpum
protein
function
chimer
viru
furthermor
found
sensit
channel
blocker
rimantadin
transmembran
domain
hiv
vpu
viroporin
subtyp
b
show
analog
influenza
tm
incorpor
axxxwmotif
approxim
posit
hxxxwsubsequ
locat
consequ
substitut
vpu
tmd
via
sitedirect
mutagenesi
result
mutant
viru
also
retain
function
unchang
replic
cultur
could
almost
complet
abolish
rimantadin
find
valid
least
extent
vpu
target
develop
antihiv
chemotherapeut
subsequ
solidst
nmr
studi
polypeptid
correspond
vpu
transmembran
domain
nativ
mutat
sequence
dhpc
micel
confirm
find
molecular
level
newli
introduc
residu
rimantadin
suscept
mutant
display
pronounc
chang
backbon
amid
reson
upon
interact
drug
suggest
bind
site
drug
locat
influenza
tm
specif
interact
drug
unmut
vpu
polypeptid
could
detect
vpu
transmembran
domain
ideal
helix
phospholipid
bicel
residu
locat
side
helix
like
residu
also
involv
interact
drug
mutat
caus
local
chang
vpu
tmd
structur
also
influenc
secondari
tertiari
structur
protein
decis
drug
interact
homooligomer
vpu
channel
channel
properti
vpu
viroporin
discoveri
molecular
mechan
action
util
rimantadinesensit
mutant
parallel
drawn
multipl
strategi
virus
chapter
discuss
class
antiherp
simpex
compound
target
membran
instead
cleancut
protein
protein
oligom
develop
least
part
fuel
known
prefer
aminoadamantan
interact
biomembran
context
interest
us
note
shown
amantadin
lysosomotrop
agent
abl
diffus
across
membran
increas
infect
hela
cell
dosedepend
next
capabl
amantadin
cross
membran
effect
associ
function
weak
base
therebi
drug
capabl
elev
ph
endosom
contain
viru
endocytosi
endosom
acidif
rais
likelyhood
infecti
particl
delet
via
lysosom
degrad
therefor
counteract
weak
base
like
amantadin
dramat
increas
overal
infect
isol
fusion
host
cell
probabl
occur
microdomain
plasma
membran
enrich
glycoshpingolipid
gsl
also
known
lipid
raft
receptor
local
hiv
well
interact
sever
gsl
synthet
analog
gsl
mimick
interact
could
antihiv
agent
inde
shown
synthet
analogu
gsl
globotriaosylceramid
gb
also
refer
fusion
cofactor
recogn
inhibit
fusion
one
deriv
adamantyl
gsl
adamantylglobotriaosylceramid
adagb
scheme
semisynthet
glycosphingolipid
deriv
one
fatti
acid
chain
replac
adamantan
modif
render
solubl
aqueou
media
also
chang
bind
ligand
recruit
gb
membran
format
fusion
complex
adagb
found
specif
bind
far
rapidli
gb
adamantyl
gsl
deriv
therefor
consid
invalu
tool
studi
glycolipid
receptor
function
effect
adamantan
substitut
ligand
bind
consid
indirect
one
adamantan
rigidifi
monolay
resembl
membran
microdomain
lipid
raft
reduc
compress
importantli
modifi
organ
carbohydr
moieti
therebi
enhanc
interact
presum
adamantan
moieti
adagb
mimick
effect
cholesterol
requir
gb
bind
microdomain
author
subsequ
studi
effect
adagb
hivinfect
cell
cultur
infect
jurkat
cell
use
reduc
dosedepend
reduct
background
valu
adagb
inhibit
shown
via
electron
microscopi
author
show
hi
virion
delet
rather
attach
host
cell
inhibit
fusion
inhibit
use
adagb
virusadagb
bind
central
import
preincub
target
cell
adagb
inhibit
hiv
multipl
author
also
suggest
reduct
lipophil
modifi
gsl
increas
specif
activ
conclus
although
adamantan
moieti
lipophil
fatti
acid
chain
replac
adamantyl
conjug
remak
watersolubl
retain
function
term
ligand
bind
adagb
act
mimic
gb
cholesterol
complex
increas
receptor
function
gb
inhibit
hivinfect
cell
cultur
modifi
gsl
could
also
offer
approach
revers
multidrug
resist
cancer
chemotherapi
adagb
modifi
glycosphingolipid
seem
offer
opportun
investig
gsl
function
cellular
physiolog
provid
new
approch
treat
infecti
diseas
membraneassoci
function
crucial
e
g
recognit
fusion
host
cell
viral
particl
anoth
group
pharmaceut
activ
compound
target
biosynthesi
bacteri
cell
wall
glycopeptid
antibiot
bestknown
exampl
vancomycin
search
glycopeptid
deriv
abl
combat
glycopeptideresist
bacteria
led
lipophil
modifi
glycopeptidederiv
compound
incorpor
adamantan
moieti
compound
also
evalu
regard
potenti
use
antihiv
compound
unmodifi
antibiot
e
g
vancomycin
eremomycin
display
antihiv
activ
lipophil
modifi
deriv
show
modest
activ
increas
cytotox
howev
semisynthet
deriv
teicoplanin
aglycon
scheme
tabl
gener
activ
cell
cultur
lipophil
modifi
deriv
activ
unmodifi
parent
howev
sinc
modif
lipophil
bullet
adamantan
gave
compar
result
context
eg
vs
scheme
tabl
activ
compound
screen
incorpor
adamantan
moieti
role
adamantan
addon
seem
limit
increas
overal
lipophil
detail
mechan
action
compound
disclos
yet
inhibit
earli
step
multipl
cycl
like
viral
entri
host
cell
membraneassoci
process
result
specif
interplay
hiv
glycoprotein
cellular
co
receptor
like
probabl
insid
lipophil
raft
neighborhood
describ
specif
antivir
activ
also
impli
antibacteri
activ
compound
use
combat
hi
viru
minim
order
prevent
format
glycopeptid
resist
bacteria
strain
goal
follow
lipophil
modifi
glycopeptid
deriv
describ
use
aglycon
led
signific
decreas
loss
antibacteri
activ
reason
present
devoid
antibacteri
activ
time
potent
hiv
relat
glycopeptid
aglycon
tabl
howev
sar
number
glycopeptid
aglycon
deriv
vancomycin
eremomycin
dechloroeremomycin
yield
compound
enhanc
antihiv
potenc
exemplifi
de
nmethyldleu
aglycon
eremomycin
scheme
tabl
author
conclud
investig
antiretrovir
activ
demonstr
amid
methyl
substitu
rule
equal
activ
compound
substitu
substitu
result
lipophil
bullet
adamantan
today
may
led
pharmaceut
routin
prescrib
combat
hiv
aminoadamantan
howev
signific
impact
understand
valid
viroporin
vpu
drug
target
moreov
recur
event
medicin
chemistri
adamantan
deriv
lipophil
addon
success
util
enhanc
pharmacokinet
andor
pharmacodynam
known
pharmaceut
sever
line
evid
point
toward
benefici
effect
adamantyl
membran
process
target
exemplifi
adamantyl
glycosphingolipid
glycopeptid
aglycon
deriv
antibacteri
addon
strategi
modifi
known
pharmaceut
also
follow
context
antimalari
earli
five
adamantyl
naphthoquinon
antimalari
scheme
screen
plasmodium
berghei
protozoan
repres
classic
model
organ
human
malaria
mice
along
deriv
antimalari
drug
chloroquin
adamantan
substitut
case
show
advantag
alkyl
cycloalkyl
naphthoquinon
deriv
atovaquon
recent
exampl
addon
approach
report
enhanc
activ
adamantyl
deriv
earli
antimalari
drug
chloroquin
adamantyl
display
excel
vitro
antimalari
activ
particular
also
chloroquin
resist
strain
plasmodium
falciparum
structur
found
activ
multidrug
resist
p
falciparum
strain
ic
nm
well
two
strain
p
falciparum
ic
chloroquin
nm
parallel
posit
control
use
test
system
class
compound
target
heme
polymer
insid
parasit
food
vacuol
resist
strain
malaria
parasit
found
way
effici
remov
drug
target
process
outsid
food
vacuol
via
plasmodium
falciparum
chloroquin
resist
transport
pfcrt
therefor
resembl
one
possibl
target
hit
develop
antimalari
chloroquineresist
strain
lastli
adamantaneeth
along
lipophil
moieti
studi
modif
antimalari
natur
compound
isol
artemisia
annua
artemisinin
vide
infra
etherderiv
found
activ
arteeth
multidrug
resist
p
yoelii
nigeriensi
mice
special
prefer
adamantan
observ
life
cycl
malaria
parasit
along
summari
possibl
actual
drug
target
antimalari
chemotherapi
review
recent
almost
implicit
adamantanederiv
compound
also
studi
regard
possibl
antimalari
activ
aim
sever
molecular
target
reportedli
membranotrop
compound
amantadin
test
along
membran
activ
drug
colchicin
vinblastin
whether
abl
alter
erythrocyt
suscept
p
knowlesi
rehsu
monkey
erythrocyt
howev
colchicin
vinblastin
inhibit
parasit
invas
extent
amantadin
weak
base
amphiphil
molecul
amantadin
hypothes
trap
acid
food
vacuol
via
mechan
chloroquin
taken
diffus
lysosomelik
compart
weak
base
becom
proton
ionic
speci
diffus
vacuol
drug
molecul
alter
local
ph
therebi
block
vacuolar
digest
host
cell
hemoglobin
ultim
caus
parasit
starvat
lysosomotrop
hypothesi
antimalari
drug
action
amantadin
show
activ
p
falciparum
particular
strain
chloroquin
resist
addit
author
also
attribut
amantadin
activ
membranemodul
properti
specif
context
modul
local
charg
densiti
membran
author
also
studi
possibl
interact
amantadin
antimalari
like
chloroquin
mefloquin
quinin
halofantrin
use
two
malaria
strain
maintain
human
red
blood
cell
strain
amantadin
potenti
effect
quinin
chloroquin
respect
author
propos
amantadin
either
increas
drug
accumul
act
resist
mechan
somehow
modifi
drug
target
unknown
time
later
research
studi
effect
ph
alter
potenc
amantadin
p
falciparum
howev
found
ph
sole
determin
amantadin
activ
lieu
thereof
presum
amantadin
interact
membran
phospholipid
inhibit
parasit
matur
erythrocyt
also
context
studi
pfcrt
drug
target
studi
recent
whether
amantadin
capabl
press
mutat
pfcrt
render
chloroquineresist
strain
plasmodium
parasit
back
chloroquin
suscept
pfcrt
incorpor
ten
put
transmembran
helic
locat
food
vacuol
membran
within
parasit
erythrocyt
data
crossresist
studi
indic
pfcrt
inde
constitut
key
determin
chloroquineand
amantadinesuscept
remain
shown
whether
amantadin
act
context
synergist
action
togeth
chloroquin
vide
supra
lysosomotrop
hypothesi
within
vacuol
directli
interact
lipophil
site
within
pfcrt
widespread
chloroquin
resist
current
circul
strain
plasmodium
parasit
render
chloroquin
nearli
halv
death
p
falciparum
children
subsaharan
africa
monotherapi
essenti
useless
today
still
need
replac
chemotherapeut
restor
chloroquin
regimen
via
amantadin
drug
develop
base
lead
presum
target
pfcrt
would
therefor
welcom
amantadin
qualifi
fulfil
requir
sinc
concentr
drug
need
effici
display
antimalari
effect
high
use
clinic
artemisinin
scheme
semisynthet
deriv
particular
artemeth
artesun
current
part
combin
therapi
multidrug
resist
malaria
natur
product
base
therapi
requir
plantat
process
larg
amount
artemisia
annua
impos
pressur
toward
develop
fulli
synthet
drug
compar
even
better
activ
pharmacophor
account
artemisinin
antimalari
activ
consequ
search
altern
result
synthesi
screen
trioxan
deriv
first
synthet
activ
malaria
vivo
mice
infect
p
berghei
report
compound
access
straightforward
acidcatalyz
condens
adamantanon
incorpor
spiroadamantan
peroxid
pharmacophor
screen
mous
model
activ
dose
low
mgkg
twice
day
intraperiton
spiroadamantan
later
also
identifi
antimalari
drug
candid
compound
scheme
provid
foundat
sar
trioxolan
complet
inact
test
p
falciparum
vitro
p
berghei
mice
wherea
mark
hit
potent
artemeth
artesun
consist
iron
activ
hypothesi
antimalari
drug
action
could
shown
react
peroxid
fe
ii
mimick
heme
present
food
vacuol
subsequ
trap
reaction
product
tempo
class
antimalari
peroxid
inde
gener
carboncent
radic
believ
crucial
alkyl
speci
plasmodium
chemotherapi
peroxid
drug
griesbaum
coozonolysi
util
omethyl
oxim
key
precursor
along
suitabl
keton
synthesi
ozonid
larg
scale
mmol
gave
satisfi
yield
without
need
chromatograph
purif
ozonid
arterolan
less
potent
artemeth
vitro
assay
p
falciparum
importantli
activ
known
peroxid
antimalari
vivo
mice
inocul
p
berghei
consequ
chosen
develop
candid
base
upon
potenc
vitro
well
vivo
toxicolog
tissu
ditribut
along
simpl
scaleabl
synthet
protocol
advanc
first
man
clinic
trial
year
also
regain
attent
new
report
show
good
activ
multidrug
resist
p
yoelii
swiss
mice
scheme
particular
suppress
parasit
complet
measur
day
begin
oral
treatment
mgkgday
five
mice
group
surviv
past
day
trioxan
also
show
promis
antimalari
activ
mous
model
given
oral
im
howev
surviv
mice
complet
compar
spirocyclohexyl
trioxan
spiroadamantyl
homolog
strike
import
adamantyl
moieti
obviou
none
mice
treat
surviv
past
day
spiroannel
kept
studi
sever
synthet
synthes
via
enereact
allyl
alcohol
subsequ
bf
catalyz
peroxyacet
screen
vitro
strain
p
falciparum
also
one
incorpor
moieti
eg
scheme
ic
nm
cytotox
ic
potent
one
compound
screen
work
spirocyclopentaneor
spirocyclohexanetrioxan
group
gener
less
activ
adamantan
motif
prove
enhanc
activ
spiroannel
malaria
chemotherapeut
trioxolan
first
fulli
synthet
antimalari
peroxid
advanc
clinic
trial
sinc
antimalari
activ
inspir
natur
compound
artemisinin
larg
determin
peroxid
group
larger
substrat
librari
compound
deriv
spiroadamantanetrioxolan
synthes
via
griesbaum
coozonolysi
subsequ
convers
screen
better
describ
mechan
action
report
pharmacolog
toxicolog
profil
class
compound
best
describ
lead
structur
scheme
chosen
start
point
sar
isoster
scheme
inact
vitro
well
vivo
likewis
spiroadamantan
motif
requir
strong
antimalari
activ
gener
lipophil
antimalari
peroxid
potent
moreov
synthet
trioxolan
show
limit
oral
bioavail
lipophil
deriv
better
activ
oral
polar
counterpart
mention
accord
iron
activ
hypothesi
antimalari
activ
peroxid
group
expos
compound
larg
lose
activ
due
high
metabol
inaccess
peroxid
group
equal
detriment
sinc
fe
ii
speci
attack
peroxid
favor
enabl
electron
transfer
consequ
compound
balanc
properti
term
steric
congest
e
g
display
antimalari
activ
compar
artemisinin
control
experi
ic
ngml
ic
ngml
lipophil
moieti
adamantan
activ
weakli
potent
vitro
complet
inact
vivo
similarli
lipophil
spiroadamantan
significantli
activ
find
along
pronounc
decreas
potenc
compar
spiroadamantan
spirobicyclo
nonan
prove
uniqu
contribut
spiroadamantan
ring
system
antimalari
activ
trioxolan
howev
poor
solubl
seem
sever
restrict
oral
absorpt
trioxolan
studi
compound
highest
bioavail
around
rat
also
lowest
plasma
clearanc
regard
toxicolog
new
spiroadamantan
trioxolan
gener
uncoml
particular
neurotox
neuroblastoma
cell
line
significantli
lower
artemisinin
author
later
studi
detail
influenc
function
group
polar
physicochem
properti
divers
function
spiroadamantan
trioxolan
compound
screen
quit
potent
p
falciparum
chloroquineresist
strain
ic
ngml
moder
high
lipophil
requir
good
antimalari
potenc
carboxyl
acid
consider
less
potent
weak
base
gener
good
potenc
vivo
model
use
p
berghei
infect
mice
deriv
good
oral
activ
lipophil
one
conclus
becam
evid
vitro
potenc
alon
reliabl
predictor
vivo
activ
mechanist
studi
fragment
process
variou
exampl
antimalari
trioxolan
react
fe
ii
speci
show
small
prefer
attack
fe
ii
nonketalperoxid
oxygen
artemisinin
less
expos
presum
biolog
stabl
peroxid
bond
relat
least
part
explain
latter
compound
much
weaker
activ
compar
artemisinin
electron
transfer
lead
carboncent
radic
seem
constitut
requir
activ
step
artemisinin
peroxid
antimalari
pharmacokinet
heavili
influenc
physicochem
properti
peroxid
antimalari
formul
play
signific
role
well
altern
approach
enhanc
pharmacokinet
synthet
ozonid
pursu
bind
spiroadamantan
antimalari
cyclodextrin
vehicl
intraven
administr
one
exampl
sinc
cyclodextrin
also
use
solubil
highli
lipophil
drug
aqueou
media
find
also
could
impact
oral
administ
formul
studi
kinet
fe
ii
mediat
degrad
antimalari
repres
anoth
attempt
elucid
moa
compoud
remain
controversi
target
alkyl
fe
ii
mediat
gener
ccenter
radic
amongst
other
plasmodium
calcium
atpas
translat
control
tumor
protein
tctp
haem
glutathion
alkyl
studi
substrat
conduct
peroxid
antimalari
requir
presenc
fe
ii
studi
degrad
kinet
compound
feso
via
lcm
analysi
use
radic
trap
isol
intermedi
author
found
scheme
essenti
unreact
wherea
scheme
degrad
fast
observ
essenti
parallel
antimalari
activ
pattern
mechan
reduct
degrad
trioxolan
involv
fe
ii
induc
homolyt
peroxidesciss
subsequ
rearrang
ccenter
radic
author
conclud
spiroadamantan
substitu
appear
impart
uniqu
physicochem
pharmacokinet
pharmacodynam
properti
either
radic
intermedi
intact
molecul
necessari
antimalari
activ
trioxolan
directli
relat
ironmedi
reactiv
fe
ii
mediat
reactiv
appear
necesseri
insuffici
prerequisit
activ
antimalari
peroxid
class
compar
correspond
former
either
inact
order
magnitud
less
activ
latter
p
falciparum
vitro
screen
p
berghei
vivo
test
respect
reason
behind
find
reaction
fe
ii
give
twoelectron
reduct
dioxolan
instead
oneelectron
reduct
trioxolan
much
less
ccenter
radic
form
cytochrom
liver
microsom
later
found
select
hydroxyl
one
two
tertiari
posit
spiroadamantan
framework
result
metabolit
see
also
chapter
devoid
antimalari
activ
demonstr
essenti
contribut
unsubstitut
spiroadamantan
motif
antimalari
activ
recent
studi
sar
arterolan
relat
spiroadamantan
antimalari
therefor
focus
modif
spirocyclohexan
moieti
maleat
combin
antimalari
drug
piperaquin
enter
phase
iii
clinic
trial
still
librari
compound
substitut
cyclohexan
moieti
studi
bear
mind
higher
lipophil
shown
gener
enhanc
oral
bioavail
basic
acid
peroxid
good
antimalari
ic
compound
librari
gener
ngml
quit
similar
artesun
control
vitro
screen
use
differ
strain
malaria
parasit
activ
ozonid
vivo
p
berghei
infect
mice
weak
base
matabol
stabl
neutral
ozonid
includ
promis
new
ozonid
depict
scheme
found
cur
p
berghei
infect
mice
given
mgkg
day
three
time
postinfect
three
five
mice
treat
group
surviv
detect
parasit
day
post
infect
ozonid
screen
also
increas
mean
surviv
time
mice
compar
control
treatment
importantli
compar
known
drug
artemisinin
chloroquin
respect
aminopiperidin
also
highest
oral
bioavail
rat
minim
toxic
given
oral
rat
dose
high
mgkg
five
day
overal
quit
simiar
toxic
profil
arterolan
conclus
line
mechanist
find
variat
cyclohexan
moieti
influenc
vitro
potenc
trioxolan
larg
extent
therefor
util
finetun
compound
adm
properti
result
followup
develop
candid
avail
develop
continu
recent
report
includ
studi
stage
sensit
malaria
parasit
arterolan
find
radiolabel
accumul
red
blood
cell
infect
p
falciparum
arterolan
also
shown
activ
p
vivax
strain
malaria
parasit
frequent
temper
climat
also
begin
develop
resist
known
drug
also
excel
activ
freshli
obtain
chloroquineresist
isol
p
falciparum
vitro
antiplasmodi
specif
also
studi
inhibit
p
falciparum
atpas
albeit
somewhat
lower
potenc
artemisinin
iron
chelat
abrog
activ
well
artemisinin
concentr
intraerythrocyt
parasit
compar
extracellular
concentr
via
fluoresc
label
author
also
studi
subcellular
concentr
find
similar
behavior
artemisinin
test
possibl
combin
therapi
combin
piperaquin
suggest
legitim
choic
develop
arterolan
seem
similarli
affect
stage
p
falciparum
least
vitro
address
moa
recent
studi
along
nonperoxid
isoster
vide
supra
nitroxyl
radic
ic
artemisinin
lower
nonperoxid
isoster
antagon
tempo
action
peroxid
antimalari
suggest
format
ccenter
radic
essenti
prerequisit
activ
class
antimalari
activ
develop
today
drug
candid
clinic
trial
close
relat
also
receiv
renew
interest
screen
larger
librari
spiroadamantan
trioxan
synthes
via
photooxygen
allyl
alcohol
hydroperoxid
react
readili
adamantanon
gave
amongst
other
novel
e
g
scheme
substitut
gave
suppress
parasitaemia
p
yoelii
swiss
mice
mgkg
day
treat
mice
surviv
beyond
day
postinfect
howev
studi
rhesu
money
infect
p
cynomolgi
activ
given
oral
mgkg
day
clear
parasitaemia
provid
longterm
protect
poorli
activ
given
intramuscular
rout
addit
requir
activ
adamantan
spiroannel
posit
skeleton
compound
scheme
also
studi
author
find
cur
rhesu
monkey
infect
p
knowlesii
given
mgkg
day
via
intramuscular
rout
author
state
compound
consid
promis
develop
treatment
sever
malaria
current
phase
ii
clinic
trial
anoth
synthet
spiroadamantan
endoperoxid
name
develop
attempt
extend
vivo
half
life
h
arterolan
rat
vitro
fe
ii
induc
degrad
time
slower
likewis
time
stabl
healthi
rat
blood
time
stabl
healthi
human
blood
sampl
rat
half
life
follow
oral
dodos
h
drug
candid
highli
activ
fast
onset
action
vivo
p
berghei
infect
mice
time
display
signific
prophylact
activ
author
express
hope
second
gener
spiroadamantan
endoperoxid
could
end
singledos
cure
sar
effort
also
ongo
field
substitut
activ
p
falciparum
addit
effort
undertaken
studi
mechan
action
spiroadamantan
endoperoxid
artemisinin
deriv
end
biotinyl
deriv
class
antimalari
report
envis
label
protein
alkyl
endoperoxid
cleavabl
biotin
moieti
streptavidinbiotin
pulldown
assay
could
subsequ
util
identifi
target
protein
isar
alkyl
antimalari
drug
said
fluorescentlabel
spiroadamantan
analogu
synthes
util
fluoresc
microscopi
clearli
show
accumul
fluoresc
label
food
vacuol
parasit
carri
label
adamantan
moieti
wherea
label
cyclohexan
moieti
show
clear
local
pattern
clearli
show
ccenter
radic
act
alkyl
agent
must
adamantanederiv
view
far
endoperoxid
prepar
screen
adamantaneannel
spirotrioxan
spirotrioxolan
seem
princip
pharmacophor
arterolan
mark
breakthrough
late
clinic
trial
possibl
altern
identifi
also
advanc
clinic
remain
seen
spiroadamantan
endoperoxid
success
reach
pharmaceut
market
protozoan
signific
impact
mainli
subsaharan
africa
parasit
trypanosoma
genu
specif
trypanosoma
brucei
gambiens
trypanosoma
rhodesiens
parasit
use
tsets
fli
insect
vector
mammal
includ
human
secondari
host
brucei
live
bloodstream
mammalian
host
readi
reinfect
fli
vector
upon
bite
later
stage
infect
mammal
area
host
affect
includ
cn
stage
infect
parasit
caus
loss
neuron
popul
result
amongst
symptom
disturb
sleepcycl
gave
human
african
trypanosomiasi
hat
familiar
name
african
sleep
sick
diseas
invari
fatal
treat
sinc
parasit
repeatedli
chang
surfac
coat
present
host
immun
system
antigen
variat
prospect
vaccin
poor
render
chemotherapeut
essenti
affect
human
popul
howev
mostli
poor
render
drug
develop
econom
unattract
reflect
least
part
small
number
avail
drug
combat
brucei
particular
neurolog
phase
infect
avail
drug
requir
medic
supervis
drug
choic
advanc
stage
diseas
melarsoprol
arsen
compound
caus
sever
sideeffect
lead
reactiv
encephalopathi
death
treat
patient
chemotherapeut
therefor
urgent
need
one
drug
eflornithin
regist
last
year
kelli
et
al
report
upon
studi
express
influenza
protein
trypanosom
discov
vitro
antitrypanosom
effect
antivir
drug
rimantadin
vide
supra
bloodstream
form
parasit
author
found
trypanocid
effect
rimantadin
amantadin
phdepend
higher
ph
drug
becom
potent
ic
valu
rang
rimantadin
somewhat
activ
amantadin
rimantadin
also
found
activ
strain
parasit
name
cruzi
relat
organ
leishmania
major
mechan
action
aminoadamantan
remain
unclear
author
assum
analog
antiinfluenza
activ
interfer
drug
phmainten
parasit
possibl
block
transmembran
transport
proton
pump
followup
studi
larger
compound
librari
aminoadamantaneand
aminocyclohexan
deriv
screen
brucei
vitro
assay
screen
compound
activ
rimantadin
depict
scheme
increas
hyrophob
obvious
enhanc
trypanocid
activ
compound
potent
screen
time
effect
rimantadin
vivo
model
use
immunosuppress
mice
infect
brucei
strain
potent
compound
discontinu
due
signific
toxic
also
case
well
possibl
number
trypanocid
compound
screen
mechan
action
rudimentari
lipophil
enhanc
potenc
sar
noth
new
discov
author
discuss
wellknown
enrich
aminoadamantan
lysosom
mammalian
cell
elev
ph
adamantan
scaffold
prerequisit
activ
number
aminocyclohexan
also
trypanocid
potent
one
still
aminoadamantan
lipophil
display
significantli
stonger
trypanocid
activ
scheme
sinc
critic
stage
brucei
infect
invas
parasit
cn
aminoadamantan
cnsactiv
drug
vide
infra
readili
distribut
cn
reason
ideal
drug
candid
treatment
advanc
stage
hat
subsequ
research
gave
compound
trypanocid
activ
compar
better
rimantadin
scheme
spiroadamantan
heterocycl
primarili
synthes
antiinfluenza
compound
also
display
trypanocid
activ
like
spiro
barbitur
analog
piperidin
cage
hydrocarbon
adamantan
also
util
scaffold
antit
brucei
compound
bisnoradamantyl
methylamin
structur
close
relat
rimantadin
gave
similar
ic
ic
valu
respect
seri
test
display
signific
activ
sinc
class
adamantylheterocycl
effect
microtubul
associ
correl
trypanocid
potenc
effect
tubulin
polymer
obvious
contribut
antitrypanosom
activ
adamantan
oxazolon
adamantan
cyclopentan
amin
also
exampl
adamantyl
substitut
heterocyl
trypanocid
activ
compar
potenc
vitro
test
combin
guanylhydrazon
pharmacophor
known
sadenosylmethionin
decarboxylas
inhibitor
trypanocid
motif
lipophil
substitut
adamantan
moieti
synergist
effect
lipophil
adamantan
scaffold
function
could
observ
compound
class
trypanocid
decan
oxadecan
substitut
matter
substitu
shown
ideal
term
vitro
trypanocid
potenc
lastli
oxaheterocycl
amin
like
oxaadamantan
secondari
amin
also
shown
display
antit
brucei
activ
vitro
furthermor
latter
oxapolycycl
amin
devoid
nmdareceptor
antagon
could
use
avoid
cnsrelat
side
effect
use
compound
combat
brucei
trypanosom
clinic
recent
addit
librari
adamantanederiv
trypanocid
compound
amino
alcohol
protoadamantan
well
spiro
carboxycl
adamantyliden
diketopiperazin
find
interest
extent
encourag
develop
low
cost
chemotherapeut
kind
neglect
diseas
data
provid
chapter
mostli
provid
vitro
potenc
variou
cage
amin
gener
use
simpl
assay
cultur
brucei
bloodstream
form
import
test
like
routin
toxic
screen
vitro
better
vivo
mostli
perform
physicochem
pharmacokinet
data
also
absent
fortuit
find
aminoadamantan
relat
compound
antitrypanosom
agent
taken
grain
salt
much
data
particular
regard
mechan
action
molecul
requir
judg
whether
aminoadamantan
could
becom
clinic
use
diseas
control
hat
earli
april
woman
moder
sever
bilater
parkinson
diseas
recount
us
three
month
take
amantadin
hydrochlorid
mg
twice
daili
prevent
flu
experienc
remark
remiss
symptom
rigid
tremor
akinesia
promptli
return
stop
drug
six
week
fortuit
find
report
schwab
et
al
may
mark
begin
medicin
chemistri
adamantan
deriv
context
diseas
affect
central
nervou
system
account
lipophil
bbbpenetr
enhanc
properti
sinc
becom
el
dorado
util
adamantan
deriv
medicin
chemistri
find
case
report
reassess
group
patient
suffer
parkinson
diseas
pd
show
improv
treat
amantadin
major
patient
kept
sustain
benefit
three
eight
month
durat
amantadin
treatment
slow
steadi
reduct
benefit
could
seen
one
third
patient
previous
improv
group
patient
shift
amantadin
placebo
without
knowledg
becam
awar
chang
within
one
day
group
patient
initi
trial
heterogen
respect
amongst
other
treatment
regimen
previou
treatment
histori
age
durat
diseas
howev
benefit
amantadin
treatment
remain
remark
schwab
et
al
conced
amantadin
hydrochlorid
lessen
rigid
akinesia
even
parkinson
tremor
clear
pharmacolog
nevertheless
second
clinic
applic
amantadin
discov
use
adjunct
therapi
pd
particular
ldopa
induc
dyskinesia
today
subsequ
clinic
trial
gener
corrobor
find
effect
amantadin
proven
benefici
particular
given
togeth
standard
therapi
ldopa
gener
typic
dose
regimen
use
mg
per
day
even
higher
dose
regard
safe
notabl
side
effect
weak
revers
one
outpati
took
capsul
mg
amantadin
hydrochlorid
attempt
suicid
surviv
aminoadamantan
antivir
market
rimantadin
also
studi
patient
give
essenti
benefici
effect
earli
clinic
trial
howev
recent
state
symptomat
benefit
could
achiev
group
patient
take
rimantadin
particular
rigid
improv
firstlin
pd
treatment
ldopacarbidopa
induc
wellknown
sideeffect
like
motor
fluctuat
amelior
also
need
amantadin
mgday
ad
stabl
antipd
drug
regimen
decreas
sever
endofdos
deterior
wearingoff
chronic
treat
pd
patient
amantadin
effect
irrespect
durat
diseas
durat
previou
treatment
anoth
simpl
aminoadamantan
initi
studi
antiinfluenza
activ
memantin
scheme
identifi
symptomat
benefit
pd
small
structral
differ
methyl
substitut
two
three
remain
tertiari
posit
adamantan
scaffold
also
lead
intrigu
differ
pharmacolog
profil
becam
particularli
obviou
drug
research
field
pd
identif
amantadin
agent
use
clinic
manag
pd
multitud
deriv
synthes
studi
obviou
approach
vide
supra
combin
pharmacophor
cholinolyt
activ
phosphoramid
found
earlier
class
compound
combin
aminoadamantan
give
phosphoamid
like
scheme
also
would
display
amantadin
dopamineenhanc
effect
possibl
improv
pharmacokinet
cnstarget
compound
reserpineinduc
catalepsi
rat
experiment
model
toxininduc
pd
sever
adamantanealkanamin
prepar
use
instanc
pb
oac
mediat
intrameolecular
chfunction
secondari
posit
found
potent
amantadin
diol
show
best
activ
paradigm
sever
aminoadamantan
includ
amantadin
memantin
report
activ
chemic
induc
via
spiroperidol
catalepsi
pd
wistar
rat
memantin
mgkg
ip
reduc
catalepsi
amantadin
dosag
gave
reduct
worker
conclud
memantin
stronger
action
cn
amantadin
protoadamantanamin
well
newli
synthes
substitut
adamantanealkanamin
screen
antipd
agent
revers
reserpineinduc
catalepsi
mice
rat
show
gave
complet
revers
catalepsi
mmolkg
ld
mmolkg
mice
systemat
studi
effect
bridgeheadsubstitut
small
librari
seven
alkylsubstitut
adamantan
amin
util
three
model
pd
stimul
spontan
locomotor
activ
mice
modif
circl
behavior
mice
unilater
striatal
lesion
inject
revers
reserpineinduc
akinesia
mice
induct
locomotor
activ
saw
strike
differ
even
within
small
compound
librari
amantadin
least
activ
memantin
activ
amphetamin
paradigm
author
attribut
differ
two
separ
dopaminerg
mechan
action
indirect
agon
memantin
methylsubstitut
aminoadamantan
direct
dopamin
agonist
compon
ethyl
deriv
like
lipophil
found
contribut
posit
antiparkinsonian
activ
aminoadamantan
clearli
sole
activitydetermin
factor
least
class
aminoadamantan
worker
state
factor
best
describ
observ
activ
trend
would
molecular
shape
similar
result
report
nalkyl
substitut
amantadin
memantin
deriv
like
compound
increas
lipophil
somewhat
enhanc
activ
howev
reason
underli
benefici
effect
nalkyl
substitut
remain
obscur
also
found
increas
dopaminereleas
dopaminerg
nerv
termin
within
seri
nine
adamantylsubstitut
aminoalcohol
studi
multiparamet
screen
mice
found
diplay
effect
antipd
activ
author
attribut
find
cnspenetr
capabl
compound
found
pronounc
compound
bear
c
c
well
c
c
alkyl
residu
comparison
bind
twelv
aminoadamantan
bind
site
nmdareceptor
memantin
bind
site
vide
infra
via
displac
h
membran
homogen
postmortem
human
frontal
cortex
found
strongest
bind
aminoadamantan
studi
k
nmethylaminoadamantan
weakest
bind
compound
memantin
nearli
strongli
bind
diethyl
analog
k
amantadin
higher
k
reflect
time
higher
dose
latter
memantin
use
clinic
pd
structur
anoth
aminoadamantan
deriv
studi
antiparkinsonian
agent
e
g
chemic
induc
parkinson
mice
recent
adamantan
deriv
studi
context
pd
tempoderiv
like
fullerenederiv
compound
shown
activ
chemic
induc
parkinson
rodent
recent
develop
also
includ
synthesi
subtypespecif
nmdareceptor
antagonist
like
compound
found
possess
select
subunit
nmdareceptor
show
effect
dopamineconcentr
rat
increas
releas
noradrenalin
dopamin
hippocamp
striatal
slice
low
micromolar
concentr
aminoadamantan
improv
pd
symptom
mechan
action
known
degener
dopaminerg
pathway
basal
ganglia
main
patholog
pd
affect
dopamin
level
metabolit
first
potenti
pharmacolog
activ
diuscuss
aminoadamantan
potenti
pd
eari
studi
base
upon
indirect
vivo
evid
howev
direct
dopaminomimet
activ
aminoadamantan
propos
remain
controversi
probabl
also
due
lack
methodolog
studi
process
dog
grelak
et
al
found
amantadin
increas
dopamin
concentr
author
assum
drug
dopamin
releaseenhanc
effect
experiment
observ
variou
model
system
report
corrobor
amantadin
antipd
activ
includ
enhanc
synthesi
releas
dopamin
blockag
dopamin
reuptak
transport
system
neuron
activ
would
end
addit
dopamin
avail
neuron
transmiss
synapt
cleft
direct
action
agonist
dopamin
receptor
also
discuss
amantadin
accord
studi
inhibitori
activ
amantadin
weak
action
fulli
explain
symptomat
benefit
pd
increas
dopamin
synthesi
ex
vivo
mgkg
amantadin
could
never
reproduc
even
controversi
vaastra
et
al
report
enhanc
effect
adamantan
dopamin
releas
inhibit
effect
dopaminereuptak
studi
even
two
potenti
action
amantadin
pd
model
consid
suffici
fulli
explain
amantadin
use
pd
cox
et
al
studi
tremor
amantadin
caus
mice
given
higher
dose
ed
mg
kg
mgkg
anim
display
tremor
assum
central
origin
pchloro
phenylalanin
somewhat
protect
amantadineinduc
tremor
depletor
brain
amin
e
g
diethyldithiocarbam
deplet
particular
brain
noradrenalin
caus
signific
potenti
amantadin
tremorinduc
effect
obvious
loss
catecholamin
store
increas
suscept
mice
effect
high
dose
amantadin
sinc
pchloro
phenylalanin
select
deplet
brain
serotonin
pretreat
drug
almost
complet
abolish
tremor
induc
amantadin
effect
amantadin
attribut
serotonin
system
effect
activ
brain
monoamin
oxidas
mao
enzym
crucial
biosynthesi
catecholamin
could
shown
likewis
effect
serotonin
reuptak
observ
result
author
conclud
amantadin
sensit
serotonin
receptor
rat
fundu
model
could
observ
enhanc
serotonin
activ
amantadin
sinc
pd
decreas
serotonin
observ
addit
wellknown
loss
dopamin
amantadin
addit
effect
could
lie
serotonin
system
wesemann
et
al
studi
serotonerg
activ
detail
use
isol
structur
like
synapt
vesicl
membran
synaptosom
uptak
bind
releas
serotonin
studi
result
favor
hypothesi
serotonin
uptak
synapt
vesicl
inhibit
amantadin
howev
high
k
low
inhibitori
effect
make
unlik
amantadin
effect
memantin
effect
respect
somewhat
stronger
inhibit
serotonin
releas
serotonin
reuptak
synaptosom
amantadin
memantin
suggest
interact
aminoadamantan
nerv
end
membran
intracellular
compartment
serotonin
howev
even
find
explain
interfer
molecular
level
da
transport
distribut
studi
effect
memantin
membran
potenti
measur
isol
nerv
fibr
bundl
effect
drug
permeabl
membran
k
na
cl
found
use
explan
aminoadamantan
activ
pd
memantin
also
found
inhibit
activ
sever
cation
channel
lead
suppress
neuron
activ
cell
cultur
experi
nmdareceptor
subsequ
intens
studi
potenti
target
aminoadamantan
activ
pd
experi
studi
bind
aminoadamantan
nmdareceptor
show
effect
memantin
site
nmdareceptor
also
much
higher
select
memantin
amantadin
receptor
interact
dopamin
opioid
gaba
adrenerg
receptor
found
studi
electrophysiolog
show
memantin
concentr
obtain
clinic
inde
prevent
nmdareceptor
mediat
neurotox
rat
retin
ganglion
cell
well
cortic
neuron
concentr
memantin
obtain
clinic
human
cerebrospin
fluid
csf
correl
serum
concentr
given
dose
mgday
could
well
within
rang
requir
bind
nmda
receptor
k
human
frontal
cortex
likewis
amantadin
concentr
obtain
clinic
also
within
rang
k
pcpbind
site
nmda
receptor
well
high
enough
stimul
post
mortem
concentr
amantadin
brain
slice
patient
amantadin
regimen
gave
homogen
distribut
drug
brain
concentr
rang
much
lower
concentr
detect
csf
serum
six
week
treatment
mice
amantadin
result
reduc
effect
stimul
cn
act
presynapt
e
g
amphetamin
propos
amantadin
effect
interact
postsynapt
side
within
membran
adjac
actual
recognit
site
therebi
increas
dopamin
receptor
affin
agonist
amantadin
also
studi
reliabl
model
pd
mptp
induc
parkinson
mice
drug
found
caus
increas
striatal
dopamin
turnov
anim
excel
summari
research
conduct
preclin
field
aminoadamantan
treat
pd
publish
danysz
et
al
summar
particular
chang
scientif
commun
attent
toward
nmdareceptor
antagon
major
activ
aminoadamantan
late
summar
earli
vitro
studi
amantadin
memantin
inhibit
nmdastimul
acetylcholin
releas
indirect
action
probabl
pivot
antiparkinsonian
effect
exert
drug
aminoadamantan
particular
amantadin
higher
concentr
obtain
clinic
may
also
act
nicotin
receptor
enhanc
noradrenerg
neurotransmiss
biochem
rel
high
concentr
aminoadamantan
would
requir
clear
antagon
nmdareceptor
depend
subtyp
memantin
consist
gave
higher
affin
ion
channel
even
high
dose
amantadin
mgkg
affect
dopamin
level
whole
brain
instead
decreas
noradrenalin
serotonin
turnov
observ
brown
et
al
well
maj
et
al
also
question
direct
dopaminomimet
effect
amantadin
high
dose
mgkg
likewis
memantin
found
chang
level
serotonin
dopamin
metabolit
variou
brain
region
studi
ex
vivo
result
highli
inconsist
small
magnitud
satisfactorili
explain
memantin
potenc
move
vivo
studi
also
highdosag
experi
discuss
cat
perfus
amantadin
increas
preload
dopamin
observ
vivo
studi
show
modest
highli
variabl
effect
aminoadamantan
dopaminerg
system
likewis
use
extrem
high
clinic
irrelev
concentr
drug
therefor
consid
reliabl
elucid
primari
moa
drug
nmdareceptor
antagon
consid
result
openchannel
block
receptor
pore
aminoadamantan
strongli
voltagedepend
antagonist
differ
activ
amantadin
memantin
found
variou
brain
region
strikingli
parallel
nmdareceptor
induc
acetylcholin
releas
area
amantadin
higher
activ
striatal
slice
compar
hippocamp
slice
clinic
relev
concentr
amantadin
activ
striatum
wherea
memantin
lower
clinic
relev
concentr
seem
activ
nonstriat
part
brain
may
explain
amantadin
better
suit
treat
pd
human
low
affin
fast
unblock
characterist
aminoadamantan
particularli
advantag
clinic
sinc
allow
receptor
stay
function
unlik
highaffin
nmdar
antagonist
e
g
distribut
nmdarsubtyp
brain
memantin
higher
select
may
also
explain
altern
block
mechan
two
drug
observ
summar
preclin
studi
perform
amantadin
memantin
particulari
emphas
nmdar
antagon
aminoadamantan
obvious
directli
act
dopaminerg
system
consensu
earlier
rather
manifest
antiparkinsonian
effect
attenu
imbal
dopaminerg
glutamaterg
pathway
least
larg
extent
mediat
nmda
receptor
antagon
reason
amantadin
seem
better
suit
pd
treatment
could
lie
addit
abovement
nmdar
subtyp
occur
brain
region
primarili
affect
patholog
amantadin
bind
site
block
neuron
nicotin
acetylcholin
receptor
capabl
increas
noradrenalinereleas
three
latter
properti
could
attribut
memantin
anoth
concept
particularli
interest
context
neurodegen
diseas
like
pd
neuroprotect
properti
becam
en
vogu
excess
concentr
excitatori
neurotransmitt
glutam
instanc
neurotox
vitro
stuti
glutamatemedi
excitotox
amongst
insult
attenu
amantadin
memantin
consequ
report
amantadin
increas
life
expect
pd
patient
effect
could
also
least
part
explain
direct
trophic
effect
drug
summar
saw
consensu
scientif
commun
antiparkinsonian
properti
aminoadamantan
explain
nmdarantagon
clinic
relev
concentr
addit
effect
observ
amantadin
could
explain
better
applic
pd
comparison
memantin
e
g
interact
receptor
etc
low
concentr
aminoadamantan
could
also
exert
neuroprotect
activ
excitotox
condit
latter
potenti
effect
clearli
interest
neurodegen
diseas
eg
dementia
huntington
chorea
well
continu
discuss
chapter
recent
studi
explain
amantadin
antiparkinsonian
activ
includ
possibl
modulatori
effect
product
reactiv
oxygen
speci
ro
effect
must
indirect
sinc
aminoadamantan
per
se
act
scaveng
quencher
amantadin
furthermor
identifi
noncompetit
antagonist
nicotin
acetylcholin
receptor
dose
alter
function
ligandg
ion
channel
rat
hippocamp
neuron
regard
nachr
amantadin
ic
close
clinic
obtain
concentr
drug
dose
mice
memantin
also
found
exert
effect
beyond
nmdaantagon
particular
stimul
effect
cholinerg
signal
via
muscarin
receptor
could
detect
mous
hippocampu
amin
transport
could
respons
monoamin
reuptak
found
block
competit
amantadin
memantin
furthermor
rat
amantadin
memantin
like
glutam
antagonist
caus
pronounc
increas
aromat
lamino
acid
decarboxylas
aadc
also
known
dopadecarboxylas
effect
also
would
contribut
enhanc
dopamin
turnov
upon
aminoadamantan
treatment
geneexpress
aadc
special
import
ldopa
therapi
pd
found
induc
amantadin
cell
cultur
effect
amantadin
dopamin
uptak
synaptosom
increas
seven
day
treatment
rat
mgday
ip
use
brain
anim
prepar
synaptosom
fraction
effect
alter
express
dopamin
transport
dat
rather
indirect
effect
via
glutam
receptor
antagon
receptor
also
regul
dat
phosphoryl
therebi
regul
dopamin
reuptak
memantin
also
inhibit
k
atp
channel
dopaminerg
neuron
corrobor
find
studi
perform
year
earlier
recent
studi
mechan
action
amantadin
show
drug
capabl
amelior
ldopa
induc
dyskensia
side
effect
primari
pd
treatment
still
far
understood
fulli
associ
modul
striatonigr
pathway
mice
rat
amantadin
reduc
activ
microglia
amelior
inflammatori
process
consequ
neuron
loss
astroglia
increas
express
neurotroph
factor
gliaderiv
neurotroph
factor
gdnf
effect
amantadin
anoth
mechan
action
summar
term
neuroprotect
lastli
noradrenalin
transport
also
block
amantadin
effect
also
seen
amphetamin
lesser
extent
aminoadamantan
conclus
usag
memantin
even
amantadin
pd
symptom
certainli
involv
interact
simpl
aminoadamantan
host
receptor
system
also
learn
previou
chapter
indirect
mode
action
via
pronounc
membran
modifi
capabl
drug
promiscu
receptor
bind
amantadin
memantin
probabl
best
summar
term
dirti
drug
might
help
drug
discoveri
process
altern
rout
drug
complex
diseas
pd
certainli
one
complex
diseas
exampl
r
scheme
briefli
mention
adamantan
deriv
also
resembl
catecholamin
structur
found
longact
select
dopamin
receptor
agonist
nanomolar
affin
rat
mptptreat
marmoset
revers
parkinsonian
symptom
wherea
enantiom
r
data
substanti
hypothesi
receptor
agonist
may
use
clinic
pd
followup
studi
show
howev
rapid
desensit
receptor
dose
escal
suit
fulli
restor
antipd
symptom
benefit
mptptreat
anim
cell
cultur
studi
later
show
r
obvious
good
agonist
receptor
dissoci
extrem
slowli
receptor
caus
long
durat
receptor
activ
subsequ
destabil
final
give
rise
behavior
toler
vivo
support
principl
suitabl
receptor
drug
target
pd
behavior
studi
mptptreat
marmoset
model
recent
studi
focus
effect
receptor
stimul
treatment
anim
ldopa
carbidopa
agonist
amongst
other
r
show
symptomat
benefit
model
pd
dopaminerg
system
depend
intact
receptor
howev
antiparkinsonian
effect
r
abovement
marmoset
model
strongli
diminish
upon
addit
select
antagonist
structur
r
subsequ
play
role
elucid
neg
feedback
regul
dopamin
releas
mammalian
brain
knowledg
may
also
signific
pd
research
compound
r
appear
bind
receptor
complex
extent
stabil
subtyp
intern
neuron
studi
receptor
recov
cell
surfac
later
demonstr
activ
potent
longact
agonist
beyond
immedi
activ
receptor
probabl
caus
alloster
interact
chapter
util
adamantan
deriv
clinic
combat
pd
symptom
well
elucid
experiment
molecular
dysfunct
underli
pd
relat
disord
could
learn
amantadin
safe
effici
clinic
particular
given
adjunct
ldopa
regimen
least
part
amantadin
even
memantin
benefit
pd
attribut
noncompetit
nmda
receptor
antagon
also
act
neuroprotect
lead
later
onset
dementia
pd
patient
treat
amantadin
effect
directli
point
toward
next
major
applic
adamantan
deriv
see
chapter
likewis
aminoadamantan
dirti
drug
host
site
interact
compound
mostli
locat
cn
identifi
could
give
rise
drug
develop
target
futur
previou
chapter
encount
sever
time
effect
adamantan
deriv
ion
permeabl
ascrib
interact
ion
channel
nmdareceptor
potassium
channel
found
cell
type
play
import
role
e
g
regul
blood
pressur
maintain
shape
membran
potenti
therefor
ion
channel
repres
reward
target
drug
develop
atp
sensit
potassium
k
atp
channel
control
intracellular
concentr
atp
open
caus
decreas
intracellular
atp
last
decad
steadi
drumbeat
studi
via
xray
crystallographi
electrophysiolog
elucid
structur
well
kinet
pharmacolog
interfer
class
ion
channel
subtyp
control
pancreat
k
atp
channel
pharmaceut
like
e
g
tolbutamid
result
increas
insulin
excret
alreadi
heard
hypoglycem
properti
adamantanederiv
sulfonylurea
start
adamantan
deriv
found
exhibit
insulin
releas
activ
vitro
studi
mous
islet
model
system
amantadin
report
potent
respect
acid
display
markedli
weaker
effect
devoid
insulinreleas
potenc
author
conclud
aminoadamantan
decreas
k
permeabl
membran
caus
depolar
voltagedepend
ca
channel
follow
ca
influx
subsequ
insulin
releas
howev
author
expect
aminoadamantan
per
se
becom
use
drug
treatment
diabet
molecul
addit
molecul
alreadi
activ
compound
may
perhap
provid
use
drug
see
also
chapter
nevertheless
aminoadamantan
far
simplest
molecul
inhibit
potassium
channel
effect
potassium
channel
report
number
adamantan
deriv
includ
scheme
found
select
block
myocardi
k
channel
antagon
effect
acetylcholin
potassium
channel
activ
sinc
open
potassium
channel
vasodil
antihypertens
antagon
highli
use
drug
develop
arena
previous
one
sulfonylurea
deriv
consist
block
action
potassium
channel
open
first
nonsulfonylurea
exhibit
profil
benefici
target
valid
process
guanidin
deriv
compound
capabl
consist
select
block
pharmacolog
respons
k
channel
open
vitro
vivo
synerg
sulfonylurea
glyburid
action
antagonist
vasodil
k
atp
channel
open
exampl
util
elucid
regul
vascular
k
atp
activ
studi
effect
analogu
follicleenclos
oocyt
xenopu
deriv
capabl
potassium
channel
blocker
studi
detail
like
abl
inhibit
k
atp
current
displac
h
bind
site
indic
decis
effect
adamantan
cage
receptor
bind
anoth
major
featur
select
unlik
amantadin
vide
supra
stimul
insulin
excret
recent
use
studi
variou
subty
clone
k
atp
chann
xenopu
oocyt
k
atp
channel
rat
middl
mening
arteri
sinc
dilat
intracrani
arteri
may
caus
migrain
reach
brain
area
also
point
part
memantin
antiparkinsonian
activ
may
addit
nmdareceptor
antagon
relat
effect
k
atp
channel
brain
k
atp
conduct
play
role
degener
dopaminerg
neuron
k
atp
channel
open
condit
metabol
stress
pharmacolog
block
channel
may
least
part
respons
memantin
antiparkinsonian
effect
anoth
ion
channel
medicin
import
socal
ampa
receptor
gate
scheme
togeth
glutam
receptor
open
nmda
kainat
ionotrop
glutam
receptor
play
crucial
role
process
longterm
potenti
ltp
longterm
depress
underli
learn
memori
therefor
valuabl
target
pharmacolog
research
xray
crystal
structur
ionotrop
glutam
receptor
avail
truncat
amino
termin
domain
ampa
receptor
subtyp
recent
refer
molecular
machineri
gate
ion
conduct
pharmacolog
manipul
remain
fulli
understood
ampar
tetramer
complex
variabl
compos
dimer
dimer
recruit
receptor
subtyp
ion
channel
assembl
four
site
bind
agonist
depend
subtyp
composit
permeabl
varieti
cation
includ
ca
na
k
notabl
ampar
impair
conduct
ca
import
excitotox
condit
known
varieti
neurolog
disord
regul
phosphoryl
four
site
well
intracellular
process
lead
increas
ampar
believ
take
part
ltp
ampar
well
ionotrop
glutam
receptor
ion
channel
mediat
vast
major
fast
excitatori
interneur
commun
studi
distributon
ampar
subtyp
differ
neuron
popul
role
neuron
network
activ
well
role
diseas
state
depend
avail
subtypeselect
ligand
receptor
addit
distinguish
nmda
kainat
receptor
field
adamantan
deriv
initi
consid
blocker
nmda
nicotin
acetylcholin
receptor
develop
success
util
preclin
dication
adamantan
deriv
scheme
use
studi
electrophysiolog
block
recombin
ampar
express
oocyt
xenopu
laevi
well
vitro
experi
use
neuron
rat
hippocampu
compound
noncompetit
block
conduct
channel
useand
voltagedepend
manner
also
display
subtypeselect
antagon
blockag
celltyp
specif
rat
neuron
studi
presenc
edit
subunit
diminish
block
capabl
adamantan
contain
dicat
indic
use
compound
select
studi
function
subtyp
ampar
edit
subunit
incorpor
arg
residu
instead
gln
residu
segment
locat
mutat
refer
qrsite
addit
posit
charg
within
pore
natur
inhibit
bind
posit
charg
molecul
simpli
electrostat
repuls
compound
found
sever
time
potent
assay
ampar
less
potent
nmda
receptor
inhibitor
case
compound
open
channel
blocker
mean
agonist
present
open
channel
pore
allow
dicat
access
pore
region
basic
function
mode
ampar
corrobor
sever
model
studi
qr
site
within
part
ampar
form
membran
reentri
loop
incorpor
sidechain
presum
complet
extend
pore
rather
form
macrocycl
stabil
interseg
hbond
tetramer
receptor
complex
rational
show
threedimension
similar
bacteri
k
channel
xray
data
avail
end
adamantyl
dicat
polyamin
toxinderiv
compound
also
util
studi
ampar
main
problem
polyamin
lack
select
consequ
librari
deriv
synthes
notabl
combin
adamantan
deriv
headgroup
ampar
channel
blocker
deriv
polyamin
toxin
found
potent
openchannel
blocker
ampar
date
compound
studi
account
via
twoelectron
voltag
clamp
techniqu
x
laevi
oocyt
express
homomer
ampar
incorpor
polyamin
motif
ac
scheme
headgroup
vari
use
variou
amino
acid
side
chain
r
well
small
larg
nacyl
sidechain
r
surprisingli
adamantylacetamid
two
potent
ampa
openchannel
blocker
one
incorpor
charg
amino
acid
side
chain
arg
prefer
compound
adamantan
deriv
potent
ampar
channel
blocker
display
higher
activ
k
nm
compar
nbutanoyl
deriv
k
nm
thu
adamantan
deriv
report
context
consid
hybrid
molecul
resembl
featur
deriv
polyamin
toxin
semipot
ampar
channel
blocker
like
surprisingli
significantli
potent
either
parent
structur
studi
determin
select
dication
adamantan
deriv
magazanik
cowork
found
maximum
activ
ampar
channel
block
oserv
ch
chain
connect
ammonium
group
seen
e
g
dicat
vari
length
use
gain
insight
topographi
ion
channel
adamantan
termin
ammonium
group
postul
interact
lipophil
nucleophil
site
assum
separ
ampar
close
one
anoth
nmdar
therebi
explain
least
part
select
dicat
ampar
mechanist
block
rate
constant
consid
respons
determin
subtyp
select
subunit
composit
actual
ampar
channel
influenc
access
bind
site
within
pore
later
base
upon
homolog
model
ampa
receptor
ion
channel
around
bound
dicat
see
figur
scheme
bind
site
spider
wasp
toxin
polyc
elucid
model
deriv
k
channel
methanobacterium
autotrophicum
belong
receptor
superfamili
recent
detail
electrophysiolog
studi
found
adamantan
contain
dicat
includ
permeat
cytoplasm
open
close
ampar
channel
appli
intracellularli
abl
block
ca
permeabl
ampar
incorpor
subunit
without
agonist
present
act
open
channel
blocker
close
channel
blocker
extracellular
block
could
decreas
intracellular
show
bind
site
case
least
overlap
significantli
clinic
use
ampar
channel
blocker
report
disclos
found
sever
applic
preclin
research
popul
ampar
variou
rat
brain
cell
popul
character
use
find
conveni
marker
absenc
subunit
ampar
cell
type
seem
express
type
ampar
sensit
unsensit
blockag
compound
also
found
decreas
excitatori
postsynapt
current
rat
hippocampu
final
along
monoand
dication
deriv
adamantan
phenylcyclohexan
use
distinguish
nmda
ampa
mediat
process
underli
prevent
pentylenetetrazolinduc
kindl
experiment
mice
main
ionotrop
glutam
receptor
cn
classifi
nmda
receptor
nmethyldaspart
select
agonist
channel
permeabl
sever
cation
characterist
ligandg
voltag
depend
requir
two
excitatori
amino
acid
glutam
glycin
becom
activ
involv
neural
transmiss
well
sever
neurolog
disord
wellknown
glutam
receptor
subtyp
gener
best
studi
drug
target
field
nmdareceptor
mediat
neurotransmiss
primari
interneuron
commun
underli
synapt
plastic
consequ
nmda
receptor
also
target
adamantan
deriv
tabl
report
first
time
medicin
chemistri
context
intermedi
prepar
hypoglycem
sulfonylurea
class
compound
follow
field
diabet
research
instead
merz
file
patent
applic
state
memantin
aminoadamantan
suit
combat
symptom
parkinson
diseas
releas
dopamin
brain
exampl
detail
studi
disclos
point
anoth
patent
applic
merz
disclos
prepar
sever
aminoadamantan
via
reaction
urea
subsequ
hydrolysi
addit
author
state
aminoadamantan
deriv
display
valuabl
pharmacolog
properti
influenc
cn
man
anim
particularli
use
pd
assum
effect
test
compound
catecholaminemetabol
line
consensu
pd
research
time
see
chapter
basic
experi
druginduc
parkinson
mice
disclos
confirm
superior
memantin
amantadin
earlier
aminoadamantan
report
valuabl
context
mostli
alkyl
aminoadamantan
later
svensson
et
al
also
report
differ
memantin
amantadin
summari
earli
studi
cn
effect
memantin
publish
maj
et
al
stress
pronounc
stimul
dopaminerg
system
also
stimul
serotoninerg
gabaerg
system
pharmacodynam
pharmacokinet
data
memantin
well
clinic
observ
corrobor
find
first
clinic
trial
memantin
dementia
report
ten
patient
suffer
sever
ad
treat
mgday
memantin
iv
signific
differ
placebo
group
could
demonstr
howev
mild
amelior
sleepwak
disturb
found
drugtreat
group
number
aminoadamantan
synthes
prevent
treatment
cerebr
ischemia
report
one
sever
patholog
caus
ischemia
ad
briefli
mention
focu
patent
applic
lay
prepar
preclin
screen
small
librari
aminoadamantan
anticonvuls
action
correl
bind
nmdar
studi
use
supermaxim
electroshock
method
mice
min
test
compound
given
ip
anim
variou
concentr
tabl
addit
memantin
shown
act
neuroprotect
model
ischemia
closur
carotid
arteri
rat
preclin
data
aminoadamantan
disclos
includ
comparison
displac
h
membran
homogen
human
postmortem
frontal
cortex
likewis
postmortem
human
frontal
cortex
homogen
also
util
detect
affin
aminoadamantan
competit
experi
aminoadamantan
h
pentazocin
perform
concentr
resembl
obtain
therapeut
amantadin
probabl
bind
nmdar
pcpsite
well
site
tabl
contrast
memantin
therapeut
concentr
probabl
bind
site
render
select
nmdar
antagonist
contribut
clinic
safe
profil
studi
includ
wholecel
patch
clamp
studi
receptor
bind
assay
three
independ
vivo
convuls
model
well
model
motor
impair
vivo
show
aminoadamantan
gener
poor
therapeut
index
epilepsi
model
summar
data
obviou
memantin
higher
affin
select
pcpsite
nmdar
amantadin
aminoadamantan
howev
within
rel
small
librari
aminoadamantan
summar
tabl
molecul
display
higher
affin
e
g
reason
develop
memantin
indic
continu
lie
favor
fast
receptor
blockingunblock
kinet
studi
extens
particular
compar
amantadin
memantin
compound
like
discuss
topic
later
see
chapter
recent
report
nmdar
blocker
incorpor
adamantan
relat
cage
includ
oxacycl
compound
like
scheme
activ
channel
blocker
block
abil
ca
influx
nmdachalleng
primari
neuron
cultur
amantadin
memantin
howev
electrophysiolog
measur
new
compound
report
date
first
clinic
trial
studi
memantin
patient
sever
ad
gave
inconclus
result
vide
supra
howev
given
short
treatment
period
studi
day
small
sampl
size
togeth
obviou
bia
due
increas
attent
patient
particip
requir
addit
trial
renew
interest
class
drug
due
lack
pharmacolog
treatment
option
along
chang
consensu
mechan
action
dopaminerg
nmdarblock
warrant
numer
trial
briefli
mention
trial
report
winblad
et
al
compris
sever
dement
patient
vascular
dementia
alzheim
diseas
gave
encourag
result
group
patient
treatment
memantin
mgday
led
signific
function
improv
reduc
care
depend
treat
group
placebo
control
togeth
find
treatment
amantadin
led
delay
onset
dementia
pd
patient
host
clinic
trial
follow
review
summar
elsewher
memantin
small
benefici
clinic
detect
effect
cognit
function
function
declin
measur
month
patient
moder
sever
alzheim
diseas
ad
patient
mild
moder
dementia
small
benefici
effect
cognit
clinic
detect
vascular
dementia
bare
detect
ad
well
toler
recent
metaanalysi
summar
data
placebocontrol
phase
iii
clinic
trial
patient
moder
sever
ad
also
support
efficaci
safeti
memantin
stage
diseas
memantin
treatment
result
statist
signific
benefit
four
efficaci
domain
cognit
function
global
behaviour
endpoint
data
basi
extens
memantin
indic
compris
moder
sever
ad
europ
meanwhil
use
clinic
germani
time
cognit
disord
memantin
approv
moder
sever
ad
ema
fda
octob
gain
blockbust
statu
sinc
memantin
efficaci
particular
mild
moder
stage
ad
sinc
question
trial
other
found
improv
commun
skill
patient
moder
ad
mechan
action
moder
affin
noncompetit
fasthow
work
memantin
found
rel
earli
patchclamp
measur
spinal
neuron
mous
embryo
equal
effect
nmdar
antagonist
like
dizolcipin
bind
receptor
open
endogen
agonist
glycin
glutam
nmda
open
channel
blocker
noncompetit
fashion
henc
memantin
displac
h
bind
site
within
nmdar
channel
postmortem
human
frontal
cortex
therapeut
obtain
concentr
k
compar
potenc
ketamin
dissoci
anesthet
ab
use
recreat
drug
known
bind
nmdar
pcpsite
howev
even
though
bind
site
receptor
compar
potenc
memantin
obvious
lack
psychotomimet
side
effect
e
g
pcp
end
behavior
neurochem
effect
competit
noncompetit
nmdar
antagonist
includ
memantin
studi
show
differ
behaviour
treat
anim
noncompetit
nmdarantagonist
memantin
resembl
stimulatori
effect
amphetamin
anim
model
addit
concept
excitotox
excess
ca
influx
neuron
mediat
overli
activ
nmdar
high
level
glutam
gain
popular
insult
caus
neurotox
process
includ
ischemia
trauma
epilepsi
neurodegener
select
block
nmdar
channel
could
least
part
decreas
ca
influx
howev
none
nmdar
antagonist
proven
effect
safe
clinic
strong
select
bind
receptor
caus
consider
side
effect
wholecel
patchclamp
measur
singl
channel
record
variou
retin
cortex
cultur
rat
show
memantin
inde
act
via
openchannel
block
similar
dizolcipin
act
antagonist
agonist
open
nmdar
ion
channel
howev
compar
memantin
display
faster
kinet
action
faster
block
unblock
rate
uncompetit
antagonist
presenc
clinic
obtain
concentr
memantin
would
allow
near
normal
physiolog
function
nmdarmedi
signal
unlik
nmdar
blocker
slower
kinet
effect
higher
concentr
agonist
nmda
block
memantin
higher
degre
lower
concentr
allow
near
normal
function
nmdar
channel
process
like
ltp
author
also
report
low
micromolar
concentr
memantin
prevent
neurotox
effect
mediat
nmdar
rat
neuron
also
act
neuroprotect
fashion
reliabl
anim
model
stroke
vitro
measur
rat
retin
ganglion
cell
delay
applic
memantin
protect
cell
neurotox
insult
exert
potenti
toxic
exposur
glutam
corrobor
find
subsequ
studi
show
memantin
dosedepend
antagon
respons
nmda
patchclamp
measur
cultur
neuron
ic
applic
memantin
affect
current
respons
neurotransmitt
ampa
gaba
uncompetit
useand
voltagedepend
mode
action
demonstr
moreov
memantin
affin
nmdar
glysit
even
glycin
revers
memantin
effect
current
respons
concentr
drug
serum
cerebrospin
fluid
csf
measur
patient
dose
regimen
use
clinic
patient
take
mg
memantin
per
day
display
serum
concentr
csf
concentr
half
concentr
well
within
rang
k
valu
pcp
site
howev
concentr
detect
csf
akin
extracellular
concentr
much
intracellular
concentr
detect
e
g
homogen
consider
higher
measur
e
g
amantadin
cerebellar
cortic
rat
neuron
amantadin
memantin
protect
glutam
toxic
memantin
model
even
potent
howev
true
mesencephal
cultur
probabl
cell
line
contain
rel
larg
percentag
dopaminerg
neuron
find
indic
rel
higher
use
amantadin
diseas
like
pd
vide
supra
chronic
month
treatment
memantin
age
rat
month
old
report
exert
effect
polyamin
glycin
bind
site
nmdar
complex
rat
treat
memantin
larger
number
site
found
along
higher
affin
glycin
author
postul
memantin
report
effect
vitro
vivo
may
due
indirect
modif
ion
channel
site
differ
bind
site
effect
discuss
includ
interact
memantin
muscarin
cholinoceptor
metabotrop
glutam
receptor
effect
phosphoinositid
turnov
also
suggest
quantit
receptor
autoradiographi
use
studi
region
variat
bind
nmdar
channel
blocker
amantadin
memantin
along
eight
nonadamantan
test
drug
brain
rule
thumb
lower
affin
faster
onoff
kinet
mean
better
toler
supplement
subtyp
specif
drug
compound
displac
h
six
differ
region
rat
brain
slice
differ
extent
gener
clinic
toler
nmdar
antagonist
higher
affin
cerebellum
lower
affin
forebrain
wherea
test
drug
highest
overal
affin
includ
troublesom
nmdar
antagonist
pcp
show
clear
region
prefer
obvious
cerebellar
forebrain
nmdar
differ
pharmacolog
profil
probabl
due
differ
subunit
receptor
complex
author
also
discuss
issu
drastic
lower
behavior
toxic
clinic
toler
memantin
compar
affin
two
drug
roughli
similar
differ
kinet
region
prefer
memantin
higher
affin
cerebellum
forebrain
could
due
subunit
express
almost
exclus
cerebellum
end
freshli
dissoci
rat
hippocamp
striatal
neuron
studi
use
patchclampand
voltag
clamp
techniqu
inward
current
respons
hippocamp
neuron
presenc
nmda
glycin
select
antagon
ketamin
memantin
amantadin
studi
striatal
neuron
ketamin
memantin
three
four
time
less
potent
wherea
amantadin
potent
neuron
popul
striatal
neuron
along
favor
fast
block
kinet
memantin
author
use
find
substanti
intrigu
differ
aminoadamantan
seri
drug
amantadin
seem
better
suit
pd
wherea
memantin
adequ
treat
ad
shift
nmdar
antagon
major
pharmaceut
mode
action
aminoadamantan
cn
review
overwhelm
accumul
preclin
evid
show
memantin
attenu
disrupt
neuron
plastic
due
overstimul
nmdar
symptomatolog
improv
probabl
best
describ
reduct
signal
nois
excitotox
increas
signalnois
ratio
normal
nmdar
mediat
signal
fulli
suppress
memantin
undesir
interact
memantin
approv
firstlin
ad
drug
revers
acheinhibitor
found
vitro
drug
report
act
synergist
instead
mechan
action
memantin
still
object
intens
studi
display
pronounc
trap
block
nmdar
channel
memantin
show
intermedi
partial
trap
properti
electrophysiolog
studi
author
ascrib
nmdar
deep
shallow
bind
site
mutat
analys
express
oocyt
x
laevi
also
hint
highaffin
site
near
mg
bind
site
channel
specif
filter
anoth
lowaffin
site
vestibul
channel
adamantan
deriv
equip
fluoresc
label
block
nmdar
tool
assay
develop
sucellular
local
studi
recent
studi
final
suggest
memantin
amelior
effect
cognit
declin
ad
patient
could
least
part
mediat
activ
histamin
neuron
still
activ
ad
abovement
find
model
briefli
describ
current
consensu
mechan
action
memantin
neuroprotect
treatment
ad
drug
approv
ema
fda
numer
detail
review
publish
advis
reader
indepth
look
memantin
moa
though
costbenefit
ratio
memantin
ad
matter
discuss
alreadi
gain
blockbust
statu
learn
memantin
career
blockbust
drug
treatment
ad
somewhat
exampl
offlabel
use
togeth
multitud
pharmacolog
effect
discuss
aminoadamantan
particular
host
psychiatr
disord
attribut
least
part
glutamaterg
dysfunct
come
surpris
numer
applic
memantin
propos
studi
clinic
trial
memantin
treatment
narcot
opiat
depend
schizophrenia
depress
obsessivecompuls
disord
bipolar
disord
aid
dementia
epilepsi
glaucoma
hepath
encephalopathi
multipl
sclerosi
stroke
tardiv
dyskinesia
forth
report
review
howev
therapeut
use
memantin
disord
recommend
developmentsa
one
major
patholog
hallmark
ad
format
amyloid
plaqu
form
app
metabolit
effect
protein
fragment
ad
studi
intens
also
act
neurotox
via
excitotox
mechan
studi
whether
memantin
could
exert
neuroprotect
action
insult
rat
treat
nine
day
memantin
plasma
concentr
show
significantli
less
neuron
damag
insult
detect
immunohistochem
histolog
find
reflect
behaviour
test
next
variou
neurotox
challeng
whose
consequ
amelior
upon
treatment
memantin
also
alreadi
learn
subtyp
prefer
aminoadamantan
nmdar
antagonist
scheme
nmdarsubtyp
select
agent
studi
use
nmdaevok
current
measur
bind
affin
toward
nmdar
express
cortic
neuron
cultur
compound
furthermor
protect
vitro
model
neurotox
increas
basal
catecholamin
releas
vitro
vivo
potent
nmdar
subtyp
physiolog
concentr
extracellular
mg
mm
found
decreas
inhibit
nmdar
mediat
current
memantin
near
subtyp
wherea
decreas
mg
concentr
threefold
subtyp
indic
primari
therapeut
neuroprotect
effect
memantin
subtyp
neuroprotect
observ
memantin
relat
compound
also
ascrib
secondari
effect
memantin
restor
level
substanc
p
neuropeptid
associ
neurogenesi
somatostatin
control
level
usual
activ
glia
frequent
observ
ad
probabl
reason
excitotox
observ
rat
treat
memantin
addit
amantadin
memantin
found
dosedepend
increas
level
glialderiv
neurotroph
factor
gdnf
glioma
cell
cultur
submicromolar
concentr
drug
modul
express
trophic
factor
gene
level
later
anoth
studi
memantin
primari
midbrain
neuronglia
cultur
cell
line
also
show
neurotroph
neuroprotect
effect
drug
author
found
effect
gliadepend
postul
probabl
memantin
enhanc
gdnfproduct
astroglia
vivo
memantin
promot
prolifer
progenitor
cell
hippocampu
adult
mice
ad
level
adult
neurogenesi
increas
probabl
part
compensatori
mechan
counteract
neuron
loss
modul
level
endogen
neurotroph
agent
small
molecul
attract
therapeut
target
usual
neurotroph
factor
cross
bloodbrainbarri
rapidli
degrad
proteolyt
enzym
memantin
like
tacrin
galantamin
shown
enhanc
neurogenesi
vitro
well
vivo
evidenc
incorpor
brdu
increas
neurogenesi
control
could
observ
vivo
furthermor
memantin
upregul
brainderiv
neurotroph
factor
bdnf
rhesu
monkey
infect
simian
hiv
earli
nonsymptomat
stage
immunodefici
studi
effect
memantin
ca
conduct
nicotin
acetylcholin
receptor
nachr
cultur
rat
hippocamp
neuron
aracava
et
al
found
mv
membran
potenti
ic
memantin
nachr
wherea
ic
nmdar
author
state
could
counteract
memantin
benefici
effect
particular
earli
stage
ad
find
howev
subject
debat
instanc
clinic
trial
shown
clinic
benefit
memantin
also
earli
stage
ad
accord
author
clear
whether
nachr
actual
involv
work
publish
nachr
antagonist
agonist
display
neuroprotect
moreov
could
speci
differ
nachr
studi
human
nachr
express
x
laevi
oocyt
show
much
lower
affin
memantin
receptor
ic
memantin
cf
clinic
obtain
concentr
howev
aracava
et
al
insist
upon
concept
ask
preclin
studi
memantin
approv
mildtomoder
ad
possibl
downstream
effect
memantin
report
de
sarno
et
al
found
increas
serinephosphoryl
glycogen
synthas
kinas
enzym
play
decis
role
ad
pathogenesi
particular
phosphoryl
microtubuleassoci
protein
tau
vide
infra
whose
abnorm
hyperphosphoryl
lie
heart
ad
second
major
patholog
hallmark
format
neurofibrillari
tangl
phosphoryl
decreas
activ
phosphoryl
kinas
would
benefici
ad
nmdar
regul
via
nitrosyl
author
suggest
use
aminoadamantan
targetdirect
shuttl
bring
close
site
within
nmdar
nitrosyl
therebi
regul
nmdar
ion
channel
conduct
terapeut
target
might
hit
memantin
adamantan
deriv
oxid
stress
possibl
combin
vitamin
addit
antioxid
acetylcholin
esteras
inhibitor
modifi
addit
adamantan
moieti
return
earli
postul
effect
direct
agonist
activ
dopamin
high
receptor
affin
similar
affin
nmdar
conclus
aminoadamantan
hit
sever
target
involv
pathogenesi
ad
enabl
uniqu
treatment
option
sever
stage
ad
addit
followup
directli
deriv
aminoadamantan
templat
help
fill
pipelin
return
ad
anoth
recent
find
field
alzheim
diseas
involv
enzym
target
hit
memantin
addit
effect
nmdar
antagonist
memantin
also
found
abl
inhibit
revers
abnorm
hyperphosphoryl
microtubuleassici
protein
tau
abnorm
hyperphosphoryl
form
protein
major
constitu
neurofibrillari
tangl
next
amyloid
plaqu
second
major
hallmark
ad
pathogenesi
major
enzym
respons
dephosphoryl
tau
protein
phosphatas
intracellularli
regul
endogen
inhibitor
name
upregul
inhibitor
led
hyperphosphoryl
tau
process
probabl
consequ
inhibit
increas
phosphoryl
tau
kinas
regul
downregul
inhibitor
therefor
repres
target
medicin
chemistri
memantin
effect
activ
obvious
interact
within
cell
therebi
reduc
tau
phosphoryl
effect
memantin
observ
vitro
also
vivo
individu
suffer
ad
order
memantin
inhibit
activ
consequ
abnorm
hyperphosphoryl
tau
must
gain
entri
neuron
brain
memantin
posit
charg
probabl
enter
neuron
primarili
excitotox
nmdar
ca
channel
open
bind
mg
site
subunit
nmdar
probabl
limit
mostli
patient
moder
sever
stage
ad
whose
brain
experi
persist
excitotox
found
benefit
memantin
thu
develop
deriv
memantin
enter
neuron
inhibit
even
absenc
excitotox
promis
treatment
ad
well
neurodegen
disord
call
tauopathi
also
character
neurofibrillari
tangl
form
abnorm
hyperphosphoryl
tau
tackl
target
excitatori
neurotransmitt
system
show
multitud
interact
aminoadamantan
adamantan
deriv
benefici
util
clinic
one
would
also
like
know
inhibitori
neurotransmitt
butyr
acid
gaba
main
inhibitori
neurotransmitt
cn
play
decis
role
signal
transmiss
medicin
point
view
patholog
chang
cn
underli
diseas
like
epilepsi
gaba
exert
inhibitori
activ
via
differ
subtyp
gaba
receptor
transport
cn
activ
pharmaceut
analogu
enhanc
lipophil
desir
ad
lipophil
conform
rigid
gaba
lead
structur
medicin
chemist
guid
gabapentin
scheme
initi
develop
treat
epilepsi
market
mainli
reliev
neuropath
pain
howev
drug
neither
target
gaba
receptor
transport
enzym
gaba
metabol
pathway
today
consensu
gabapentin
interact
subunit
voltageg
ca
channel
modul
reduc
ca
influx
neuron
final
reduc
releas
neurotransmitt
modul
like
glutam
norepinephrin
substanc
p
reduc
releas
excitatori
neurotransmitt
lead
control
e
g
epilept
seizur
alkyl
analogu
gabapentin
develop
includ
adamantanebas
acid
adgaba
sever
alkyl
gabapentin
deriv
report
display
higher
affin
site
nm
nm
compar
anticonvuls
activ
vivo
anim
model
adamantanederiv
acid
shown
bind
site
reduc
neuron
ca
current
measur
electrophysiolog
addit
anticonvuls
properti
also
shown
act
analges
mice
notabl
conform
rigid
analogu
like
acid
yet
studi
analogu
gaba
howev
use
recent
studi
pharmacolog
ltype
ca
channel
subunit
elabor
numer
applic
aminoadamantan
deriv
remark
simpl
structur
particular
drug
research
target
patholog
nervou
system
strikingli
aminoadamantan
report
frequent
addon
modifi
neuropeptid
neuropeptidederiv
compound
attempt
render
peptidederiv
compound
druggabl
memantin
report
increas
cck
bind
mous
brain
directli
use
cckpeptid
templat
drug
develop
field
involv
compound
librari
adamantanemodifi
molecul
briefli
discuss
base
upon
cck
trpmetaspph
davey
et
al
report
design
cckb
receptor
antagonist
bear
protect
group
nterminu
mous
cerebr
cortex
scheme
displac
label
cck
cckb
site
ic
nm
next
potenc
pharmacokinet
need
address
larger
librari
compound
base
upon
lead
screen
subsequ
potent
member
k
nm
measur
guinea
pig
cortex
bind
obvious
adamantan
moieti
essenti
compound
incorpor
motif
display
k
valu
nm
estim
cross
bloodbrainbarri
ip
administr
mice
exampl
futur
applic
author
mention
anxiolyt
compound
sinc
select
agonist
gprotein
coupl
cckb
receptor
caus
anxieti
memori
perturb
first
select
agonist
ccka
receptor
structur
similar
incorpor
motif
deriv
reportedli
smallest
biolog
activ
ccka
agonist
report
time
develop
compound
yield
select
ccka
agonist
like
next
full
agonist
ccka
receptor
pancreat
cell
rat
also
longer
act
octapeptid
cck
start
peptoid
like
conform
constrain
peptid
screen
attempt
identifi
conform
requir
potent
bind
cckb
receptor
antagonist
favor
select
cckb
receptor
requir
r
stereochemistri
trp
ci
configur
pyrrolidin
moieti
compound
k
nm
cckb
site
affin
higher
ccka
site
due
problem
oral
bioavail
peptoid
report
hitherto
smaller
compound
sought
cckb
antagonist
notabl
motif
maintain
compound
structur
display
favor
select
k
cckb
nm
k
ccka
nm
improv
oral
bioavail
rat
well
better
penetr
bbb
therefor
compound
select
develop
candid
anxiolyt
drug
signific
medicin
chemistri
field
reflect
also
labori
synthes
includ
cradiolabel
analogu
studi
pharmacokinet
structur
modif
lead
compound
like
h
label
util
identif
two
distinct
cckb
site
rat
cortex
also
prove
stabl
upon
incub
membran
min
return
search
select
cck
receptor
agonist
report
full
agonist
cck
high
affin
site
antagonist
low
affin
site
cck
receptor
antagonist
incorpor
type
ii
mimet
gave
conform
rigidifi
peptoid
maintain
nanomolar
affin
cck
receptor
increas
select
reli
motif
revers
select
cck
cck
receptor
observ
amongst
modif
replac
group
nboc
scheme
albeit
overal
low
potenc
compound
repres
first
select
cck
antagonist
field
peptoid
measur
ratio
k
valu
upon
inhibit
specif
bind
h
pcck
cck
receptor
rat
pancrea
cck
rat
cortex
homogen
k
cck
k
cck
ratio
adamantan
deriv
peptoid
display
significantli
higher
affin
toward
cck
receptor
nm
nm
finetun
hydrophil
even
smaller
cck
antagonist
led
substitut
imidazol
display
nanomolar
receptor
affin
e
g
method
call
scaffold
hop
involv
silico
screen
compound
unrel
scaffold
similar
pharmacophor
led
compound
like
synthes
found
potent
indol
pyrazol
describ
suffer
reduc
bilari
excret
lower
molecular
weight
notabl
adamantan
substitu
stay
present
ligand
amongst
compound
adamantyl
cck
receptor
ligand
use
improv
theoret
method
standard
screen
sometim
troublesom
screen
compound
librari
vast
differ
backbon
scaffold
best
knowledg
none
adamantyl
cck
receptor
ligand
routin
use
clinic
sever
use
elucid
structur
function
variou
cck
receptor
target
valid
endogen
tridecapeptid
neurotensin
nt
play
dual
role
peptid
hormon
peripheri
ii
neuromodu
neurotransmitt
dopaminerg
system
cn
exhibit
hypotherm
psychotrop
analges
properti
ctermin
pentamer
subsequ
necessari
analges
effect
modul
pentam
led
discoveri
adamantanecarbonylnt
scheme
longer
durat
action
compar
parent
peptid
leav
path
peptid
backbon
identifi
act
antagonist
neurotensin
receptor
nanomolar
affin
vitro
display
better
bioavail
h
label
isotopom
use
elucid
bind
properti
distribut
neurotensin
receptor
ntr
ntr
rat
brain
also
found
util
develop
antipsychot
drug
close
relat
deriv
found
applic
molecular
model
studi
identifi
bind
site
ntr
antagonist
andagonist
block
ntr
attenu
amphetamineinduc
locomotor
sensit
therefor
compound
propos
clinic
use
agent
neuropsychiatr
disord
recent
use
studi
action
neurotensin
midbrain
neuron
descend
analges
pathway
nonapeptid
bradykinin
hargproproglypheserpropheargoh
act
vasodil
well
play
role
pain
increas
calcium
level
neuron
cocultur
astroglia
neuron
cultur
stimul
glutam
excret
astroglia
rat
ntermin
acidacyl
bradykinin
antagonist
dargargprohypglythiserdphethiarg
result
tenfold
increas
bradykininantagonist
potenc
acyl
shorter
peptid
bradykinin
antagonist
acid
nterminu
gave
bradykinin
antagonist
least
activ
adamantan
deriv
differ
substructur
modif
bradykinin
sequenc
synthes
util
gain
insight
pharmacolog
bradykinin
receptor
e
g
character
bradykinin
receptor
human
nasal
airway
elucid
thrombinbradykinin
interplay
inflammatori
respons
studi
deal
stimul
product
vasodil
mediat
bradykinin
recent
regul
blood
pressur
possibl
bradykinin
receptor
subtyp
rat
vasopressin
nonamer
peptid
hormon
act
three
receptor
system
one
arginin
vasopressin
receptor
locat
brain
play
role
hormon
secret
stress
concept
reminisc
modif
neurotensin
cterminu
obtain
also
util
design
vasopressin
analogu
simpli
ad
acid
nterminu
argvasopressin
gave
scheme
act
select
antagonist
v
receptor
deriv
use
studi
function
vasopressin
cholinerg
system
argininevasopressin
believ
stimul
ach
releas
rat
hippocampu
therebi
facilit
learn
memori
rodent
compound
act
antagonist
vasopressin
receptor
consequ
use
local
intravascular
vasopressin
receptor
play
import
role
regul
blood
pressur
earli
amantadin
studi
rat
uteru
vitro
vivo
oxytoc
effect
aminoadamantan
report
lastli
also
one
report
modifi
oxytocin
deriv
incorpor
adamantan
build
block
enkephalin
two
pentapeptid
act
ligand
opioid
receptor
brain
differ
sequenc
ctermin
amino
acid
met
enkephalin
htyrglyglyphemetoh
leu
enkephalin
htyrglyglypheleuoh
act
neurotransmitt
neuromodul
brain
due
opioid
receptor
activ
use
lead
structur
develop
peptidederiv
analges
fewer
sideeffect
like
e
g
propens
addict
includ
peptid
incorpor
acid
base
upon
adamantan
scaffold
exemplifi
scheme
likewis
adamantyl
acid
adamantyl
glycin
ada
also
use
structur
three
time
potent
analogu
incorpor
leu
instead
ada
ad
benefit
adamantan
deriv
markedli
increas
stabil
toward
proteolyt
degrad
human
plasma
enhanc
penetr
bbb
due
higher
lipophil
octapeptid
hpheleupheglnproglnargphenh
neuropeptid
ff
npff
member
larger
famili
rf
peptid
amid
play
role
pain
modul
insulin
releas
food
intak
memori
blood
pressur
nocicept
modul
opioidinduc
analgesia
particular
opioid
toler
although
two
gprotein
coupl
receptor
npffr
npffr
clone
lack
pharmacolog
tool
studi
pharmacolog
effect
messag
system
hamper
research
dansyl
peptid
amid
ctermin
fragment
npff
among
compound
studi
purpos
dansylproglnargphenh
displac
radiolabel
npff
analogu
h
tyrleupheglnproglnargphenh
rat
spinal
cord
membran
prepar
k
nm
start
ntermin
benzoyl
rf
amid
synthesi
screen
small
librari
acyl
rf
peptid
amid
later
identifi
small
compound
favor
affin
npff
receptor
one
scheme
show
good
affin
human
npff
receptor
k
nm
hnpffr
k
nm
hnpffr
adamantanoyl
dipeptid
deriv
found
block
effect
npff
name
increas
blood
pressur
heart
rate
rat
coadminist
heroin
prevent
hyperalgesia
daili
heroin
administr
ad
benefit
exert
effect
use
system
recent
year
compound
help
elucid
function
clinic
relev
npff
system
next
abovement
effect
prevent
heroininduc
hyperalgesia
found
direct
agonist
activ
administ
intraventricularli
antagon
npffinduc
hypothermia
attenu
lipopolysaccharideinduc
fever
help
prove
idea
npff
receptor
mediat
process
opioidinduc
hypothermia
consciou
rat
rf
peptid
amid
share
ctermin
dipeptid
motif
also
act
receptor
prolactinreleas
peptid
prrp
interact
npff
receptor
found
util
select
pharmacolog
tool
latest
benefit
avail
select
npff
receptor
antagonist
includ
find
mark
speci
variat
npff
system
activ
mous
npffr
human
npffr
find
rodent
gonadotrop
effect
serotoninnext
role
regul
blood
pressur
serotonin
also
neurotransmitt
cn
involv
depress
anxieti
serotoninerg
system
diffus
involv
numer
receptor
subtyp
select
agonistsantagonist
therfor
need
studi
patholog
involv
serotoninerg
transmiss
possibl
therapeut
option
numer
effect
aminoadamantan
serotoninerg
system
report
see
chapter
discuss
sever
program
focus
identif
select
ligand
serotonin
receptor
subtyp
led
adamantan
deriv
compound
promis
drug
candid
scheme
earli
postsynapt
antagonist
site
display
good
affin
target
receptor
k
nm
also
signific
affin
adrenerg
receptor
k
nm
consequ
select
ligand
sought
thu
elimin
intrins
risk
unwant
side
effect
amid
retain
postsynapt
antagonist
activ
k
nm
drastic
reduc
affin
site
k
nm
adamantanederiv
benzodioxan
later
describ
agonist
receptor
antagonist
subtyp
vitro
radioligand
bind
assay
compound
display
high
affin
serotonin
receptor
subtyp
k
nm
receptor
k
nm
subtyp
serotonin
receptor
subtyp
virtual
affin
furthermor
also
activ
vivo
rodent
show
good
bioavail
behavior
effect
rat
mice
qualifi
potent
antidepress
anxiolyt
compound
screen
librari
substitut
indazol
benzimidazol
identifi
potent
oral
activ
antagonist
whose
select
profil
durat
action
led
develop
indazol
receptor
select
compound
affin
adrenerg
dopaminerg
histaminerg
muscarinerg
gabaerg
receptor
po
iv
dose
ratio
indic
good
oral
bioavail
rat
anoth
screen
program
wyeth
base
upon
substitut
arylor
heteroaryl
piperazin
buspiron
drug
use
anxieti
depress
serv
templat
sinc
receptor
serv
primari
target
antidepress
screen
involv
variat
imid
function
attempt
improv
potenc
select
receptor
adatanserin
display
high
affin
k
nm
receptor
significantli
higher
subtyp
k
nm
furthermor
affin
receptor
also
lower
k
nm
adatanserin
agonist
antagonist
vivo
variat
cage
hydrocarbon
moieti
also
studi
acid
deriv
display
significantli
lower
affin
receptor
k
nm
noradamantan
deriv
k
nm
show
good
affin
mean
hydrocarbon
moieti
probabl
directli
relev
receptor
bind
piperazin
display
highest
affin
target
receptor
k
nm
rat
pigeon
inde
show
anxiolyt
properti
less
strong
side
effect
sed
action
known
drug
along
strong
antidepress
activ
find
led
develop
advanc
phase
ii
clinic
trial
carboxamid
use
studi
peripher
activ
receptor
aminopyrrolidin
shown
possess
high
affin
select
receptor
k
nm
receptor
k
nm
receptor
k
nm
receptor
exert
also
antiplatelet
effect
vitro
vivo
finetun
led
affin
abovement
receptor
nm
nm
nm
respect
vitro
antiplatelet
aggreg
effect
measur
ic
nm
nm
respect
substitut
tetrahydroisoquinolin
also
screen
select
receptor
ligand
find
highaffin
compound
incorpor
adamantan
motif
prototyp
structur
k
nm
subtyp
k
nm
subtyp
show
high
select
nm
nm
nm
nm
respect
show
higher
select
compound
better
describ
dual
affin
deriv
subsequ
studi
includ
solidphas
synthesi
librari
deriv
alongsid
arylpiperazin
core
pharmacophor
sar
field
serotonin
receptor
ligand
continu
also
find
deriv
like
select
agonist
affin
nm
agonist
rat
also
ligand
affin
nm
somatostatinnext
role
digest
system
somatostatin
also
produc
sever
brain
cell
popul
somatostatin
receptor
express
mani
differ
site
brain
e
g
arcuat
nucleu
hippocampu
somatostatin
along
neuropeptid
like
neuropeptid
reduc
organ
mental
disord
neurodegen
diseas
fact
amantadin
memantin
along
dopaminerg
drug
increas
somatostatin
level
brain
normal
rat
one
numer
effect
aminoadamantan
neurochemistri
among
neuropeptid
somatostatin
one
significantli
reduc
postmortem
brain
ad
patient
five
receptor
subtyp
identifi
late
sst
somatostatin
peptid
act
ligand
therapeut
use
somatostatin
peptid
hamper
short
halflif
less
three
minut
rat
plasma
pharmacophor
within
tetradecamer
disulfid
bound
cyclopeptid
identifi
repres
tyrtrplysmotif
peptid
somatostatin
deriv
enhanc
stabil
bioavail
sought
strategi
maintain
decis
residu
truncat
peptid
chain
add
conform
rigid
nmethyl
amino
acid
cycliz
introduc
unnatur
amino
acid
inadequ
pharmacokinet
select
sst
receptor
subtyp
pose
challeng
drug
develop
field
numer
peptid
ligand
somatostatin
receptor
studi
one
ligand
sst
select
ultrashort
somatostatin
analogu
scheme
incorpor
rigid
diaminoadamantan
moieti
dtrp
stabil
conform
analogu
high
affin
k
nm
inhibit
releas
growth
hormon
vitro
vivo
rat
take
pharmacophor
region
somatostatin
synthes
linear
lipophil
peptid
anoth
strategi
obtain
somatostatin
deriv
enhanc
stabil
found
potent
deriv
number
test
compound
inhibit
cellular
prolifer
cell
process
believ
mediat
sst
receptor
inhibit
cellular
prolifer
gave
inhibit
tertbutylamid
show
almost
antiprolif
activ
concentr
adamantanemodifi
neuropeptid
consid
typic
exampl
adamantan
impact
medicin
chemistri
use
lipophil
build
block
directli
influenc
compound
stabil
system
distribut
particular
bbb
penetr
biocompat
ad
benefit
peptid
structur
enhanc
stabil
proteolyt
degrad
enhanc
halflif
peptid
peptidederiv
compound
significantli
biophys
properti
also
play
decis
role
sever
cnstarget
hit
adamantan
deriv
alreadi
discuss
adamantyl
deriv
enkephalin
sometim
refer
endogen
opioid
discuss
adamantan
deriv
target
opioid
receptor
gprotein
coupl
transmembran
protein
three
main
subtyp
orl
separ
brief
opioid
receptor
ident
somatostatin
receptor
togeth
opioid
action
enkephalin
knowledg
natur
occur
short
peptid
opioid
activ
modifi
short
peptid
start
point
research
develop
select
opioid
receptor
ligand
adamantan
modif
proven
highli
use
tool
influenc
affin
select
well
pharmacokinet
result
compound
ctermin
modifi
truncat
analogu
dermorphin
htyrdalapheglytyrprosernh
frog
heptapeptid
bind
select
opioid
receptor
maintain
opioid
activ
particular
deriv
like
scheme
found
produc
central
peripher
opioid
activ
anoth
studi
focus
develop
peptid
inhibitor
human
renin
report
adamantan
substitut
peptid
also
display
high
affin
opiat
receptor
deriv
display
ic
radioligand
bind
assay
use
rat
brain
homogen
higher
affin
morphin
assay
ic
deltorphin
htyrdmetphehisleumetaspnh
deltorphin
c
htyrdalapheaspvalvalglynh
two
opioid
peptid
high
affin
select
receptor
truncat
deriv
like
studi
found
lose
select
ctermin
adamantan
modifi
triand
dipeptid
fragment
deriv
enkephalin
vide
supra
like
hand
identifi
function
opioid
receptor
agonist
electr
stimul
longitudin
muscl
stripe
guinea
pig
ileum
assay
receptor
ic
nm
activ
ic
nm
mous
va
defen
muscl
strip
model
studi
opioid
receptor
markedli
less
activ
ic
nm
also
show
nanomolar
activ
k
nm
gener
adamantan
unit
cterminu
short
enkephalin
deriv
led
decreas
receptor
activ
lead
increas
select
author
postul
membran
incorpor
lipophil
peptid
preced
interact
receptor
exampl
popular
peptidederiv
pharmacophor
high
affin
opioid
receptor
dmttic
group
enhanc
affin
select
opioid
receptor
intens
studi
hdmtticoh
display
high
affin
receptor
k
nm
along
vitro
antagon
establish
use
knockout
mice
receptor
subtyp
primari
target
analges
action
morphin
nonaddict
opioid
primarili
exert
analges
effect
agon
potent
receptor
antagonist
obtain
enhanc
lipophil
respect
parent
peptid
display
high
receptor
bind
k
nm
also
act
agonist
enhanc
lipophil
compound
benefici
cross
bbb
compar
hdmtticoh
bbb
penetr
also
depend
interact
braindirect
pharmaceut
human
multidrug
resist
glycoprotein
abund
within
bbb
found
interact
favor
properti
chemosensit
agent
cancer
chemotherapi
regimen
comparison
k
nm
k
nm
k
nm
k
nm
k
nm
k
nm
reveal
affin
ctermin
adamantan
modif
benefici
affin
larg
maintain
peptid
opioid
receptor
ligand
inspir
endogen
peptid
opioid
call
endomorphin
truncat
ctermin
adamantan
modifi
analogu
studi
find
mix
agonist
antagonist
deriv
adamantan
deriv
analogu
among
compound
studi
display
nanomolar
affin
structur
display
rel
high
affin
receptor
k
nm
good
select
k
nm
thought
anoth
subtyp
opioid
receptor
pharmacolog
receptor
still
poorli
understood
recent
year
develop
select
opioid
ligand
becam
clear
receptor
involv
e
g
psychot
disord
neuroprotect
depress
also
involv
regul
nmdar
receptor
found
involv
modul
dopaminerg
transmiss
amantadin
consequ
select
receptor
ligand
need
develop
yet
anoth
cn
target
hit
adamantan
deriv
earli
sar
select
ligand
report
scherz
et
al
systemat
studi
deriv
n
dtg
adamantan
deriv
studi
amongst
highestaffin
ligand
studi
eg
scheme
ic
nm
activ
compound
screen
close
relat
exonorbornan
guanidin
ic
nm
aminoadamantan
bind
affin
site
also
studi
mention
see
chapter
find
affin
low
micromolecular
rang
deriv
measur
radioligand
bind
competit
assay
use
human
postmortem
frontal
cortex
homogen
amantadin
memantin
affin
receptor
studi
other
particular
dimethylamino
deriv
like
k
exhibit
much
higher
affin
among
potent
ligand
cyclopropyl
deriv
modifi
aminoadamantan
k
nm
adamantan
deriv
seri
furthermor
display
receptor
subtyp
select
receptor
also
involv
ca
signal
via
intracellular
site
action
site
plasma
membran
also
found
retin
neuron
success
use
neuroprotect
agent
ischemia
model
use
retin
degrad
rat
receptor
ligand
found
possess
highli
interest
pharmacolog
properti
yeast
sterol
isomeras
enzym
involv
inflammatori
process
e
g
rheumathoid
arthriti
found
structur
homolog
extent
kda
receptor
human
sterol
isomeras
also
show
pharmacolog
similar
receptor
ligand
latter
studi
cyclohexan
deriv
develop
ligand
strong
inhibit
time
compound
also
stimul
excret
antiinflammatori
problem
compound
howev
rapid
metabol
degrad
cytochrom
adamantanederiv
backup
compound
show
even
higher
affin
site
also
higher
affin
human
sterol
isomeras
compound
character
vitro
vivo
proven
trigger
antiinflammatori
pathway
expect
could
make
adamantanederiv
use
pharmaceut
treatment
rheumathoid
arthriti
inflammatori
diseas
steroid
hormon
estrogen
influenc
growth
differenti
mani
target
tissu
receptor
activ
hormon
ligand
induc
conform
chang
whereupon
receptor
dimer
er
dimer
bind
chromatin
modul
transcript
target
gene
due
tissu
select
mani
estrogen
differenti
agonist
antagonist
action
well
subtyp
select
pharmocolog
studi
er
delic
end
knockout
mice
bred
anim
reduc
fertil
reflect
primari
distribut
breast
uteru
contrast
knockout
mice
show
impair
cognit
function
locat
mainli
brain
compound
display
er
bind
micromolar
concentr
includ
phenol
like
substitut
diamantyl
phenol
scheme
even
though
compound
bind
er
lower
affin
compar
number
lipophil
phenol
ubiqu
human
environ
possibl
pose
health
risk
er
modul
properti
class
compound
studi
fluoresc
polar
also
via
competit
experi
bind
affin
measur
addp
bound
human
somewhat
lower
affin
ic
nm
human
ic
nm
affin
adp
somewhat
lower
ic
nm
ic
nm
base
upon
bind
studi
adamantyl
phenol
propos
novel
nonsteroid
er
ligand
potenti
use
start
point
design
er
modul
adamantyl
estradiol
nonreceptor
bind
estrogen
analogu
found
display
neuroprotect
properti
decreas
glutamateinduc
excitotox
therapeut
applic
seem
interest
androgen
effect
neuroprotect
compound
certainli
desir
neuroprotect
cortic
neuron
also
found
act
neither
er
pathway
nmdar
antagonist
activ
radic
scaveng
postul
neuroprotect
rat
retin
ganglion
cell
glutam
toxic
model
glaucoma
later
studi
detail
activ
compound
studi
sinc
shown
bind
era
predominantli
express
retin
ganglion
cell
obviou
neuroprotect
must
ascrib
characterist
like
e
g
antioxid
activ
sinc
protein
phosphatas
involv
mediat
neuroprotect
influenc
phosphatas
kinas
could
also
involv
neuroprotect
effect
inde
protect
insult
phosphatas
inhibitor
okada
acid
calyculin
primari
cortic
neuron
furthermor
coadministr
glutam
prevent
reduct
phosphatas
level
observ
glutam
treatment
without
neuroprotect
exampl
compound
develop
subtyp
select
er
ligand
display
high
affin
subtyp
select
howev
hydrocarbon
cage
instead
residu
appear
better
suit
chapter
particular
chapter
strong
propens
adamantan
deriv
test
pharmaceut
display
activ
cn
owe
pronounc
lipophil
ad
adamantan
build
block
repeatedli
elabor
also
encount
target
play
role
cn
outsid
therefor
discuss
noncn
target
hit
lipophil
bullet
follow
chapter
atpactiv
ligand
gate
ion
channel
refer
receptor
seven
subtyp
known
homomer
heteromer
trimer
select
permeabl
cation
ca
na
k
though
signific
progress
made
elucid
channel
function
still
pauciti
potent
select
pharmacolog
tool
homomer
receptor
found
immun
cell
glia
allow
passag
larger
molecular
weight
compound
upon
extend
interact
agonist
mediat
cytokin
releas
import
inflammatori
process
cell
prolifer
well
apoptosi
seri
druggabl
compound
develop
antagonist
includ
adamantan
deriv
astrazeneca
initi
highthroughput
screen
identifi
antagonist
use
chronic
inflammatori
diseas
activ
receptor
mediat
releas
proinflammatori
cytokin
chronic
diseas
longterm
treatment
promis
larg
market
base
cellbas
highthroughputscreen
format
adamantan
bisamid
scheme
identifi
hit
howev
molecul
consid
larg
lipophil
hittoleadstudi
perform
notabl
replac
adamantan
moieti
found
instead
identifi
fulfil
requir
molecular
weight
essenti
due
requir
conform
prefer
detriment
potenc
screen
compound
librari
identifi
amid
lead
structur
structur
develop
sinc
blood
knockout
mice
atpstimul
extracellular
lower
blood
normal
mice
ko
mice
also
suffer
less
sever
arthriti
anticollagen
antibodi
arthriti
model
target
receptor
seem
valid
justifi
develop
compound
discov
highli
select
metabol
stabl
antagonist
human
receptor
less
activ
strongli
activ
rat
receptor
vitro
well
vivo
latter
compound
also
show
good
oral
bioavail
phase
ii
clinic
trial
inhibitor
treatment
rheumatoid
arthriti
initi
sinc
howev
neither
astrazeneca
pfizer
disclos
structur
respect
drug
adamantan
deriv
also
success
hit
enzym
target
earli
exampl
discoveri
nadamantylurea
deriv
inhibitor
solubl
epoxid
hydrolas
seh
next
hepat
microsom
epoxid
hydrolas
seh
present
mammal
two
hydrolas
complement
detoxifi
activ
hydrolysi
variou
mutagen
toxic
carcinogen
epoxid
furthermor
sever
diol
produc
via
seh
catalysi
caus
inflamm
therefor
inhibit
seh
repres
valuabl
target
number
diseas
compound
involv
recombin
human
murin
seh
avail
crystal
structur
render
design
studi
seh
inhibitor
promis
field
medicin
chemistri
adamantyl
urea
report
seh
inhibitor
inhibit
recombin
murin
seh
mseh
ic
recombin
human
seh
hseh
ic
potent
lead
structur
identifi
howev
pronounc
lipophil
caus
solubl
issu
therefor
solubl
druggabl
compound
sought
addit
polar
function
group
end
long
aliphat
chain
one
side
urea
pharmacophor
retain
inhibitori
activ
increas
solubl
short
aliphat
chain
less
seven
carbon
atom
modifi
carboxyl
acid
group
enhanc
solubl
howev
reduc
inhibit
ester
group
toler
result
urea
ester
retain
activ
notabl
class
inhibitor
adamantyl
substitut
give
markedli
stronger
seh
inhibitor
ic
cyclohexyl
deriv
ic
dodecano
acid
deriv
auda
use
seh
inhibitor
anim
model
hypertens
manipul
endogen
lipid
oral
activ
seh
inhibitor
like
benefici
angiotensininduc
hypertens
studi
vivo
show
effect
blood
pressur
normal
mice
reduc
angiotensininduc
hypertens
howev
adamantylurea
inact
mous
model
hypertens
seh
inhibit
obvious
inhibit
hypertens
effect
angiotensin
ii
mice
decreas
renal
excret
salt
water
subsequ
develop
seh
inhibitor
focus
synthesi
compound
warrant
simpler
formul
replac
urea
motif
amid
result
drop
activ
human
seh
ic
howev
inhibitori
activ
murin
seh
retain
ic
compar
time
solubl
amid
aqueou
buffer
higher
correspond
urea
deriv
solidphas
method
subsequ
util
synthes
librari
seh
inhibitor
combinatori
approach
screen
inhibitor
found
case
adamantan
moieti
replac
signific
drop
seh
inhibit
inhibit
human
seh
potenc
ic
nm
variat
cyclohexyl
motif
gave
compound
like
human
seh
ic
nm
excel
oral
bioavail
addit
prodrug
approach
follow
enhanc
durat
action
auda
ester
facilit
formul
glycosyl
deriv
like
human
seh
ic
significantli
inceas
water
solubl
nacetyl
piperidin
urea
recent
select
develop
candid
base
upon
potenc
vitro
vivo
preclin
test
compound
higher
potenc
report
suffer
decreas
oral
exposur
adamantan
base
seh
inhibitor
use
establish
seh
target
inflammatori
diseas
inhibit
seh
decreas
plasma
concentr
proinflammatori
cytokin
furthermor
seh
inhibitor
also
led
enhanc
format
lipoxin
epoxyeicosatrieno
acid
eet
possess
antiinflammatori
activ
seh
catalyz
hydrat
seh
inhibit
result
enhanc
level
eet
therefor
allevi
inflammatori
process
mice
challeng
lipopolysaccharid
seh
inhibitor
inde
acceler
inflammatori
resolut
use
audanbutyl
ester
cisplatinnephrotox
neuroprotect
effect
auda
rat
model
cerebr
ischemia
support
concept
adamantan
deriv
seh
inhibitor
multifactori
multitarget
agent
amongst
effect
modul
acut
inflammatori
respons
vivo
excel
oral
bioavail
exampl
nadamantylurea
seh
inhibitor
prime
effect
field
regul
blood
pressur
endotheli
dysfunct
adamantanederiv
repres
candid
clinic
develop
field
metabol
syndrom
multibillion
market
alreadi
describ
earli
studi
hypoglycem
effect
adamantanemodifi
sulfonylurea
adamantanemodifi
truncat
bchain
insulin
later
also
report
real
breakthrough
adamantan
deriv
develop
antidiabet
drug
publish
discoveri
vildagliptin
scheme
research
novarti
potent
oral
activ
inhibitor
dipeptidyl
peptidas
iv
dppiv
treatment
type
diabet
mellitu
dppiv
ubiquit
yet
highli
specif
exopeptidas
cleav
dipeptid
fragment
nterminu
substrat
incorpor
either
lpro
lala
penultim
posit
modif
sever
circul
regulatori
peptid
regul
amongst
other
incretin
hormon
glucagonlik
peptid
peptid
potent
insulinotrop
hormon
trigger
elev
glucos
level
excret
activ
releas
insulin
respons
glucos
intak
action
dppiv
inactiv
truncat
consequ
inhibit
dppiv
promis
target
treatment
known
dppiv
inhibitor
analogu
dipeptid
unit
cleav
dppiv
similarli
discoveri
vildagliptin
commenc
peptidederiv
structur
assay
variou
deriv
inhibit
human
dppiv
caco
cell
identifi
hit
ic
nm
structur
start
point
first
candid
clinic
develomp
deriv
ic
nm
xray
crystal
structur
dppiv
complex
inhibitor
reveal
larg
enough
caviti
socal
worker
studi
nsubstitut
glycin
deriv
posit
inhibitor
e
g
deriv
ic
nm
deriv
ic
nm
deriv
ic
nm
clearli
bulki
biand
tricycl
aliphat
residu
glycin
amino
group
like
substitu
benefici
potenc
subtl
modif
lipophil
bullet
caus
mark
decreas
potenc
studi
primari
metabolit
indic
adamantan
moieti
worker
synthes
screen
hydroxyl
adamantan
deriv
well
vildagliptin
identifi
ic
nm
potent
oral
activ
dppiv
inhibitor
led
increas
insulin
level
rat
model
furthermor
monkey
oral
bioavail
found
longer
halflif
vivo
indic
possibl
oncedaili
dose
regimen
human
clinic
trial
prove
amongst
aspect
studi
activ
man
sustain
insulin
level
upon
treatment
vildagliptin
improv
mealrel
function
becom
epidem
industri
countri
pharmacolog
treatment
necessarili
need
chronic
drug
highli
interest
big
pharma
therefor
surprisingli
bristolmyerssquibb
disclos
discoveri
close
relat
dppiv
inhibitor
similar
discoveri
process
report
vildagliptin
worker
also
start
previous
identifi
amino
acid
link
primari
pharmacophor
dppiv
inhibitor
found
strongli
inhibit
format
inact
activ
via
ntermin
truncat
two
residu
process
known
repres
major
degradt
rout
vivo
logic
extens
earlier
find
prototyp
scaffold
scheme
modifi
find
cyclopentyl
substitut
yield
potent
inhibitor
k
nm
favor
durat
action
low
oral
bioavail
oral
bioavail
rat
also
found
turnov
rat
liver
microsom
high
put
metabolit
hydroxymethyl
deriv
k
nm
bishydroxyl
k
nm
display
significantli
better
oral
bioavail
ladamantylglycin
deriv
potent
k
nm
low
bioavail
convey
rational
hydroxyl
deriv
constantli
equip
markedli
higher
bioavail
synthes
screen
saxagliptin
k
nm
also
display
expect
oral
bioavail
anim
model
well
long
durat
action
rat
plasma
inhibit
dppiv
min
h
bishydroxyl
put
metabolit
k
nm
markedli
wors
absorpt
saxagliptin
select
candid
clinic
develop
rat
model
zucker
fafa
rat
saxagliptin
proven
suitabl
vivo
long
durat
action
appear
promis
oncedaili
regimen
man
vildagliptin
recent
year
intens
studi
preclin
vitro
well
vivo
number
clinic
trial
perform
drug
slowli
bind
transitionst
mimet
display
twostep
inhibit
kinet
select
inhibit
dppiv
signific
inhibitori
activ
shown
screen
use
e
g
dppii
dppviii
brief
vildagliptin
reduc
concentr
activ
dppiv
therebi
increas
level
furthermor
two
rodent
model
vildagliptin
shown
oral
bioavail
augment
level
intact
anim
effect
vildagliptin
antihyperglycem
hypoglycem
therebi
bear
intris
improv
safeti
profil
clinic
applic
vildagliptin
saxagliptin
enter
clinic
trial
largescal
synthes
work
includ
enzymat
catalyz
transform
shown
scheme
lipas
b
util
transform
ester
group
amid
genet
engin
dehydrogenas
thermoactinomyc
intermediu
util
stereospecif
transform
deriv
adamantylglycin
transform
scale
batch
sever
hundr
kg
close
convers
develop
dppiv
inhibitor
abbott
also
studi
adamantan
deriv
like
k
nm
scheme
focu
research
modif
cyanopyrrolidin
motif
therebi
enhanc
select
dppiv
inhibiton
enzym
howev
candid
clinic
develop
piperidin
deriv
pfizer
report
e
g
k
nm
achir
select
oral
bioavail
bioactiv
vivo
mechan
inhibit
could
corrobor
experiment
cocrystal
dppiv
inhibitor
show
inhibitor
coval
bind
nitril
group
ser
proton
nmr
reson
low
field
also
support
bind
mode
worker
suggest
develop
candid
chemic
effort
cours
develop
two
adamantanederiv
dipeptidyl
peptidas
iv
inhibitor
vildagliptin
saxagliptin
also
includ
synthesi
label
compound
requir
support
anim
adm
studi
synthesi
c
label
deriv
en
rout
saxagliptin
tenstep
synthes
report
scheme
potent
nonnitril
dppiv
inhibitor
also
report
research
bristolmyerssquibb
elucid
uniqu
structur
featur
impart
inhibitor
hydroxyadamantylglycin
group
appear
capabl
confer
signific
potenc
nonnitril
ad
benefit
compound
increas
stabil
one
possibl
degrad
reaction
would
cycliz
via
cyano
group
methanopyrrolidin
report
one
compound
k
nm
mechanist
studi
suggest
twostep
bind
mode
cyanopyrrolidin
first
form
initi
encount
complex
whereupon
coval
bound
intermedi
strong
enzymeinhibitor
hbond
form
activ
site
mutant
recombin
dppiv
cocrystal
inhibitor
support
mechan
action
figur
inhibitor
e
g
saxagliptin
bind
coval
revers
process
assist
typic
catalyt
triad
serin
proteas
involv
act
gener
base
enhanc
nucleophil
format
coval
bound
adduct
multibillion
dollar
market
big
pharma
initi
drug
develop
program
toward
develop
dppiv
new
target
target
success
hit
adamantan
compound
vildagliptin
saxagliptin
approv
recent
year
clinic
result
gener
favor
mostli
case
new
drug
adamantan
deriv
hit
yet
anoth
target
strategi
pharmaceut
block
format
androgen
e
g
treatment
prostat
cancer
involv
blockad
format
androgen
dihydrotestosteron
end
potent
inhibitor
type
dehydrogenas
would
use
hit
target
adamantan
deriv
report
successfuli
modifi
lead
androsteron
adt
enhanc
inhibit
adt
inhibit
enzym
ic
nm
adamantan
deriv
scheme
show
tentim
enhanc
potenc
ic
nm
howev
author
also
found
adamantan
substitut
essenti
compound
like
equal
potent
anoth
target
enzym
type
catalyz
reaction
cortison
cortisol
scheme
select
inhibit
enzym
type
valuabl
target
pharmacolog
treatment
metabol
syndrom
atherosclerot
diseas
adamantan
tetrazol
like
nonsteroid
hit
target
howev
establish
clean
sar
difficult
potenc
screen
librari
member
directli
influenc
structur
modif
compound
also
shown
activ
vivo
mous
model
inhibit
ic
nm
vs
nm
murin
ic
nm
vs
nm
host
studi
deal
design
synthesi
screen
inhibitor
incorpor
adamantan
base
build
block
publish
sinc
dual
human
mous
inhibitor
gave
like
scheme
hit
k
nm
ic
nm
k
nm
ic
nm
nonadamantan
deriv
like
bicyclo
octan
deriv
potent
ic
nm
ic
nm
ic
nm
ic
nm
refin
adamantylcarboxamid
gave
butyrolactam
like
ic
nm
ic
nm
ic
nm
ic
nm
compound
addit
potenc
select
also
show
good
pharmacodynam
profil
select
vivo
efficaci
evalu
obes
mice
anim
model
metabol
syndrom
therefor
scalabl
highyield
synthes
work
relat
deriv
like
somewhat
less
potent
similar
select
ic
nm
ic
nm
ic
nm
ic
nm
refin
goal
push
potenc
nm
high
select
rodent
model
one
candid
inhibitor
ic
nm
ic
nm
ic
nm
ic
nm
inhibitor
display
good
potenc
assay
cell
ic
nm
well
reason
stabil
compound
present
min
incub
mous
liver
microsom
introduct
metabol
stabl
inhibitor
goal
anoth
report
find
like
promis
compound
k
nm
ic
nm
vivo
half
life
rat
h
guid
xray
crystal
structur
enzym
complex
inhibitor
sar
adamantan
base
hsd
inhibitor
advanc
sulfon
like
also
display
low
nanomolar
affin
good
select
k
nm
ic
nm
k
nm
ic
nm
stabil
mous
liver
microsom
assay
good
address
tissu
select
anoth
import
aspect
come
clinic
applic
found
display
full
inhibitori
activ
tissu
like
liver
fat
brain
kidney
smaller
compound
adamantan
moieti
could
replac
without
drastic
loss
potenc
lastli
util
ht
hit
cocrystal
insid
hsd
bind
pocket
led
design
protoadamantan
k
nm
ic
nm
dock
approach
util
identifi
smallmolecul
inhibitor
submicromolar
potenc
human
dehydrogenas
type
cell
compound
could
cocrystal
figur
substitut
adamantanesulfon
bind
steroid
bind
site
amid
close
enzym
residu
respons
substrat
keton
reduct
best
knowledg
clinic
applic
adamantanederiv
inhibitor
hydroxysteroid
dehydrogenas
report
import
adamantan
framework
structur
maintain
potenc
select
favor
absort
metabol
vivo
impress
unlik
exampl
adamantan
modif
pharmacophor
ad
alkyladamantyl
residu
test
drug
influenc
properti
dehydrogenas
inhibitor
describ
also
util
rigid
adamantan
framework
scaffold
capabl
orient
pharmacophor
threedimension
structur
degre
conform
flexibl
favor
enzymeinhibitor
interact
concept
outlin
previou
chapter
also
follow
synthesi
isom
adamantaplatensimycin
everincreas
need
new
antibiot
particular
multidrug
resist
bacteria
challeng
drug
discoveri
field
strongli
influenc
isol
natur
product
synthet
chemist
one
class
natur
product
potent
antibiot
properti
target
fatti
acid
synthesi
bacteria
via
natur
product
screen
platensimycin
scheme
identifi
novel
antibiot
numer
public
deal
biosynthesi
signifi
relev
nicola
et
al
reason
replac
platensimycin
central
cagelik
domain
approxim
isoster
adamantan
would
facilit
synthesi
maintain
platensimycin
bioactiv
synthesi
adamantaplatensimycin
includ
rhodium
acet
catalyz
ch
bond
insert
reaction
diazoketon
decompos
tetracycl
intermedi
follow
step
includ
separ
enantiom
util
menthol
auxiliari
furnish
adamantaplatensimycin
inde
adamantan
scaffold
obvious
maintain
appropri
function
group
orient
show
compar
bioactiv
parent
compound
cancer
research
make
signific
chunk
medicin
chemistri
research
conduct
academia
pharmaceut
compani
come
surpris
adamantan
deriv
also
success
util
chapter
discuss
import
exampl
select
erad
cancer
cell
spare
normal
one
ultim
goal
chemotherapeut
classic
chemotherapeut
dnscrosslink
agent
cisplatin
scheme
repres
cornerston
presentday
chemotherapi
still
tumor
resist
cisplatin
less
nephrotox
analogu
carboplatin
lead
signific
number
relaps
cisplatin
carboplatin
use
addit
oral
bioavail
cisplatin
limit
henc
effect
less
toxic
platinumbas
cancer
chemotherapeut
desir
activ
even
cisplatinresist
cancer
cell
line
end
adamantan
deriv
also
studi
drug
discoveri
program
focus
transplatinum
complex
tran
pt
iv
complex
inde
display
cytotox
number
human
tumor
cell
line
vitro
contrari
earlier
establish
structureact
rule
platinum
complex
particular
interest
seem
find
vivo
found
amongst
tran
pt
complex
retain
activ
cisplatinresist
tumor
display
significantli
higher
therapeut
index
compar
cyclohexyland
cycloheptyl
analogu
respect
close
relat
ci
pt
iv
complex
synthes
screen
vitro
seri
cisplatinresist
tumor
cell
line
find
crossresist
cisplatin
sinc
dnacrosslink
mechan
action
platinum
drug
requir
entri
cell
capabl
ptcomplex
cross
cell
membran
utmost
import
end
group
research
also
studi
physicochem
data
amongst
other
featur
one
lipophil
amino
ligand
unfortun
studi
vitro
cytotox
studi
hplcbase
studi
compound
rate
ligand
exchang
cl
h
number
buffer
show
signific
influenc
lipophil
amin
ligand
though
correl
cell
uptak
lipophil
main
reason
enhanc
cytotox
seem
obviou
display
cytotox
cancer
cell
line
display
differ
mechan
cisplatin
resist
suggest
anoth
effect
bulki
lipophil
adamantan
ligand
directli
relat
cell
uptak
complex
also
found
display
higher
degre
cytotox
cisplatinsensit
cisplatinresist
ovarian
cancer
cell
compar
presum
due
addit
activ
ad
known
apoptosisinduc
capabl
latter
complex
reach
phase
clinic
trial
oral
dose
regimen
studi
mous
model
intrins
cisplatinresist
ovarian
adenocarcinoma
cytokinet
paramet
differ
markedli
compar
pt
ii
complex
subtl
differ
cell
cycl
modul
cisplatin
also
found
ovarian
carcinoma
cisplatin
treatment
led
g
cell
cycl
arrest
equitox
h
treatment
result
accumul
sphase
cell
author
attribut
accumul
increas
uptak
accumul
aminoadamantan
complex
lead
inhibit
dnapolymer
sloweddown
dnarepair
increas
dnaprotein
crosslink
pt
complex
led
increas
howev
exert
cytotox
presum
via
dnadepend
dnaindepend
pathway
rat
liver
epithel
cell
also
display
enhanc
induct
apoptosi
compar
cisplatin
result
rapid
penetr
adamantanederiv
drug
cell
attack
dna
wherebi
guardian
genom
activ
complex
obvious
shift
gene
express
cancer
cell
pathway
disrupt
prolifer
cell
regardless
howev
function
amplifi
effect
found
panel
human
carcinoma
cell
line
possess
distinct
status
pronounc
proapoptot
effect
found
cell
cell
inact
chang
transcript
induc
differ
cisplatin
induc
may
part
cytotox
effect
cisplatinresist
cancer
cell
line
word
spectrum
gene
express
action
platinum
complex
cancer
cell
differ
compar
cisplatin
direct
interact
chaperon
found
via
immunoprecipit
cell
treat
pt
could
detect
immunoprecipit
via
atom
absorpt
spectroscopi
inhibit
could
therefor
also
contribut
mechan
action
lastli
recent
report
effect
cisplatin
adress
combin
platinum
complex
trail
tnfrelat
apoptosi
induc
ligand
cisplatin
found
enhanc
cellkil
capac
trail
studi
colon
prostat
cancer
cell
line
compar
cisplatin
aminoadamantan
complex
display
similar
enhanc
trail
time
lower
dose
platinum
complex
obvious
modul
part
upstream
trail
signal
extrins
apoptot
pathway
line
conclus
earlier
report
ask
dnaindepend
addit
effect
tran
pt
complex
tran
pt
ii
tran
pt
iv
complex
incorpor
alkylamino
ligand
remain
cytotox
select
two
cisplatinsensit
two
cisplatinresist
cell
line
transplatin
corrobor
find
author
also
found
thirtyfold
cellular
uptak
adamantylamin
complex
compar
cisplatin
obvious
introduct
adamantan
ligand
simpli
enhanc
uptak
cell
expand
therapeut
window
full
pictur
number
modif
mechan
action
pt
complex
accompani
modif
lipophil
bullet
screen
librari
deriv
protein
tyrosin
kinas
ptk
inhibitor
lavendustin
scheme
panel
sixti
differ
cancer
cell
line
ester
incorpor
primari
pharmacophor
start
compound
lavendustin
seen
methyl
ester
ester
studi
surpris
context
review
report
especi
promis
term
broadband
antiprolif
effect
vivo
biolog
activ
hollow
fiber
assay
mice
subcutan
xenograft
mice
vitro
structureactivityrelationship
confirm
superior
lipophil
steric
hinder
ester
compar
methyl
ester
probabl
hydrolyz
much
faster
adamantan
analogu
contribut
fast
biolog
halflif
three
minut
iv
administr
mice
adamantyl
ester
contrast
display
plasma
clearanc
rate
lower
lead
mean
resid
time
min
phenol
ether
hydroquinon
moieti
test
compound
abrog
antiprolif
activ
quinon
e
g
show
reduc
antikinas
activ
well
decreas
growth
inhibit
potenti
mechan
action
author
consid
intracellular
oxid
drug
correspond
quinon
subsequ
modifi
target
protein
coval
via
reaction
maximum
activ
hollow
fiber
assay
use
panel
leukemia
cell
also
found
show
maximum
cell
growth
inhibit
vitro
vivo
maintain
autokinas
inhibitori
activ
initi
synthes
therefor
select
develop
refer
later
studi
adaphostin
respect
work
compar
one
anoth
svingen
et
al
also
found
adaphostin
inhibit
kinas
respons
major
chronic
myelogen
leukemia
cml
bcrabl
potent
methyl
ester
adaphostin
downregul
express
kinas
threefold
stronger
also
induc
apoptosi
cell
stronger
comparison
inhibitor
tyrosin
kinas
alter
atp
bind
site
bcrabl
inhibitori
activ
adaphostin
instead
alter
bind
site
peptid
substrat
test
ten
human
leukemia
glioblastoma
cell
subsequ
show
adaphostin
broader
applic
leukemia
consistenli
show
lower
ic
valu
structur
unrel
antileucem
compound
via
mechan
later
report
supplement
find
studi
adaphostin
three
differ
glioblastoma
cell
line
simpl
oxid
tertbutyl
hydroperoxid
found
predict
adaphostinsensit
found
cell
line
clearli
support
mechan
action
latter
gener
reactiv
oxygen
speci
ro
cell
prostat
cancer
cell
adaphostin
induc
g
phase
cell
cycl
arrest
drug
also
inhibit
growth
mani
adher
suspens
cell
line
ic
valu
nm
recent
adaphostin
also
found
activ
nonsmal
cell
lungcanc
cell
line
ncih
least
two
differ
mode
action
import
adaphostin
select
cytotox
tyrphostin
effect
inhibit
tyrosin
kinas
rosmedi
mechan
gener
ro
preced
dnadamag
heuman
leukemia
cell
expos
adaphostin
also
act
upstream
perturb
stress
surviv
cellcycleassoci
protein
well
mitochondri
injuri
monitor
adaphostininduc
chang
transcript
releas
free
iron
lead
redox
perturb
also
found
altern
addit
mode
action
kinas
inhibit
adaphostin
also
found
cell
line
resist
tyrosin
kinas
inhibitor
gleevec
due
sever
point
mutat
nacetyl
cystein
radic
scaveng
trigger
partial
reduct
ro
gener
leukemia
cell
wildtyp
mutat
tyrosin
kinas
rosgener
subsequ
pathway
probabl
confer
vast
major
adaphostin
antileukemia
activ
howev
induct
oxid
stress
still
suffici
fulli
explain
adaphostin
action
adaphostin
concentr
cell
mitochondria
compar
extracellular
medium
respir
mitochondria
suspect
prime
origin
adaphostininduc
rise
level
ro
within
mitochondria
adaphostin
probabl
bind
act
respiratori
complex
iii
corrobor
also
silico
dock
studi
human
multipl
myeloma
cell
adaphostin
caus
upregul
cjun
activ
caspas
cellgrowth
arrest
final
apoptosi
proteom
profil
adaphostintr
leukemia
cell
reveal
similar
effect
tyrphostin
seen
treat
cell
oxid
h
hydroquinon
studi
two
adaphostin
resist
gene
identifi
adaphostin
also
identifi
activ
agent
screen
agent
increas
level
hypoxiainduc
factor
multipl
myeloma
number
studi
focus
combin
adaphostin
anticanc
drug
instanc
gleevec
act
synergist
adaphostin
leukemia
cell
fludarabin
display
synergi
chronic
lymphot
leukemia
multikinas
inhibitor
sorafenib
enhanc
adaphostininduc
apoptosi
leukemia
cell
combin
adaphostin
bortezomib
inhibitor
proteasom
found
highli
effici
leukemia
cell
bear
point
mutat
tyrosin
phosphatas
three
differ
leukemia
cell
line
combin
adaphostin
peptid
aldehyd
proteasom
inhibitor
act
synergist
induct
apoptosi
shift
balanc
toward
stressrel
signal
transduct
pathway
increas
rosdepend
cell
death
normal
hematopoiet
cell
spare
rel
transform
one
recent
caffein
also
found
benefici
leukemia
therapi
coadminist
adaphostin
even
though
adaphostin
obvious
act
via
number
differ
mode
one
enhanc
stabil
target
cell
penetr
lipophil
bullet
adaphostin
analog
character
csa
compound
class
drug
consist
structur
activ
relationship
could
warrant
studi
novel
deriv
compound
modifi
adamantan
moieti
enhanc
adaphostin
low
oral
bioavail
compound
report
literatur
date
retinoid
structur
relat
vitamin
metabolit
alltran
retino
acid
atra
tabl
bind
activ
retino
acid
receptor
class
nuclear
receptor
capabl
dnabind
regul
gene
express
consequ
retinoid
atra
analogu
capabl
direct
modul
e
g
cellular
prolifer
differenti
apoptosi
therefor
togeth
natur
synthet
ligand
retino
acid
receptor
repres
target
divers
seri
patholog
acn
vulgari
multifactori
diseas
lead
wellknown
lesion
treat
atra
decad
atra
interact
retino
acid
receptor
rar
retinoid
x
receptor
rxr
without
pronounc
select
rar
subtypespecif
analogu
sought
reduc
side
effect
adapalen
tabl
identifi
screen
mix
agonist
low
rara
affin
select
develop
topic
treatment
acn
vulgari
pharmacolog
chemic
properti
includ
photochem
stabil
local
activ
high
stabil
expectedlow
local
sideeffect
profil
subsequ
proven
equal
activ
atra
lower
concentr
topic
treatment
acn
vulgari
use
today
hydrogel
contain
adamantyl
retinoid
activ
pharmaceut
ingredi
brand
name
differin
pimpal
gallet
respect
combin
adapalen
antimicrobi
benzoyl
peroxid
offer
enhanc
effici
maintain
adapalen
favor
safeti
profil
recent
adapalen
studi
close
via
molecular
model
uvvi
spectroscopi
respect
direct
bind
dna
dock
reveal
retinoid
without
adamantan
moieti
might
conveni
contact
dna
minor
groov
howev
presenc
lipophil
bullet
adamantan
shown
clearli
contribut
stronger
dna
bind
adamantylsubstitut
mainli
base
upon
lipophil
interact
success
introduct
yet
anoth
adamantan
deriv
adapalen
pharmaceut
market
howev
end
stori
analog
adapalen
similar
simpl
chang
group
found
modifi
test
drug
select
render
interest
tool
studi
retino
acid
receptor
relev
e
g
dermatolog
found
upregul
express
alkalin
phosphatas
teratocarcinoma
cell
importantli
induc
cell
cycl
arrest
apoptosi
human
breast
carcinoma
human
leukemia
cell
line
fashion
effect
obvious
rar
independ
involv
enhanc
express
compon
cyclincdk
complex
also
inhibit
dna
polymeras
activ
addit
substitut
stilben
bear
substitut
pattern
also
found
select
comparison
growthinhibitori
activ
natur
synthet
retinoid
eight
nonsmal
cell
lung
cancer
nsclc
line
gave
strike
proof
import
adamantan
moieti
induct
growth
inhibit
independ
rar
subtyp
select
adamantanesubstitut
retinoid
success
growth
inhibitor
studi
one
retinoid
display
nsclc
growth
inhibit
one
cell
line
incorpor
diamantyl
moieti
compound
bulkier
diamondoid
residu
howev
potent
growth
inhibitor
display
ic
valu
rang
moreov
three
retinoid
show
signific
growth
inhibit
nsclc
panel
incorpor
adamantan
moieti
complet
list
adapalen
one
four
test
select
retinoid
found
activ
studi
lack
adamantan
group
inhibit
nsclc
growth
via
rarindepend
mechan
wealth
studi
aim
demonstr
scope
elucid
mechan
also
refer
induc
cellcycl
arrest
apoptosi
follow
activ
upregul
transcript
factor
human
melanoma
cell
human
lung
cancer
cell
line
shown
act
via
nonretinoid
acid
receptor
rar
retinoid
x
receptor
rxr
mediat
pathway
mice
bear
xenograft
human
ovarian
cancer
cell
found
activ
ip
oral
applic
unlik
adaphostin
cf
chapter
seem
increas
ro
cancer
cell
wealth
studi
cover
scope
cellular
model
system
sensit
cell
cyclemodifi
apoptosisinduc
action
cover
human
lung
cancer
cell
leukemia
hepatoma
cell
line
prostat
cancer
cell
primari
microglia
rat
show
capabl
regul
cellular
differenti
neuroinflammatori
diseas
extens
studi
review
elsewher
consensu
exist
find
vast
major
proapoptot
activ
mediat
without
direct
interact
molecul
receptor
initi
develop
respect
clearli
evid
cytotox
effect
adapalen
parent
structur
ahpn
display
multipl
experiment
set
encourag
synthesi
screen
librari
deriv
aim
enhanc
potenc
select
improv
pharmacokinet
tabl
adamantyl
stilben
inhibit
differenti
human
head
neck
squamou
myeloma
cell
via
process
link
rar
interact
also
induc
apoptosi
via
rarindepend
pathway
bind
unidentifi
kd
protein
nuclear
extract
human
breast
carcinoma
shown
sizeexclus
chromatograph
analysi
link
activ
adamantyl
retinoid
orphan
receptor
nucleu
question
whether
also
bind
orphan
receptor
specif
extent
comparison
deem
essenti
elucid
nonrarrxrmedi
mechan
action
retinoid
least
human
prostat
carcinoma
natur
synthet
retinoid
screen
panel
head
neck
squamou
carcinoma
emerg
promis
deriv
show
lower
ic
valu
cell
line
compar
nonadamantyl
retinoid
adamantyl
deriv
minim
raror
rxrtransactiv
goal
design
novel
adamantyl
retinoid
report
equal
good
induc
apoptosi
reduc
transactiv
rar
molecular
model
studi
suggest
reduc
interact
rar
adamantan
moieti
extrud
plane
naphthalen
moieti
data
nonadamantyl
retinoid
use
deriv
model
proapoptot
activ
retinoid
involv
rardepend
rarindepend
pathway
adamantyl
arotinoid
consid
retinoid
exert
apoptot
activ
complet
independ
rar
retinoidrel
molecul
includ
rar
antagonist
scheme
target
kinas
phosphatas
kinas
ikk
rar
antagonist
potent
inhibitor
trigger
signal
transduct
pathway
ultim
lead
apoptosi
intracellular
pathway
appear
converg
mitochondria
support
nonrarmedi
apoptosisinduc
properti
bcell
chronic
leukemia
acut
lymphoblast
leukemia
cell
result
compar
cell
line
nonchlorin
analog
scheme
emerg
lead
structur
display
potent
antiprolif
activ
panel
human
tumor
cell
line
almost
complet
devoid
rar
transactiv
regard
copharmacophor
togeth
carboxyl
acid
group
away
activ
adamantyl
retinoid
studi
detail
bind
activ
rar
twist
central
biaryl
bond
examin
compound
adamantyl
group
resid
plane
aromat
scaffold
chloro
deriv
acetamidopropoxi
deriv
adamantyl
group
forc
plane
shown
dft
comput
dock
studi
model
show
one
hand
bound
ligand
bind
domain
model
latter
two
deriv
bear
orthochlorosubstitut
caus
alter
bind
complex
coactiv
repressor
protein
reduc
rar
transactiv
antagon
apoptosi
induc
panel
variou
cancer
cell
compound
mechan
action
propos
earlier
question
name
direct
freerad
gener
phenol
group
present
apoptot
deriv
antagonist
nonspecif
mitochondri
permeat
expect
similar
apoptot
deriv
antagonist
narrow
molecular
target
event
upstream
direct
effect
mitochondri
membran
could
involv
enhanc
proteolysi
epiderm
growth
factor
receptor
egfr
serthr
kinas
akt
extens
screen
reveal
rel
strict
requir
apoptot
activ
retinoid
requir
presenc
carboxyl
acid
group
econfigur
acycl
doubl
bond
doubl
bond
must
incorpor
larg
substitu
substitu
aromat
ring
per
se
enhanc
apoptot
activ
bulki
lipophil
substitu
necessari
far
best
also
shown
alogp
data
summar
tabl
lipophil
alon
prerequisit
activ
alogp
synthet
retinoid
mostli
logp
valu
consid
upper
limit
druglik
molecul
lipinski
classic
rule
five
also
hold
true
atra
precis
orient
pharmacophor
includ
substitu
instead
shape
main
determin
rar
subtyp
specif
also
cellcycl
modifi
activ
retinoid
compound
select
evalu
optim
distanc
carboxyl
acid
group
lipophil
addon
also
mention
critic
author
consequ
aromat
scaffold
rigid
one
furthermor
also
observ
qualit
correl
logp
antiprolif
activ
retinoid
relat
molecul
cinnam
acid
deriv
exert
apoptot
effect
least
leukemia
cell
mechan
action
significantli
higher
apoptot
index
effect
gene
express
cinnam
acid
deriv
naphthoic
acid
deriv
similar
furthermor
cinnam
acid
deriv
oral
activ
scid
mice
bear
xenograft
notabl
increas
influx
ca
retinoid
relat
molecul
bear
adamantan
moieti
tend
spare
untransform
cell
larg
varieti
leukemia
solid
tumor
cell
line
inhibit
two
probabl
beststudi
adamantyl
retinoid
low
toxic
vivo
potent
vivo
studi
molecular
mechan
action
class
compound
must
continu
author
conclud
consid
least
clinic
interest
combin
therapi
apprais
particularli
feasibl
request
studi
elucid
moa
subsequ
satisfi
ovarian
carcinoma
found
induc
apoptosi
stronger
cell
combin
egfr
inhibitor
human
ovarian
lung
breast
carcinoma
found
synergist
sensit
ovarian
tumor
vivo
mice
cytotox
action
cisplatin
activ
nuclear
factor
presenc
similar
mechan
observ
prostat
cancer
cell
result
enhanc
express
proapoptot
mediat
reduc
express
inhibitor
apoptosi
crossresist
observ
lung
cancer
cell
develop
resist
support
common
moa
gene
express
profil
likewis
gave
similar
result
develop
adamantyl
retinoid
exert
genotox
stress
cancer
cell
gave
amongst
other
scheme
human
promyelot
leukemia
cell
still
potent
inhibitor
prolifer
ic
ic
ic
structur
also
potent
mother
compound
atra
preclin
model
neuroblastoma
vitro
well
xenograft
mice
respect
elucid
one
precis
molecular
target
probabl
convinc
find
relat
bind
retinoid
nuclear
orphan
receptor
small
heterodim
partner
shp
nuclear
receptor
shp
bind
amongst
other
rar
rxr
receptor
form
heterodimer
complex
carboxyl
acid
acid
group
retinoid
essenti
format
complex
highli
apoptot
wherea
carboxyl
acid
isoster
tetrazol
larg
inact
subsequ
structureanticancerrelationship
studi
highlight
import
group
phenol
hydroxi
group
apoptot
activ
bind
pocket
shp
requir
interact
pharmacophor
replac
group
andor
hydroxi
group
isoster
group
impact
induct
apoptosi
concentr
acut
myelot
leukemia
cell
wellknown
retinoid
alogp
tabl
induc
apoptosi
cell
strikingli
almost
equal
lipophil
analog
alogp
scheme
induc
apoptosi
apoptot
cell
ident
condit
tetramethylcyclohexyl
deriv
alogp
gave
apoptot
aml
cell
likewis
expect
cinnam
acid
analog
induc
apoptosi
potent
apoptot
cell
experiment
set
analog
gave
apoptot
cell
compar
effect
attenu
induct
apoptosi
upon
deviat
lipophil
bullet
substitu
observ
cell
cultur
set
well
hydrohob
paramet
symmetri
chain
length
also
play
role
shp
bind
non
small
cell
lung
cancer
cell
adamantylderiv
gave
ic
parent
compound
significantli
potent
ic
import
shape
lipophil
underscor
bind
studi
seri
adamantyl
retinoid
recombin
shp
lack
xray
structur
data
homolog
model
shp
class
orphan
nuclear
receptor
nr
transcript
factor
util
dissect
molecular
moa
adamantyl
retinoid
bind
pocket
identifi
examin
via
silico
dock
studi
featur
hbond
retinoid
carboxyl
acid
edgetofac
bind
phenol
hydroxi
group
phe
sidechain
lipophil
pocket
adamantyl
substitu
incorpor
residu
shp
bind
heterodim
partner
amongst
other
rar
rxr
respect
form
heterodimer
receptor
complex
act
classic
nr
transcript
factor
rather
bridg
protein
nr
repressor
protein
format
oligomer
nr
complex
probabl
molecular
target
adamantylretinoid
mediat
apoptosi
cellcycl
regul
respect
shp
consid
adopt
orphan
nuclear
receptor
sever
ligand
modul
interact
heterooligomer
partner
form
multiprotein
repressor
complex
identifi
format
repressor
protein
complex
probabl
major
process
directli
target
adamantyl
retinoid
chang
protein
express
lead
cell
cycl
arrest
andor
apoptosi
celltyp
specif
manner
explain
moa
summar
prototyp
retinoid
relat
molecul
rrm
similar
natur
retinoid
display
moa
depend
rar
rxr
major
advantag
absenc
crossresist
current
anticanc
chemotherapi
multimolecular
repressor
complex
form
shp
sin
repres
target
adamantyl
retinoid
human
breast
carcinoma
leukemia
cell
cell
lost
express
senstit
toward
induct
apoptoti
absent
still
inhibit
prolifer
observ
togeth
find
shp
ist
respons
bind
nuclear
extract
emphas
shp
primari
target
adamantyl
retinoid
improv
synthet
protocol
util
microwaveassist
suzukicoupl
assembl
central
biphenyl
report
effort
screen
orthosubstitut
retinoid
panel
six
cell
line
use
mtt
assay
monitor
inhibit
cell
prolifer
adamantyl
deriv
scheme
strongest
induc
apoptosi
also
found
summar
recent
review
research
head
lead
group
field
develop
candid
select
combin
therapi
regimen
base
upon
fact
nontox
concentr
mice
found
low
monotherapi
synerg
cisplatin
warrant
develop
combin
chemotherapi
howev
rel
high
toxic
vivo
togeth
rapid
glucuronid
excret
drug
human
vide
infra
also
led
author
conclud
still
structur
modif
lead
compound
may
use
one
modifi
deriv
scheme
deriv
equal
activ
vitro
vivo
mice
cancer
cell
knockeddown
shp
lost
apoptot
activ
support
moa
mediat
shp
xenograph
sever
combin
immunodefici
scid
mice
carri
tf
vsrc
cell
atraresist
leukemia
cell
line
treat
show
mark
increas
length
surviv
evid
leukemia
anim
higher
solubl
aqueou
media
heteroatom
deriv
could
least
part
account
equal
even
higher
biolog
activ
recent
screen
effort
strategi
enhanc
pharmacolog
properti
toxic
solubl
bioavail
pursu
next
introduct
heteroatom
cinnam
acid
ring
yield
e
g
substitut
pyridin
pyrimidin
replac
aromat
cinnam
acid
ring
satur
heterocycl
replac
cinnam
acid
doubl
bond
sever
heteroatom
function
report
howev
heteroaromat
deriv
maintain
strong
apoptot
effect
panel
acut
myeloid
leukemia
cell
solid
tumor
cell
bind
screen
candid
recombin
gstshp
studi
proton
nmr
reveal
bind
shp
fusion
protein
dock
show
test
drug
display
apoptot
activ
bound
mode
similar
pyrimidin
may
potenti
treatment
acut
myelot
leukemia
final
moa
prototyp
adamantyl
retinoid
also
shown
mediat
shp
retinoid
act
regul
shp
gene
express
promot
shptransloc
mitochondria
result
use
variou
vitro
vivo
cellular
model
author
demonstr
role
shp
regul
mitochondri
activ
next
moa
involv
kinas
phosphatas
transcript
factor
could
account
apoptot
activ
molecular
mechan
action
adamantyl
retinoid
discuss
recent
literatur
includ
genotox
stress
dnadamag
nuclear
factor
activ
phosphoryl
kinas
turn
activ
human
ovarian
cancer
cell
line
retinoid
studi
identifi
growth
inhibitor
cancer
cell
ic
ic
ic
share
mechan
action
influenc
gene
express
shown
proteom
major
protein
whose
express
influenc
latter
three
retinoid
role
ca
homeostasi
regul
shp
probabl
target
protein
adamantyl
retinoid
also
signific
metabol
anorm
diabet
fatti
liver
insulin
resist
therefor
shp
regul
valuabl
goal
field
also
develop
select
shp
ligand
therefor
sure
warrant
togeth
advanc
overcom
intrins
low
solubl
adamantyl
retinoid
aqueou
media
via
e
g
format
complex
success
shown
preclin
clinic
drug
develop
field
adamantyl
retinoid
expect
happen
adamantanederiv
pharmaceut
administ
final
chapter
briefli
discuss
metabol
degrad
drug
incorpor
adamantan
build
block
mice
amantadin
dose
given
found
excret
unchang
urin
within
hour
oral
applic
drug
found
fece
good
oral
absorpt
metabol
occur
still
part
dose
collect
anim
urin
fece
rat
recoveri
amantadin
lower
likewis
dog
drug
could
recov
urin
nmethyl
occur
dog
speci
excret
amantadin
actual
metabol
scheme
monkey
halflif
drug
h
metabol
convers
also
occur
report
also
state
man
drug
recov
urin
evid
acyl
methyl
otherwis
modifi
amantadin
metabolit
urin
sampl
human
analyz
glc
howev
analyz
sampl
individu
attempt
suicid
take
larg
amount
drug
indic
metabol
convers
occur
human
metabol
amantadin
therapeut
dose
regimen
revisit
take
mg
oral
still
vast
major
amantadin
detect
urin
major
metabolit
urin
acetyl
found
urin
total
eight
metabolit
could
identifi
incorpor
unmodifi
adamantan
moieti
modif
tricycl
hydrocarbon
moieti
howev
found
memantin
scheme
tissu
urin
sampl
rat
ip
inject
rat
hydroxymethyl
deriv
found
tissu
urin
main
metabolit
likewis
rat
memantin
administ
metabol
secondari
alcohol
substitut
carbinol
cage
hydroxyl
main
metabol
degrad
take
place
memantin
mark
contrast
amantadin
antiherp
drug
tromantadin
scheme
bear
amid
function
along
tertiari
amin
therefor
metabol
somewhat
differ
still
drug
detect
unmodifi
urin
human
take
singl
dose
mg
drug
metabolit
identifi
includ
cleavag
product
amid
form
amantadin
ether
give
two
major
metabolit
modif
tertiari
amino
group
account
metabolit
amantadin
adamantyl
cage
modifi
contrast
metabol
antivir
rimantadin
scheme
mainli
take
place
adamantan
cage
singl
dose
mg
po
still
unmodifi
drug
major
compound
isol
urin
man
cage
hydroxyl
metabolit
account
combin
drug
recov
urin
sampl
h
postdos
anoth
studi
trace
glucuronid
deriv
could
also
detect
use
clabel
drug
rat
dog
major
metabol
pathway
establish
oxid
adamantan
moieti
ii
oxid
amin
give
hydroxylamin
iii
abovement
glucuronid
sulfat
ester
format
human
total
recov
drug
found
hydroxyl
studi
cckb
receptor
antagonist
scheme
also
contain
moieti
bound
electroneg
atom
compound
consid
develop
antianxieti
drug
metabol
studi
total
eight
metabolit
identifi
even
though
compound
bear
numer
function
group
could
modifi
metabol
major
metabolit
unmodifi
compound
modifi
paraffin
residu
give
find
corrobor
result
vitro
studi
use
liver
microsom
dppiv
inhibitor
vildagiptin
scheme
studi
oral
give
mg
clabel
test
drug
healthi
human
volunt
plasma
sampl
radioact
detect
unmodifi
drug
wherea
present
carboxyl
acid
metabolit
urin
sampl
cleavag
amid
account
dose
isol
glucuronid
give
oxid
modif
pyrrolidin
moieti
lead
less
primari
elimin
rout
renal
excret
radioact
initi
radioact
found
fece
furthermor
shown
hydrolysi
nitril
vildagliptin
actual
catalyz
target
enzym
dppiv
vide
supra
similar
result
report
speci
includ
rat
dog
second
approv
adamantanebas
dppiv
inhibitor
saxagliptin
scheme
incorpor
residu
primari
metabol
clearanc
rout
shown
involv
bishydroxyl
antimalari
ozonid
scheme
studi
human
liver
microsom
rat
plasma
experi
two
metabolit
hydroxyl
spiroadamantan
moieti
isol
major
ci
minor
tran
metabolit
devoid
antimalari
activ
metabol
proapoptot
adamantyl
retinoid
scheme
studi
earli
phase
clinic
trial
ovarian
cancer
patient
low
variabl
absorpt
drug
observ
appli
oral
five
consecut
day
show
excel
plasma
stabil
elimin
halfliv
vari
two
seven
hour
drug
underw
glucuronid
three
differ
site
dramat
lower
bioavail
glucuronid
metabolit
could
detect
patient
blood
sampl
via
lcm
method
two
shown
scheme
site
glururonid
third
identifi
metabolit
probabl
cinnam
acid
doubl
bond
via
cglucuronid
rational
behind
metabol
adamantan
base
drug
clear
compound
incorpor
electronrich
adamantan
core
mostli
modifi
via
hydroxyl
involv
cytochrom
deduc
crystal
structur
cam
complex
adamantan
process
gener
select
absenc
function
group
drug
could
orient
cage
hydrocarbon
sever
site
hydroxyl
seen
e
g
rimantadin
memantin
chapter
summar
major
field
medicin
chemistri
drug
develop
tricycl
c
h
isom
adamantan
strike
impact
remark
simpl
aminoadamantan
structur
hit
target
like
viroporin
combat
influenza
well
nmda
receptor
symptomat
relief
parkinson
diseas
alzheim
diseas
lipophil
bullet
build
block
favor
modifi
known
pharmacophor
also
learn
drug
use
adamantan
addon
interact
lipophil
pocket
proxim
activ
site
target
give
rise
enhanc
select
lastli
dppiv
inhibitor
approv
recent
adamantan
moieti
bear
function
group
differ
short
akyl
group
consid
orient
effect
rigid
adamantan
scaffold
exert
function
group
capabl
form
hydrogen
bond
even
coval
attach
enzym
activ
site
sever
drug
introduc
chapter
includ
adamantanebas
experiment
drug
deriv
neuropeptid
chapter
also
dppiv
inhibitor
saxagliptin
vildagliptin
exemplifi
process
util
endogen
peptid
subsequ
thereof
lead
structur
drug
develop
seven
adamantanebas
drug
approv
far
aminoadamantan
recommend
antiinfluenza
agent
resist
circul
strain
viru
memantin
becom
blockbust
drug
probabl
dppiv
inhibitor
also
becom
success
multibillion
market
notabl
none
approv
drug
discov
directli
via
modern
ht
strategi
dppiv
inhibitor
howev
indirect
result
ht
effort
valid
dipeptidyl
peptidas
iv
drug
target
case
initi
htshit
contain
lipophil
bullet
anoth
notabl
stori
behind
adamantan
base
pharmaceut
deriv
small
librari
adamantan
deriv
mostli
simpl
aminoadamantan
adamantan
carboxyl
acid
probabl
commerci
avail
therefor
frequent
consid
build
block
test
drug
librari
synthes
advent
larg
varieti
select
ch
bond
function
method
adamantan
core
avail
even
lipophil
diamondoid
build
block
scheme
much
expect
use
uniqu
hydrocarbon
modifi
enhanc
activ
pharmacophor
unchart
territori
certainli
hold
great
promis
pharmaceut
industri
consid
major
arena
futur
drug
develop
seen
dppiv
inhibitor
develop
select
inhibitor
dehydrogenas
chapter
also
somatostatin
analogu
bisfunction
adamantan
deriv
alreadi
hit
sever
target
oligofunction
adamantan
deriv
also
avail
encourag
medicin
chemist
consid
build
block
earli
stage
drug
discoveri
process
particular
util
today
power
method
combinatori
chemistri
make
globular
paraffin
special
first
size
matter
hit
target
like
ion
channel
adamantan
methyl
substitut
deriv
obvious
appropri
molecular
dimens
function
block
conduct
viroporin
calcium
channel
secondli
lipophil
direct
effect
affin
sever
case
also
indirect
one
enhanc
cnsaccess
facilit
penetr
bloodbrainbarri
lipophil
also
benefici
test
drug
hit
target
membran
particular
lipid
raft
addit
rigid
hydrocarbon
protect
function
group
proxim
metabol
cleavag
enhanc
durat
action
amongst
other
peptidederiv
drug
hand
biocompat
metabol
take
place
liver
toxic
effect
accumul
upon
chronic
treatment
expect
adamantanebas
drug
metabolit
studi
fact
excret
larg
unmodifi
ad
benefit
possibl
side
effect
aris
bioactiv
metabolit
intrins
improb
lastli
trend
larger
molecul
exploit
pharmaceut
trend
also
reflect
adamantan
deriv
describ
articl
control
function
group
orient
everincreas
relev
optim
potenc
select
expect
adamantanebas
scaffold
becom
highli
relev
especi
respect
adamantan
may
magic
bullet
adamantanebas
pharmaceut
certainli
silver
bullet
yet
lipophil
bullet
expect
hit
even
target
medicin
chemistri
year
come
natur
occur
natureinspir
heteroadamantan
recent
adamantan
deriv
antihsv
properti
given
parenthes
ec
determin
plaquereduct
assay
use
vero
cell
adamantan
deriv
display
antihepat
properti
hexamethyleneamilorid
silver
sculptur
cloud
gate
chicago
ill
reflect
seven
drug
market
today
incorpor
adamantan
motif
chicagoan
refer
cloud
gate
bean
reserach
univers
near
bean
contribut
elucid
mechan
action
drug
photograph
taken
l
wanka
sequenc
comparison
influenza
influenza
b
protein
transmembran
domain
underlin
protong
hxxxw
motif
bold
ser
residu
presum
render
bm
channel
amantadin
resist
make
insid
channel
less
hydrophob
bold
ital
